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INTRODUCTION 
 
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal stem cell 
disorders characterized by a hypercellular bone marrow, peripheral cytopenias and 
dysplastic features in blood and bone marrow. The spectrum of the disease may vary 
from an indolent course over several years to more rapid progression to acute myeloid 
leukemia (AML).1 In this review leukemia evolving from MDS is named secondary acute 
myeloid leukemia (sAML). 
MDS is predominantly diagnosed in elderly patients. In a population-based study in 
Germany the annual incidence of MDS in patients over 50 years was 4.9 per 100 000 
persons compared to an incidence of 1.8 per 100 000 for acute myeloid leukemia in the 
same age-group.2 In the last decades the incidence of MDS seems to increase. In part 
this may be due to a greater readiness to perform bone marrow examinations in elderly 
patients, but there is also some evidence for a real increase due to occupational and 
environmental exposure to chemicals like benzene and other organic solvents.3-5 
Furthermore, treatment with radiotherapy and/or certain chemotherapeutic agents 
promotes the development of therapy-related MDS and AML (tMDS/tAML). Alkylating 
substances have the strongest leukemogenic potential. The risk of developing MDS or 
AML after treatment for Hodgkin’s disease is 7-8% and appears to be closely related to 
the cumulative dose administered.6,7 Also drugs targeting at topoisomerase II are capable 
to induce tMDS and tAML even in young children in whom a diagnosis of MDS is rare.8,9  
Since 1982 the myelodysplastic syndromes have been classified according to FAB 
(French-American-British) criteria.10 Five subcategories have been described: refractory 
anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with 
excess of blasts (RAEB), refractory anemia with excess of blasts in transformation 
(RAEBt) and chronic myelomonocytic leukemia (CMML). The clinical course of MDS is 
variable. Patients with RA and RARS have a low risk of developing sAML and their 
median survival is more than 30 months. The majority of these patients die of 
consequences of bone marrow failure or due to iron overload as a result of repeated 
blood transfusions. The median survival of patients presenting with RAEB and RAEBt is 
generally shorter than 12 months. 
The FAB-classification has several limitations. There are significant differences in 
outcome of patients within each subcategory. The FAB classification is entirely based on 
morphological criteria and the number of blasts in blood and bone marrow, whereas other 
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clinical and biological variables have not been incorporated in this classification. 
Therefore, numerous other classification systems have been proposed to predict the 
prognosis of individual patients.1,11-14 In 1997 an international workshop combined the 
data of seven previous reported studies 1,11-13,15-17 to generate an International Prognostic 
Scoring System (IPSS).18,19 Greenberg et al. distinguished four risk groups for survival 
and AML evolution (low, intermediate-1, intermediate-2 and high risk) based on 
cytogenetic subgroup, percentage of bone marrow blasts and number of cytopenias 
(Table 1). Age was an additional prognostic factor for survival, but not for AML evolution.  
 
 
Table 1. IPSS (International Prognostic Scoring System). 
Score values  
Prognostic variables 0 0.5 1.0 1.5 2.0 
BM blasts (%) 
Karyotype 
Cytopeniasa 
<5 
Good 
0/1 
5-10 
Intermediate 
2/3 
- 
Poor 
11-20 21-30 
Low risk group 
Intermediate-1 risk group 
Intermediate-2 risk group 
High risk group 
Score 0 
Score 0.5-1.0 
Score 1.5-2.0 
Score 2.5-3.5 
    
Good karyotype 
Intermediate karyotype 
Poor karyotype 
Normal, -Y, del 5q, del 20q 
Other abnormalities 
Chromosome 7 or complex (> 3) abnormalities 
a: Cytopenias: hemoglobin < 10 g/dl, platelets < 100 x 109/l, neutrophils < 1.8 x 109/l 
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The IPSS seems to be an improved classification system for evaluating prognosis in 
MDS.20 However, Estey et al. applied the IPSS to 219 untreated patients referred to M.D. 
Anderson and reported a lower survival expectation in the low, intermediate-1 and 
intermediate-2 categories compared to the corresponding IPSS patients.21 Furthermore, 
the IPSS has been derived from patients treated with transfusions, biologic response 
modifiers and low-dose oral chemotherapy. Patients treated with intensive chemotherapy 
including stem cell transplantation have been excluded from this analysis. It is still 
unknown whether the IPSS is also applicable to patients treated with intensive treatment 
strategies.22  
Cytogenetic abnormalities occur in approximately 40-60% of patients with primary MDS, 
whereas more than 80 % of patients with therapy-related MDS have abnormal 
karyotypes.23-25 Jotterand and Parlier collected data on 2372 patients from 18 studies.26 
The incidence of clonal defects in primary MDS was 52%. Abnormal clones occurred 
more frequently in RAEBt (67%) and RAEB (62%), compared with RA (49%), RARS 
(36%) and CMML (36%). Both structural and numeric changes are found in MDS 
patients. MDS is more often associated with chromosomal deletions as a primary 
karyotypic anomaly, whereas balanced translocations are the most typical changes found 
in de novo AML. In therapy-related MDS and AML after the use of alkylating agents, 
cytogenetic abnormalities involving chromosome 5 or 7 and complex abnormalities, which 
are also associated with primary MDS are frequently found. Balanced translocations to 
chromosome bands 11q23 and 21q22 occur after treatment with topoisomerase-II 
inhibitors.9,27 Cytogenetic abnormalities are independent prognostic factors for both 
survival and progression to AML.13,28-30 Table 2 shows the cytogenetic abnormalities 
found in the studies of Greenberg 18 and Solé 30 and the impact on survival. 
In 1997 a new classification system for MDS has been proposed by the World Health 
Organization (WHO).31 This classification recognizes several limitations of the FAB 
classification. The importance of cytogenetic abnormalities in MDS reflects the definition 
of the 5q- syndrome as cases with de novo isolated del(5q), less than 5% marrow 
myeloblasts and the characteristic morphologic finding of hypolobulated megakaryocytes 
as a distinct entity.32 One of the major changes in the WHO classification compared to the 
FAB classification is lowering the blast percentage for the diagnosis of acute myeloid 
leukemia from 30% to 20%. Several studies have suggested that there is little difference 
between RAEBt and AML in terms of prognosis and response to chemotherapy.33,34 As a 
consequence RAEBt (refractory anemia with excess of blasts in transformation) has been 
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eliminated from the MDS classification. The new WHO classification distinguishes MDS 
with morphologic dysplasia restricted to the erythroid lineage (RA: refractory anemia) 
from MDS with multilineage dysplasia (RCMD: refractory cytopenia with multilineage 
dysplasia). A German study reported a better outcome of patients with dysplasia 
restricted to one cell lineage 35, but this observation was not confirmed by Nosslinger et 
al.36 Whether this finding is an independent prognostic factor for MDS remains unclear. 
The definition of chronic myelomonocytic leukemia (CMML) in the FAB is problematic. 
This definition is based primarily on the peripheral blood monocyte count with less 
consideration of the blast percentage in the bone marrow. Besides, many patients with 
CMML display both myeloproliferative and myelodysplastic features. The WHO 
classification removes CMML from MDS to a myeloproliferative-myelodysplastic overlap 
category.  
The new classification system has been criticized for several reasons: (1) Lowering the 
blast percentage for a diagnosis of AML to 20% in stead of 30% is arbitrary as well and 
introduces difficulties in comparing future AML/MDS studies with historical controls. (2) 
The definition of MDS as a clonal stem cell disorder based solely on dysplasia in the 
erythroid lineage is precarious. (3) The prognostic value of cytogenetic abnormalities is 
inconsistently incorporated in the classification. Clearly the optimal classification system 
for MDS and AML cannot be based on clinical features only, but also on data on gene 
expression patterns and other biologic parameters. Insight gained from the molecular 
analysis of MDS provides the basis for a more refined classification and future revisions 
of the WHO proposal will be necessary.  
The majority of MDS patients are older than 60 years. For these patients supportive care, 
including biologic response modifiers and low dose chemotherapy, is the mainstay of 
therapy.  
This review will discuss intensive treatment strategies, mainly used with the aim to cure 
young patients with MDS. Other treatment strategies, such as treatment with 
hematopoietic growth factors or low dose cytostatics and immune-modulation are not 
discussed in this review.  
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Table 2. Cytogenetic abnormalities and impact on prognosis. 
Source Greenberg et al.18 Solé et al.30 
Karyotype Frequency (%) Frequency (%) Median survival (yr.) 
No abnormalities 489 (60) 313 (49) 4.2 
    Single 203 (25) 190 (29) 2.1 
    Double          43   (5) 49   (8) 1.1 
    Complex 81 (10) 88 (14) 0.5 
Total 816 460  
Single abnormalities    
   del 5q 48 (6) 32 (5) 3.9 
   -7/del 7q 10 (1) 24 (4) 1.4 
   + 8 38 (5) 31 (5) 1.1 
   del 11q   6  (1) 5.4 
   del 12p  13 (2) > 6 
   del 20q 16 (2) 8 (1) 3.2 
   - X  6 (1) 1.1 
   - Y 17 (2) 8 (1) > 6 
Miscellaneous single 74 (9)   
 
 
 
ALLOGENEIC STEM CELL TRANSPLANTATION 
 
The primary curative option for patients with myelodysplastic syndromes is allogeneic 
stem cell transplantation (SCT). Disease-free survival (DFS) ranges from 29% to 40%, 
with corresponding treatment-related mortality (TRM) of 37% to 50% and rate of relapse 
ranging from 23% to 48% after transplantation with an HLA-identical sibling donor.37-45 
Alternative donors like genotypically non-identical related donors and voluntary unrelated 
donors have been used as well since only one-third of MDS patients have an HLA-
identical sibling. 
Risk factors having an impact on the outcome of transplantation include age, disease 
duration, disease stage at time of transplantation, percentage of blasts in the bone 
marrow, presence of cytogenetic abnormalities, source of stem cells, application of T-cell 
depletion of the graft, type of donor and pre-transplant conditioning.  
Anderson et al. analysed the outcome of 250 consecutive patients who underwent 
allogeneic transplantation in Seattle.44 Disease-free survival at 5-year was comparable for 
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patients with a matched related donor (N=147) and a partially matched or unrelated donor 
(N=103), namely 38% versus 39%. After partially matched or unrelated donor 
transplantation the advantage of a lower relapse risk (10% versus 24% for a matched 
related donor) is counterbalanced by a significantly higher non-relapse mortality (51% 
versus 39%). The European Group for Blood and Marrow Transplantation (EBMT) 
reported on 1378 patients, who received a transplant between 1983 and 1998.43 A total of 
885 patients were transplanted with an HLA-identical sibling. The 3-year actuarial 
probability of disease-free survival was 36%, overall survival 41%, treatment-related 
mortality 43% and relapse 36%. Age had a significant effect on outcome. The DFS was 
45% for patients aged less than 20 years, 37% for patients aged between 20-40 years, 
and 31% for patients older than 40 years at time of SCT. These significantly better results 
can be explained by a lower treatment-related mortality in younger patients. The EBMT 
analysis shows that the results of allogeneic SCT have improved over the years, due to a 
decrease in treatment-related mortality. A report from the International Bone Marrow 
Transplant Registry (IBMTR) on 452 recipients of HLA-identical transplants between 1989 
and 1997 showed a 3-year DFS of 40%, overall survival 42%, TRM 37% and relapse rate 
23%.45 In an attempt to lower the toxicity of the conditioning regimen Deeg et al. used 
busulfan at a targeted plasma concentration in combination with cyclophosphamide.46 
This approach resulted in a 3-year TRM of 28%, relapse rate 16% and DFS 56%. The 
majority of transplant centres consider allogeneic stem cell transplantation as a treatment 
option in patients aged less than 45 or 50 years, but the upper age limit for SCT gradually 
increased in recent years. A study from Seattle on 50 patients aged between 55 and 66 
years, who underwent allogeneic SCT, showed the feasibility of this treatment in fit 
elderly patients.47 Overall survival at 3-year was 46%, relapse-free survival 42%, TRM 
39% and relapse rate 19%.  
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Table 3. Allogeneic bone marrow transplantation for MDS and sAML. 
 
 
Source 
Number 
of 
patients 
Median 
age 
(years) 
Outcome 
calculated 
at N yr. 
DFS or 
EFS 
(%) 
 
Relapse 
(%) 
 
TRM 
(%) 
 HLA-identical sibling       
Anderson 1995 39 93 30 5 40 29 44 
Sutton 1996 40 71 37 7 32 48 39 
Runde 1998 42 131 33 5 34 39 44 
Nevill 1998 41 60 40 7 29 42 50 
Anderson 2000 44 147 38 5 38 24 39 
De Witte 2000 43 885 33 3 36 36 43 
Sierra 2002 45 452 38 3 40 23 37 
Deeg 2002 46 41 46 3 56 16 28 
Anderson 1997 53 a 46 42 5 24 31 44 
Yakoub-Agha 2000 55 a 70 37 2 28 42 49 
Witherspoon 2001 57 a 69 -- 5 11 32 58 
 Voluntary Unrelated Donor       
Anderson 1996 70 52 33 2 38 28 48 
Arnold 1998 71  118 24 2 28 35 58 
Anderson 2000 44 103 38 5 39 10 51 
De Witte 2000 43  198 -- 3 25 41 58 
Deeg 2002 46 64 46 3 59 11 30 
Witherspoon 2001 57 a 41 -- 5 24 32 44 
Castro-Malaspina 2002 73  510 38 2 29 14 54 
 Reduced Intensity Conditioning     
Martino 2002 63 37 57 1 66 28 5 
Ho 2004 67   24 56 1 61  5 
Ho 2004 67 (VUD) 38 52 1 59  21 
 a: Transplantation for therapy related MDS and AML (tMDS/tAML) 
41: Including 22 unrelated donors 
46: Age 46 years overall 
53: Including 17 tAML and 29 sAML patients 
55: Including 8 unrelated donors, 3 mismatched related donors 
44: Age 38 years overall, 70 unrelated donors, 33 non-identical family donors  
63: Including 17 AML patients 
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Disease stage 
Patients with less advanced stages of MDS such as RA and RARS may profit optimally 
from allogeneic stem cell transplantation with a myeloablative regimen, with long-term 
disease-free survival in more than 50% of patients,48,49 owing largely to the substantially 
lower relapse rate compared to patients with more advanced disease.43,49 Older age and 
longer disease duration before transplantation are associated with an increased risk of 
death after transplantation.49 Therefore, the intention should be to transplant these 
patients early in the course of the disease before sensitisation due to transfusions and 
before development of iron overload and opportunistic infections. Transplantation may be 
postponed in selected patients without life-threatening cytopenias and cytogenetic 
abnormalities.  
Data on allogeneic stem cell transplantation in CMML patients are limited.37,50,51 
Prognostic modelling shows that marrow infiltration with more than 5% monoblasts, a 
neutrophil count of more than 16 x 109/l and/or a monocyte count of more than 2.6 x 109/l 
are associated with an unfavourable prognosis and therefore patients with these features 
should be considered for allogeneic transplantation. In an analysis of 50 CMML patients 
reported to the EBMT registry, the estimated 2-year DFS was 18% with a relapse risk of 
42%.51 
The outcome after stem cell transplantation in patients with RAEB and RAEBt is less 
favourable than the outcome in patients with RA(RS), due largely to a higher risk of 
relapse. The European Group for Blood en Marrow Transplantation (EBMT) reported a 5-
year actuarial relapse-rate of 44% and 52% in 35 RAEB patients and 28 RAEBt patients, 
who underwent allogeneic transplantation without prior remission induction 
chemotherapy.42 The Fred Hutchinson Cancer Research Center (FHCRC) reported on a 
group of 93 MDS patients.39 The 5-year actuarial disease-free survival, relapse and non-
relapse mortality rates were 40%, 29% and 44% respectively. For the 47 patients with 
excess of blasts the relapse rate was 49% versus 4% for the 40 patients without excess 
of blasts, with actuarial disease-free survival of 31% versus 54%, respectively. The EBMT 
published the long-term results of 1378 patients transplanted for MDS.43 A total of 885 
patients were transplanted with an HLA-identical sibling. Both age and disease stage had 
independent prognostic significance for all three end-points.  
In patients with secondary AML after MDS, most European transplant centres have 
adopted the strategy of stem cell transplantation after remission-induction chemotherapy, 
based on the high failure rate of transplantation in patients with active leukemia.40,52,53 
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Sutton et al. transplanted 11 patients with overt AML at time of transplantation. 
Treatment-related mortality was 60%, all patients relapsed and there were no long-term 
survivors.40 The EBMT reported a 2-year disease-free survival of 18% in 13 untreated 
sAML patients in contrast with a 60% DFS in 16 patients transplanted in first CR.52 In a 
report from Seattle on 46 patients with sAML (29 patients) and tAML (17 patients) who 
underwent transplantation as front line treatment the 5-years actuarial DFS, relapse rate 
and non-relapse mortality were 24%, 31% and 44% respectively.53 A higher blast 
percentage before transplantation was associated with a significantly higher incidence of 
relapse. Younger age and shorter time from diagnosis to transplantation were associated 
with decreased non-relapse mortality. The results of these 46 previously untreated 
patients have been compared with a group of 20 patients (8 sAML, 12 tAML) who 
received induction chemotherapy before transplantation. There were no statistically 
significant differences in outcome for the patients who received induction chemotherapy 
before transplantation compared to the patients who did not. However, these results 
should be interpreted with caution since the decision to use chemotherapy before 
transplantation was made by the treating physician before referring patients to the 
transplant centre.  
Whether patients with advanced stages of MDS or sAML benefit from chemotherapy prior 
to transplantation is still unresolved. The superior outcome of patients with a lower blasts 
percentage supports the use of chemotherapy to lower the disease burden before 
transplantation. Only prospective randomised studies analysed based on an intention-to-
treat principle may circimvent the selection biases associated with retrospective analyses. 
This issue is addressed in a recently launched EBMT study. 
 
Cytogenetic abnormalities 
Cytogenetic abnormalities have a major influence on the outcome after stem cell 
transplantation. A French study reported a 7-year relapse rate of 83% in patients with 
complex anomalies.40 Nevill et al. categorized patients according to the cytogenetic risk 
categories proposed by the IPSS.18 Event-free survival for the entire group was 29%. 
Event-free survival for the poor-risk, intermediate-risk en good-risk groups were 6%, 40% 
and 51%, respectively, with actuarial risk of relapse 82%, 12% and 19%, respectively.41   
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Therapy-related MDS/AML 
Ballen et al. treated 18 patients with therapy-related MDS/AML and 25 patients with 
primary MDS.54 DFS and relapse rate were 43% and 8% for primary MDS and 24% and 
22% for therapy-related MDS. These differences did not reach statistical significance. The 
EBMT analysis reported 67 patients who underwent allogeneic stem cell transplantation 
for therapy-related MDS and AML.43 The 3-year DFS of 35% and relapse rate of 36% 
were identical to the outcome of patients with primary MDS. A French report involving 70 
patients with therapy-related MDS and AML included 34% of patients in complete 
remission at the time of transplantation.55 Two-year event-free survival, relapse and TRM 
rates were 28%, 42% and 49%, respectively. Only five of the 46 patients with active 
disease at the time of transplantation were long-term survivors. A large study from Seattle 
reported on 99 patients (47 tMDS, 52 tAML). Sixty-five patients received marrow from a 
family member and 34 received marrow from an unrelated donor. The probability of 
survival, relapse and non-relapse mortality was 13%, 47% and 78%, respectively. Non-
relapse mortality was a significant impediment to survival: death from infection occurred 
in 27% and death from organ failure in 24% of patients.56 In a later report a conditioning 
regimen with cyclophosphamide (CY) and targeted dose busulfan (BU) predicted for a 
better DFS. The 5-year DFS for the entire group was 16% versus 30% for a regimen with 
targeted BU/CY. The incidence of relapse was strongly affected by the stage of the 
disease at transplantation. In 12 patients with RA and RARS no relapses were observed. 
This finding argues for transplantation early in the disease evolution.57      
 
T-cell depletion 
Mattijssen et al. showed in a single centre study a 39% DFS at 2 years after 
transplantation with T-cell depleted grafts from HLA-identical siblings using elutriation in 
35 patients. In 11 RA patients DFS was 73%, similar to the results for comparable 
patients receiving non-T-cell depleted grafts.58 However the risk of GVHD is lower after T-
cell depletion, which may reduce long-term morbidity and mortality. An EBMT analysis 
showed no differences in survival and DFS after T-cell depletion, but an increased risk of 
relapse was reported with a hazard ratio of 6.30.42 
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Bone marrow stem cells versus peripheral blood stem cells 
In the setting of autologous transplantation peripheral blood stem cells have largely 
replaced bone marrow stem cells because of more rapid hematological repopulation and 
lower requirements for supportive therapy. Also, after allogeneic stem cell transplantation 
the use of peripheral blood stem cells resulted in a faster hematopoietic recovery in a 
prospective study.59 In an EBMT survey in 234 MDS patients comparing marrow and G-
CSF mobilized peripheral blood stem cells (PBSC) the use of PBSC reduced the median 
duration of neutropenia and thrombocytopenia by 4 and 12 days, respectively.60 A lower 
treatment failure incidence (relapsed disease and refractory disease) was found when 
PBSC were used as stem cell source (38% versus 13%). There was a trend towards 
more chronic Graft-versus-host-disease (GVHD) among patients who received PBSC in 
univariate analysis, but the use of PBSC was not significantly associated with an 
increased risk for chronic GVHD in multivariate analysis. The treatment-related mortality 
was reduced with PBSC except for patients with RA and patients with high-risk 
cytogenetic abnormalities. The low treatment failure observed with PBSC in more 
advanced stages of MDS suggests that a graft-versus-MDS effect exists and that it could 
be enhanced by the use of G-SCF mobilized PBSC. The Spanish registry compared the 
outcome of 45 patients receiving bone marrow stem cells with 36 patients receiving 
peripheral blood stem cells.61 Patients who received PBSC displayed a faster engraftment 
and showed a significantly reduced TRM at day 100 (14% versus 42%). In high-risk MDS 
(RAEB, RAEBt) overall survival and event-free survival appeared significantly longer after 
the use of PBSC. 
 
Reduced Intensity Conditioning (RIC) 
The principle idea of reduced intensity conditioning regimen is to minimize toxicity 
associated with conventional myeloablative regimens and to harness the graft-versus-
MDS effect of the infused donor lymphocytes. The RIC regimens largely depend upon 
intensive immune suppression either during conditioning and/or after stem cell infusion in 
order to facilitate donor engraftment and to establish complete donor chimerism. 
Reduced intensity conditioning regimens have been tested in view of the high treatment-
related mortality in older patients after conventional marrow ablative conditioning 
regimens. RIC regimens might also be of interest in patients with high blast counts 
particularly, if debulking with chemotherapy before transplantation is successful. Kröger 
et al. reported 37 patients with MDS or secondary AML, half of whom had a related 
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donor, who were ineligible for conventionally conditioned transplants.62 The reduced 
intensity conditioning consisted of fludarabine, busulphan and antithymocyt globulin. 
Overall TRM was 27%, with significantly higher mortality in those with poor risk 
cytogenetics (75% versus 29%) or with an HLA-matched unrelated donor (45% versus 
12%). In total, 32% of patients relapsed, and actuarial DFS at 3 years was 38% with a 
median follow-up of 20 months. A Spanish study showed a TRM of only 5% after 
transplantation of 37 patients with MDS and AML utilizing a regimen based on fludarabine 
and busulfan.63 The 1-year progression-free survival was 66%. The incidence of grade II-
IV acute GVHD was 19% and the 1-year incidence of chronic extensive GVHD was 46%. 
In multivariate analysis including GVHD, achievement of complete donor chimerism within 
100 days and disease phase, only GVHD showed a protective effect on disease 
progression. The estimated DFS in patients with GVHD was 58% compared with 13% for 
those without GVHD. These results support the notion that a graft-versus-MDS/AML 
response is critical in reducing the risk of relapse after an RIC transplant. Parker et al. 
compared outcome of 23 MDS patients conditioned with reduced-intensity regimen 
consisting of fludarabine, busulfan and alemtuzimab (Campath-1H) with 29 patients 
treated with a myeloablative regimen.64 The patients treated with RIC were considered 
ineligible for standard conditioning due to age (median 48 year) and co-morbidity. 
Contrary to the findings of Martino et al., acute and chronic GVHD appeared low after 
reduced intensity regimen (17% and 15%), due to the adding of Campath-1H. The 2-year 
DFS rates were 39% after RIC and 44% after standard conditioning with a reported TRM 
of 31% and 50%, respectively. Stuart et al. described the results of 91 patients with a 
diagnosis of MDS (77 patients) or MPD (myeloproliferative disorder) (14 patients) who 
were conditioned with fludarabine and a single fraction of total body irradiation (2 Gy) 
followed by infusion of stem cells from an HLA-matched related (N=49) or unrelated 
(N=42) donor.65 Patients with low risk MDS (RA, RARS, RAEB) at the time of transplant 
(N=33) had an 18 month relapse rate of 32% ± 18%, resulting in overall survival rates at 
18 months of 40% ± 18%. This relatively high relapse risk is in line with the observations 
of a recent EBMT study. The EBMT analysis showed a low TRM (16%), but a 54% 
relapse risk for the 24 patients transplanted with RIC protocols.66  
The King’s College Hospital group from London reported more favourable results 
following conditioning with fludarabine, busulphan and Campath-1H in 62 patients with 
MDS (24 matched sibling donors and 38 unrelated donors).67 One-year DFS was 61% 
and 59% in patients transplanted with sibling and unrelated donors, respectively. 
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Nevertheless, no long-term surviving patients were observed in patients with progressive 
disease. The favourable results may be explained by the low estimated 1-year treatment-
related mortality of 15% (5% sibling, 21% VUD), the relatively high number of patients 
transplanted with less than 5% marrow blasts at the time of transplant conditioning (> 
75% of the patients), the high number of patients who received donor lymphocyte 
infusions (67% of sibling recipients and 26% of VUD recipients) and the relatively short 
period of follow-up. Late events occur often after RIC and survival curves do not begin to 
plateau until after day 200, with a suggestion that the curves may merge after 3 to 4 
years.68  
 
Transplantation with alternative donors 
Through lack of HLA-identical family donors in the majority of young MDS patients, 
alternative donor sources have been used. Demuynck et al. treated 8 out of 24 patients 
with alternative donors (five HLA non-identical family donors and three unrelated 
donors).69 There was only one long-term survivor after alternative donor transplantation. 
Infections and graft-versus-host disease were the main causes of death. Despite T-cell 
depletion severe acute GVHD > grade 2 was noticed in 6 out of 8 patients. Among 
patients with MDS treated in Seattle with an unrelated donor following myeloablative 
conditioning, 2-year disease-free survival was 38%, with a relapse rate of 28%, and non-
relapse mortality of 48%.70 Both older age and longer disease duration were associated 
with a greater risk of death from non-relapse causes. The EBMT collected data on 118 
patients treated with an unrelated donor.71 Disease-free survival at 2 years, relapse risk 
and transplant-related mortality were 28%, 35% and 58% respectively. The transplant-
related mortality was significantly influenced by age (younger than 18 years: 40%; 18-35 
years: 61%; older than 35 years: 81%). Patients with more severe acute graft-versus-host 
disease experienced a lower relapse risk, suggesting an increased graft-versus-MDS 
effect in these patients. A later EBMT survey reported 198 patients, who underwent 
voluntary unrelated donor (VUD) transplantation. The reported DFS, survival, relapse rate 
and TRM at 3 year were 25%, 26%, 41% and 58% respectively.43 This analysis also 
showed data of 91 patients transplanted with stem cells from a genotypically non-identical 
related donor. The 3-year DFS, survival and relapse rate were 28%, 31% and 18% 
respectively. Noteworthy the treatment related mortality was 66%, higher than in any 
other type of transplantation. De Witte et al. compared outcome of 58 patients 
transplanted with mismatched family donors and 78 patients transplanted with unrelated 
donors, matched for stage of disease and age at transplantation.72 The 3-year DFS, 
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relapse risk and TRM after mismatch family transplantation were 23%, 18%, and 72% 
versus 28%, 29% and 61% after unrelated donor transplantation. The American National 
Marrow Donor Program (NMDP) presented data on 510 patients receiving a transplant 
from an unrelated donor.73 The incidence of relapse at 2 years was 14%. A higher relapse 
rate was associated with advanced MDS and no GVHD. The 2-year DFS was 29% and 
TRM 54%. Improved DFS was associated with less advanced MDS, higher cell dose, 
recipient CMV seronegativity, shorter interval from diagnosis to transplantation and 
transplantation in recent years. 
Table 3 shows a summary of studies published in the past years on allogeneic BMT for 
MDS and sAML. 
 
INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS TRANSPLANTATION 
 
For those patients lacking a suitable donor, intensive chemotherapy with AML-like 
schedules may be an alternative approach. Complete remission rates have improved in 
recent years, ranging between 15% and 65%.34,74-78 Remission duration, however, is brief 
due to the high rate of relapse. Karyotype is the most important prognostic factor 
influencing disease-free survival with a median of 16.5 months for patients with a normal 
karyotype compared to 4 months in those with an abnormal karyotype.76 In 1995 the 
Leukemia Cooperative Group of the European Organisation for the Research and 
Treatment of Cancer (EORTC) reported results of the first prospective multicenter study 
using cytarabine and idarubicin as remission-induction treatment in patients with high-risk 
MDS and sAML.77 There was no difference in remission rates between patients with MDS 
(50%) and sAML patients (63%). Again the outcome of patients without cytogenetic 
abnormalities was better than the outcome of patients with an abnormal karyotype. In an 
analysis of 158 patients with high-risk RAEB and RAEBt and 372 AML patients treated at 
the MD Anderson Cancer Center, remission rates were comparable for RAEB, RAEBt 
and AML, but event-free survival and overall survival were inferior in RAEB compared to 
AML or RAEBt.34 Multivariate analysis indicated that the poorer outcome was due to the 
association between RAEB and poor prognostic features particularly complex cytogenetic 
abnormalities rather than to the diagnosis itself. A recent study investigated the value of 
fludarabine in addition to cytarabine and G-CSF in 91 MDS and 43 AML patients.79 
Combining cytarabine and fludarabine did not improve overall survival (39% FLAG vs. 
24% AG) and DFS (23% FLAG vs. 16% AG). 
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Several studies combined chemotherapy with hematopoietic growth factors in an attempt 
to improve the outcome.80,81 The reason for this approach is a reduction of the hypoplastic 
period and sensitising of the malignant cells for chemotherapy by recruiting these cells 
into the cell cycle. In an Italian study on 105 MDS and sAML patients, the CR rate was 
not affected by the use of G-CSF (33% versus 43%). Also, the use of G-CSF did not 
prolong remission duration and survival.80 The HOVON cooperative group reported a 
73% response rate for patients assigned to the G-CSF arm compared to 52% in the 
standard arm (p=0.08). The neutrophil recovery was significantly shorter after the use of 
G-CSF and this resulted in a reduced interval of 9 days between the induction and 
consolidation course.81 Again no differences in overall survival and DFS were observed. 
Wattel et al. studied the use of quinine as multidrug resistance (mdr) modulator.82 In a 
subgroup of 42 P- glycoprotein (Pgp) positive patients both CR rate and median survival 
were higher in patients receiving quinine. 
In view of the high relapse rate after chemotherapy only, transplantation with autologous 
stem cells has been applied in an attempt to intensify the post-remission therapy. In a 
French study 7 patients with sAML received an autograft in CR after remission-induction 
chemotherapy.83 One patient died before engraftment, for the other patients the median 
time to engraftment for the white blood cells was 41 days, in two patients engraftment for 
platelets did not occur, in the five other patients median time to engraftment was 120 
days. In 1997 the European Group for Blood and Marrow Transplantation (EBMT) 
reported the results of 79 patients autografted for MDS and sAML in first complete 
remission.84 Two-year survival, disease-free survival and relapse rate were 39%, 34% 
and 64%, respectively. Patients younger than 40 years showed a significantly better DFS 
(39%) than patients older than 40 years (25%). A cohort of 55 patients was compared 
with a matched control group of 110 patients with de novo AML. The MDS/sAML cohort 
showed a lower DFS (28%) when compared with de novo AML patients (51%), due to a 
higher relapse rate. The treatment-related mortality rate was less than 10%. In 1999 the 
first prospective study on autologous stem cell transplantation in myelodysplastic 
syndromes was published.85 A complete remission was attained in 42/83 patients (51%). 
In 24 out of 39 patients (62%) transplantation with autologous bone marrow cells (ABMT: 
16 patients) or autologous peripheral stem cells (APSCT: 8 patients) was performed. 
Hematological reconstitution occurred in all autografted patients. However, this study, 
perhaps given its size limitation, did not confirm a faster hemopoietic recovery for 
peripheral blood stem cells compared to bone marrow cells, as has been demonstrated in 
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primary AML.86 The median DFS of the autografted patients was 29 months from 
transplantation. A multicenter study of the EORTC, EBMT, SAKK and GIMEMA included 
197 patients with high-risk MDS and sAML.87 The CR rate after remission-induction 
chemotherapy was 54%. Both allogeneic and autologous stem cell transplantation were 
employed as post-consolidation treatment, depending on the donor availability. The 
overall survival and DFS at 4-years were 26% and 29% respectively. Sixty-one percent of 
the patients without a donor (36/59) received an autologous stem cell transplantation in 
first CR and 72% of the patients with a donor (28/39) were allografted in first CR. The 
EBMT report included 173 patients, who underwent autologous transplantation.43 
Outcome of patients transplanted in first complete remission (N=126) was significantly 
better than outcome of patients transplanted in more advanced disease stage (N=47). In 
CR-1 the reported 3-year OS, DFS, TRM and relapse rate were 38%, 33%, 25%, and 
55% versus 14%, 18%, 51%, and 64% after no CR-1.  
The results of several studies employing intensive chemotherapy with or without stem cell 
transplantation are summarised in Table 4. 
 
Stem cell mobilization 
Since MDS is a clonal stem cell disorder, there remains concern regarding contamination 
of the graft by residual malignant cells and regarding the presence of sufficient residual 
normal stem cells to support rapid reconstitution. However, several studies reported that 
patients with an abnormal karyotype can achieve a cytogenetic remission if a 
morphological remission is reached after chemotherapy.   
Delforge et al. demonstrated that polyclonal immature hematopoietic progenitors can be 
mobilized and harvested in patients with high-risk MDS after treatment with intensive 
chemotherapy.88 Clonality analysis was performed in females heterozygous for the X-
linked human androgen-receptor (HUMARA) gene, demonstrating a polyclonal pattern in 
the CD34+ cell population in 4 of 5 patients. 
In a separate report involving 11 patients in CR after chemotherapy, stem cell 
mobilization was attempted either with G-CSF alone or with G-CSF after recovery from 
the consolidation course. In 7/11 patients sufficient cell numbers were harvested resulting 
in a CD 34 progenitor cell yield > 1 x 106/kg.89 Carella et al. were able to collect normal 
progenitor cells in 6/9 patients who presented with an abnormal karyotype.90 In our own 
experience stem cell mobilization was feasible in about 50% of patients in the recovery 
phase after chemotherapy with G-CSF.91 
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Table 4. Intensive chemotherapy with or without autologous SCT in MDS and sAML. 
 
Source 
Number 
of 
patients 
Median 
age 
(years) 
Induction 
chemotherapy
CR 
(%) 
Number of 
patients 
transplanted 
Outcome 
Fenaux 1991 76 MDS 31 
sAML 16   
54 Z + A 47 -- DFS: 11 mo     
OS:   14 mo 
De Witte 1995 77 MDS 34  
sAML 16 
46 I + A 54 -- DFS: 11 mo     
OS:   15 mo 
Parker 1997 78 MDS 13     
sAML 3 
44 I + A + F  
+ G-CSF 
63 6a  
Estey 1997 34 MDS 158 60 I + A or F + A  
± G-CSF 
65 -- DFS: 5-12 mo 
(RAEB/RAEBt) 
Ossenkoppele 
1999 81 
MDS 64 62 D + A  
± G-CSF 
63 -- OS: 29-16% 
Ossenkoppele 
2004 79 
MDS 91 
AML 43 
65 / 69 A + G-CSF ± F 68 -- DFS: 23-16% 
OS:   39-24% 
De Witte 1997 84 b MDS 19 
sAML 60 
39  -- 79 DFS:     34%        
OS:       39%   
relapse: 64% 
Wattel 1999 85 MDS 37 
sAML 46 
45 M + A ± Q  51 24 DFS: 29 mo     
OS:   33 moc 
De Witte 2001 87 MDS 138 
sAML 46 
47 I + A + E 54 36 auto CR-1 
28 allo CR-1 
DFS: 29% 
OS:   26% 
A = cytarabine, Z = zorubicine, I = idarubicin, F = fludarabine, D = daunomycin, M = mitoxantrone,  
Q = quinine, E = etoposide 
a: 3 allogeneic BMT, 3 autologous stem cell transplantation 
b: Report on 79 patients transplanted in first CR 
c: Calculated from transplantation 
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CONCLUSIONS 
 
Allogeneic stem cell transplantation is the treatment of choice for the majority of young 
patients with MDS or sAML who have an HLA-identical sibling donor. Overall, 
approximately 40% of patients are likely to be cured with allogeneic stem cell 
transplantation. Long-term disease-free survival can be attained if transplantation is 
performed early in the disease course. An increased blast percentage and poor 
prognostic cytogenetic features are associated with an increased risk of relapse and, 
thereby, shorter disease-free survival. Longer disease duration, advanced patient age, 
therapy-related MDS, and the use of alternative donors are associated with increased 
non-relapse mortality. 
Since outcome of transplantation is superior for patients with a low blast percentage, this 
supports the use of chemotherapy prior to transplantation in patients with high blast 
marrow infiltration. The issue whether patients with a blast percentage over 5% may 
benefit from remission-induction chemotherapy prior to transplantation, is addressed in a 
recently launched EBMT study.  
Outcome after transplantation remains worse for patients with MDS than for those with de 
novo AML, mainly due to a higher transplant-related mortality and a higher relapse rate. 
Therefore, subsequent studies should focus on optimising pre-treatment schedules, 
conditioning regimens and post-transplant immune-modulation. Immunotherapy with 
donor lymphocyte infusions has been reported in cases of relapse after allogeneic stem 
cell transplantation.92-94  
Application of RIC regimen approach is a logical consequence of these principles. RIC 
regimens allow allogeneic transplantation in recipients of older age or with co-morbidity, a 
frequent reality in the treatment of patients with MDS. In addition, the RIC approach is 
attractive since it allows optimal utilization of post-transplant immune-modulations with 
donor lymphocyte transfusions. However, the place of RIC regimens remains to be 
determined since the results of conventional, bone marrow ablative regimens have 
improved in recent years. Prospective, randomised studies are necessary to elucidate the 
contribution of RIC regimens to the treatment of MDS patients. 
For patients lacking an HLA-identical sibling the choice is ambiguous. Although the 
reports on autologous stem cell transplantation are still limited, the disease-free survival 
after autologous transplantation seems comparable with disease-free survival after 
allogeneic stem cell transplantation with genotypically non-identical related donors and 
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voluntary unrelated donors. The high incidence of relapse in autologous transplantation is 
counterbalanced by the high TRM in alternative donor transplantation. A prerequisite for 
autologous transplantation is that patients enter complete remission before 
transplantation and that sufficient numbers of stem cells can be harvested. Autologous 
transplantation is a valid option for a patient who fulfils these criteria. For patients who fail 
to enter complete remission allogeneic stem cell transplantation with a genotypically non-
identical related donors or a voluntary unrelated alternative donor may constitute an 
alternative treatment option.  
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ABSTRACT 
 
High-risk MDS patients are candidates for several treatment strategies, including 
matched family donor stem cell transplantation (SCT), alternative donor SCT, autologous 
SCT, high-dose chemotherapy and/or supportive care. The purpose of the present 
analysis was to assess prospectively the value of different treatment strategies. In all, 11 
European centres have registered 248 patients, who were untreated at time of HLA-
typing. A matched family donor was identified in 52% of patients. The 3-year survival 
rates were 46% and 43% for patients with and without a donor. Seventy-eight percent of 
patients with a donor received the intended allogeneic stem cell transplantation (SCT). In 
patients without a donor a lower percentage received the intended treatment; 46% 
underwent the intended alternative donor SCT, 50% autologous SCT, 67% high-dose 
chemotherapy and 97% supportive care. In multivariate analysis age, chromosomal 
abnormalities and RA(RS) FAB subtype appeared prognostic for survival, while intended 
treatment was not prognostic for survival. On intention-to-treat basis the estimated 3-year 
survival was 48% for immediate allogeneic SCT, 34% for allogeneic SCT after remission-
induction chemotherapy, 37% for alternative donor SCT, 36% for autologous SCT, and 
35% for patients intended for chemotherapy only. This analysis confirms that alternative 
donor SCT, autologous SCT and high-dose chemotherapy may provide an alternative 
therapy for patients lacking a matched family donor.  
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INTRODUCTION 
 
Myelodysplastic syndromes (MDS) form a heterogeneous group of clonal stem cell 
disorders. In 1982 the FAB classification proposed five subgroups based on the 
percentage of blast cells in blood and bone marrow, the percentage of ringed sideroblasts 
and monocytes: RA (Refractory anemia), RARS (Refractory anemia with ringed 
sideroblasts), RAEB (Refractory anemia with excess of blasts), RAEBt (Refractory 
anemia with excess of blasts in transformation) and CMML (Chronic myelomonocytic 
leukemia).1 In 1997 the World Health Organization (WHO) proposed a re-classification of 
MDS.2 One of the major changes between the WHO and FAB classification is the 
distinction between single lineage versus multilineage dysplasia (RA(RS) versus RCMD 
(Refractory cytopenias with multilineage dysplasia). Furthermore, the WHO classification 
lowered the threshold value to 20% blasts in the bone marrow to define AML instead of 
30% in the FAB classification. As a consequence RAEBt has been eliminated from the 
WHO classification. Another important difference is the removal of CMML from MDS to a 
myeloproliferative-myelodysplastic overlap category. 
The natural course of MDS is variable. RA and RARS are defined as less advanced 
MDS. These patients have a low risk of developing acute myeloid leukemia and their 
median survival is over 30 months.3 Most patients die due to bone marrow failure or due 
to iron overload as a result of repeated blood transfusions. Advanced MDS is defined as 
RAEB, RAEBt and CMML. Median survival of patients presenting with RAEB and RAEBt 
is generally shorter than 12 months.4 However, the prognosis of patients within the 
different FAB categories varies and RA(RS) patients with severe cytopenias and poor 
prognostic cytogenetic features have a poor outcome despite a low blast percentage in 
the bone marrow. Therefore, multiple scoring systems have been proposed to predict the 
natural history of an individual patient. At present, the most widely accepted scoring 
system is the IPSS (International Prognostic Scoring System).5 The IPSS analysed data 
of 816 patients with de novo MDS, who received supportive care. Four categories are 
distinguished based on the percentage of blasts in the bone marrow, the number of 
cytopenias and the presence of cytogenetic abnormalities (Low, Intermediate-1, 
Intermediate-2 and High risk). 
For elderly patients supportive care is the mainstay of treatment. Also, growth factors, 
hypomethylating agents and anti-apoptosis approaches are investigated currently, but 
these strategies do not intend to cure MDS patients.6-8 The primary curative option for 
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myelodysplastic syndromes is allogeneic stem cell transplantation (SCT). This treatment 
is only available for younger MDS patients (aged less than 50-60 years) with an HLA-
identical sibling donor. Disease-free survival ranges from 29-41%, relapse rate from 28-
52% and non-relapse mortality from 39-50%.9-11 For patients lacking an HLA-identical 
donor intensive chemotherapy regimens with or without autologous stem cell 
transplantation may be an alternative approach.12-17 After autologous transplantation in 
first complete remission the 2-year survival, disease-free survival, and relapse rates were 
39%, 34%, and 64%, respectively.13  
However, the superior results after allogeneic stem cell transplantation may be due to 
selection of patients fit enough to undergo SCT and exclusion of patients with an early 
relapse. The value of SCT compared to intensive chemotherapy only or chemotherapy 
followed by autologous stem cell transplantation has never been defined. Randomisation, 
the classical approach to test the value of different treatment strategies is not feasible. An 
alternative approach is registration at a fixed point in time; the time of HLA-typing of 
patient and siblings. In 1992 the CLWP (Chronic Leukemia Working Party) of the EBMT 
(European Group for Blood and Marrow Transplantation) asked centres to participate in a 
prospective registration study. The principal aim was to make an assessment of the value 
of SCT compared to other therapeutic modalities. A second question was whether 
patients with more than 5% blasts in the bone marrow benefit from remission-induction 
therapy prior to transplantation. 
 
PATIENTS AND METHODS 
 
Between April 1992 and October 1995 88 patients have been registered prospectively in 
the study at time of HLA family typing or at time of referral to a transplant centre. 
Information was collected on age, sex, FAB classification, cytogenetics, date of primary 
diagnosis, date of HLA-typing and disease status at time of HLA-typing. The physicians 
were asked to give the intention-to-treat depending on the outcome of the donor search 
at time of registration. In case of an available HLA-identical sibling donor the possibilities 
were immediate SCT (without preceding chemotherapy), SCT after chemotherapy or SCT 
at progression of disease. In case no donor was available, the options were search for an 
alternative donor, intensive chemotherapy only, chemotherapy followed by autologous 
stem cell transplantation or supportive care. The registration forms were collected 
centrally before outcome was known. Data about results of HLA-typing, disease stage at 
                                                                                      OUTCOME OF PATIENTS FROM HLA-TYPING 
43 
typing, applied treatment, current disease status, survival status and causes of death 
were collected between 1996 and 1998. Six patients were excluded from the analysis for 
the following reasons: no HLA-typing performed (N=1), and no diagnosis of MDS (N=5). 
In 13 patients no follow-up data could be collected. Consequently, 69 out of 88 patients 
were prospectively included. 
Since the number of registered patients was not sufficient for statistical analyses, the 
HLA-typing laboratories were asked to provide the investigators a list of all MDS patients, 
who had HLA family typing in their centre after 1992. So, retrospectively another 227 
patients have been registered (23 of these patients were typed between 1985 and 1991). 
The physicians were asked to give the intention-to-treat according to the policy of the 
centre depending on the availability of a donor. Data of these patients were collected 
between 2000 and 2002. In all, 11 European centres have registered 296 patients.  
 
Definitions 
The classification of MDS was performed according to the criteria of the French-
American-British (FAB) working group. AML that developed after pre-existing MDS was 
defined as secondary AML (sAML). 
 
Statistical analysis 
The duration of survival was calculated from the date of HLA-typing until death, whatever 
the cause. Actuarial curves were calculated according to the Kaplan-Meier technique. 
The differences between curves were tested statistically using the two-tailed log-rank test 
(Breslow). For ordered variables, the log-rank test for linear trend was used. The 
prognostic value of covariables was studied by Cox’s regression. 
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RESULTS 
 
In all, data on 296 patients have been collected. Out of 296 patients, 248 patients were 
untreated at time of HLA typing. Seventeen patients were typed in first CR, 22 patients 
with refractory disease and 9 patients were typed in more advanced disease. Since our 
purpose was to avoid selection as much as possible, we focussed on the 248 patients 
who underwent HLA-typing before administration of any treatment. Patients with an HLA-
identical donor, a syngeneic donor and a phenotypical identical family donor were 
classified in the matched family donor group (N=130), all other patients in the group 
without a matched family donor (N=118). Patients were treated according to local 
protocols. Patients with and without a matched family donor did not differ regarding age, 
sex, sub-classification at HLA typing and cytogenetics. Clinical characteristics are given in 
table 1. 
 
Table 1. Characteristics of patients according to donor availability (N=248). 
 All patients 
 
N=248 (%) 
Matched 
family donor 
N=130 (%) 
No matched 
family donor 
N=118 (%) 
 
 
P-valuea 
Age at HLA-typing (yr.) 
    < 20 
  20-40 
    > 40 
 
 36 (15) 
105 (42) 
106 (43) 
 
15 (12) 
51 (39) 
64 (49) 
 
21 (18) 
54 (46) 
42 (36) 
 
0.08 
Male 
Female 
130 (52) 
118 (48) 
66 (51) 
64 (49) 
64 (54) 
54 (46) 
0.59 
Sub-classification at HLA typing 
  RA(RS) 
  RAEB 
  RAEBt 
  CMML 
  sAML 
  Unclassified 
 
78 (31) 
72 (29) 
64 (26) 
     17  (7) 
     16  (7) 
       1 
 
45 (35) 
37 (28) 
36 (28) 
      4  (3) 
      8  (6) 
 
 
33 (28) 
35 (30) 
28 (24) 
13 (11) 
     8  (7) 
       1 
 
0.23 
Prospective study 
Retrospective 
64 (26) 
   184 (74) 
36 (28) 
94 (72) 
28 (24) 
90 (76) 
0.48 
Cytogenetics 
  Normal  
  Abnormal 
 
104 (42) 
  88 (35) 
 
53 (41) 
47 (36) 
 
51 (43) 
41 (35) 
 
0.93 
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  Not done/failed/unknown 56 (23) 30 (23) 26 (22) 
Sub-classification at SCT 
  RA(RS) 
  RAEB 
  RAEBt 
  CMML 
  sAML 
  No transplantation 
 
36 (15) 
28 (11) 
38 (15) 
      9  (4) 
34 (14) 
   103 (42) 
 
31 (24) 
20 (15) 
25 (19) 
      3  (2) 
22 (18) 
29 (22) 
 
5  (4) 
8  (7) 
13 (11) 
6  (5) 
12 (10) 
74 (63) 
 
< 0.0001 
Applied treatment 
  Chemotherapy only 
  Autologous SCT  
  Allogeneic SCT 
  Supportive care  
 
42 (17) 
13  (5) 
    132 (53) 
  61 (25) 
 
13 (10) 
 
101 (78) 
16 (12) 
 
29 (25) 
13 (11) 
31 (26) 
45 (38) 
 
< 0.0001 
Allogeneic transplantation  
  Matched family donor 
  Mismatched family donor 
  Unrelated donor 
 
    101 (77) 
12   (9) 
19 (14) 
 
    101 
 
 
 
 
     12 
     19 
 
< 0.0001 
 
 
Stage at transplantation 
  Direct transplantation 
  CR-1 
  Refractory disease 
  More advanced disease 
  No transplantation 
 
69 (28) 
56 (22) 
12  (5) 
  8  (3) 
103 (42) 
  
54 (42) 
39 (30) 
 4  (3) 
 4  (3) 
29 (22) 
 
15 (13) 
17 (14) 
8  (7) 
4  (3) 
74 (63) 
 
< 0.0001 
Alive 
Dead 
109 (44) 
139 (56) 
55 (42) 
75 (58) 
54 (46) 
64 (54) 
0.58 
a: Comparison matched family donor versus no matched family donor 
 
 
Intended therapy and actually applied therapy 
 
Patients with a matched family donor (N=130) 
Immediate SCT without prior remission-induction chemotherapy was performed in 42 out 
of 47 patients (89%) intended for this treatment option according to the physician. SCT 
after chemotherapy was performed in 45 out of 58 patients (78%) and 14 out of 25 
patients (56%) underwent allogeneic transplantation at progression of the disease (Table 
2). In all, 101 of 130 patients (78%) with a matched family donor received the intended 
allogeneic transplantation. Progression of disease between HLA-typing and allogeneic 
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transplantation was reported in 20 patients. In 29 patients no allogeneic transplantation 
was performed: 9 RA(RS) patients, 12 RAEB patients, 7 RAEBt patients and 1 sAML 
patient. Overall, in the matched family donor group 101 patients underwent allogeneic 
transplantation, 13 patients received chemotherapy only and 16 patients received 
supportive care. 
 
Patients without a matched family donor (N=118) 
Fifty patients without a matched family donor were intended for alternative donor 
transplantation (mismatched family transplantation or matched unrelated transplantation) 
and 23 patients (46%) received this treatment. Autologous transplantation after 
chemotherapy was intended for 20 patients and 10 of these patients (50%) were treated 
with ABMT. Sixty-seven percent (8/12 patients) intended for chemotherapy only actually 
received chemotherapy. Supportive care was administered to almost all patients intended 
for this approach (97%). Another six patients, for whom the intention-to-treat was 
unknown, underwent alternative donor transplantation. 
Overall, in the group without a matched family donor 31 patients underwent alternative 
donor allogeneic transplantation, 29 patients received chemotherapy only, 13 patients 
received chemotherapy followed by autologous transplantation and 45 patients received 
supportive care only (Table 2). Progression of disease between HLA-typing and 
alternative donor transplantation was reported in 9 patients.  
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Table 2. Intention-to-treat at time of HLA family typing and applied treatment. 
 Intention-to-treat Applied treatment 
Matched family donor (N=130) 
  Immediate SCT 47 42 SCT (89%) 
  5 Supportive care 
  SCT at progression 25 14 SCT (56%) 
11 Supportive care 
  SCT after chemotherapy 58 45 SCT after chemotherapy (78%) 
13 Chemotherapy only 
No matched family donor (N=118)  
  Search alternative donor 50 23 Alternative donor SCT (46%) 
  1 Autologous SCT 
12 Chemotherapy only 
14 Supportive care 
  Chemotherapy only 12   8 Chemotherapy only (67%) 
  1 Alternative donor SCT 
  2 Autologous SCT 
  1 Supportive care 
  Autologous SCT 20 10 Autologous SCT (50%) 
  1 Alternative donor SCT 
  8 Chemotherapy only 
 1 Supportive care 
  Supportive care 30 29 Supportive care (97%) 
  1 Chemotherapy only 
  Missing 6   6 Alternative donor SCT 
 
 
Outcome of patients according to intended treatment 
Median survival from HLA-typing of all 248 patients was 33 months. Median survival from 
HLA-typing of the patients with a matched family donor was 28 months versus 35 months 
for the patients without a matched family donor. The estimated 3-year survival rates were 
46% for patients with a matched family donor compared to 43% for patients without a 
matched family donor (p=0.98) (Table 3). To investigate the influence of alternative donor 
transplantation in patients without a matched family donor, we censored at time of 
alternative donor transplantation. By doing this, median survival of the patients without a 
matched family donor became 45 months, with an estimated 3-year survival of 52%.  
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In the group with a matched family donor, median survival of the patients intended for 
immediate BMT was 39 months, 20 months for patients intended for BMT after remission-
induction chemotherapy and 86 months for patients intended for BMT at progression of 
disease (p=0.25). The estimated 3-year survival rates were 48%, 34%, and 72%, 
respectively (Figure 1A).  
 
Figure 1A. Overall survival from HLA-typing in patients with a matched family donor according to 
intended treatment. 
 
In the group of patients without a matched family donor median survival was 32 months 
for the patients intended for alternative donor transplantation, 20 months for patients 
intended for chemotherapy only, 27 months for patients intended for autologous 
transplantation and 69 months for patients intended for supportive care only (p=0.11). 
The estimated 3-year survival rates were 37%, 35%, 36% and 71%, respectively (Figure 
1B). 
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Figure 1B. Overall survival from HLA-typing in patients without a matched family donor according 
to intended treatment. 
 
Outcome of patients according to applied treatment 
In the matched family donor group, median survival according to applied treatment was 
39 months after allogeneic transplantation, 11 months after chemotherapy only and not 
reached after supportive care. The estimated 3-year survival rates were 49%, 0% and 
57% (Figure 2A). In the group without a matched family donor, median survival after 
alternative donor transplantation was 27 months, 12 months after chemotherapy only, not 
reached after autologous transplantation and 69 months after supportive care. The 
estimated 3-year survival rates were 34%, 9%, 67%, and 68%, respectively (Table 3) 
(Figure 2B). Clearly, the patients receiving supportive care form a subgroup of MDS 
patients. Although HLA-typing was initiated in these patients, there was no need yet for 
starting intensive antileukaemic treatment.  
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Table 3. Survival from HLA-typing according to matched family donor availability, intended 
treatment and applied treatment (3 patients data lacking). 
 Number Median survival  
(months) (95% CI) 
3-year survival 
(%) (s.e.) 
P-value 
Donor availability 
   Matched family donor 
   No matched family donor 
 
128 
117 
 
     28 (13-44) 
     35 (27-43) 
 
46 (4.6) 
43 (5.2) 
 
0.98 
Intention-to-treat (donor) 
   Immediate SCT 
   SCT at progression 
   SCT after chemotherapy  
 
46 
25 
57 
 
     39 (21-56) 
     86 (66-106) 
     20 (11-29) 
 
48 (7.6) 
72 (9.8) 
34 (6.4) 
 
0.25 
Intention-to-treat (no donor)a 
   Search alternative donor 
   Chemotherapy only 
   Autologous SCT 
   Supportive care 
 
49 
12 
20 
30 
 
     32 (23-42) 
     20 (9-32) 
     27 (10-44) 
     69 (57-81) 
 
  37   (7.7) 
  35 (15.1) 
  36 (11.4) 
  71   (9.8) 
 
0.11 
Applied treatment (donor) 
   Matched family donor SCT 
   Chemotherapy only 
   Supportive care 
 
99 
13 
16 
 
     39 (7-70) 
     11 (0-26) 
   Not reached 
 
 49   (5.1) 
        0 
 57 (13.5) 
 
0.45 
 
Applied treatment (no donor) 
   Alternative donor SCT 
   Chemotherapy only 
   Autologous SCT 
   Supportive care 
 
30 
29 
13 
45 
 
     27 (5-49) 
     12 (10-14) 
   Not reached 
     69 
 
34   (9.7) 
  9   (5.8) 
67 (13.8) 
68   (8.4) 
 
0.11 
 
a: 6 patients with an alternative donor (matched unrelated donor) no intention-to-treat without a 
donor was given 
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Figure 2A. Overall survival from HLA-typing in patients with a matched family donor according to 
applied treatment. 
 
 
Figure 2B. Overall survival from HLA-typing in patients without a matched family donor according 
to applied treatment. 
Months
12010896847260483624120
1.00
.80
.60
.40
.20
0.00
allogeneic SCT (N=99)
chemotherapy only (N=13)
supportive care (N=16)
Months
12010896847260483624120
1.00
.80
.60
.40
.20
0.00
autologous SCT (N=13)
supportive care (N=45)
altern. donor SCT(N=30)
chemo only (N=29)
CHAPTER 2 
52  
Multivariate analyses 
To evaluate whether the similar outcome of patients with and without a matched family 
donor was a true finding or due to differences in the patients groups a multivariate 
analysis was performed. The following factors were considered in the model: age, FAB 
classification at HLA-typing (RA(RS) versus other FAB subtypes), cytogenetic 
abnormalities, and intended treatment (allogeneic SCT, alternative donor SCT, 
autologous SCT, chemotherapy only and supportive care). The results of the multivariate 
Cox's proportional hazards model for survival are shown in table 4. Age, as a continuous 
variable, appeared to be most predictive for survival with a HR of 1.02 (95% Confidence 
Interval (CI) 1.01-1.04) (p<0.0001). A diagnosis of RA(RS) at time of HLA-typing and 
cytogenetic abnormalities were prognostic for survival as well. Survival of patients 
intended for allogeneic SCT was not better than for patients intended for other treatment 
strategies (Figure 3). 
 
Table 4. Results of Cox's proportional hazards model for overall survival. 
 Hazard ratioa 95% CI P-value 
Age 1.02 1.01-1.04 < 0.0001 
Chromosomal abnormalities 
   Normal 
   Abnormal 
   Not done/unknown/failed 
 
1.00 
1.28 
1.86 
 
 
0.85-1.93 
1.19-2.92 
0.03 
Intended treatment 
   Allogeneic SCT  
   Alternative donor SCT 
   Autologous SCT 
   Chemotherapy only 
   Supportive care 
 
1.00 
1.35 
1.02 
1.06 
0.53 
 
 
0.86-2.12 
0.56-1.86 
0.48-2.34 
0.26-1.06 
0.21 
RA(RS) 0.58 0.38-0.88 0.01 
a: A value >1 indicates that the outcome is worse in that category in comparison with the baseline. 
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Figure 3. Overall survival from HLA-typing in all patients according to intended treatment. 
 
In addition, we considered the influence of the different treatment strategies on survival of 
patients with and without a matched family donor (Table 5). In the subgroup of patients 
with a matched family donor age and chromosomal abnormalities were predictive for 
survival. The intended treatment (direct transplantation, chemotherapy followed by 
transplantation or transplantation at progression of disease) was not predictive for 
survival in patients with a matched family donor. Survival of patients intended for 
transplantation after chemotherapy was not different from survival of patients intended for 
immediate allogeneic transplantation without preceding chemotherapy. A diagnosis of 
RA(RS) had no significant impact on survival. 
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In the subgroup of patients without a matched family donor age and FAB subtype 
appeared prognostic for survival. In the overall group chromosomal abnormalities 
appeared not prognostic, although the subgroup of patients with an abnormal karyotype 
showed a worse survival with a HR of 1.98 (95% C.I. 1.07-3.66) (p=0.03) compared to 
patients with a normal karyotype. The intended treatment (alternative donor 
transplantation, chemotherapy only, chemotherapy followed by autologous 
transplantation, supportive care) was not prognostic for survival.  
 
DISCUSSION 
 
This study was initiated to assess the role of allogeneic stem cell transplantation (SCT) 
compared to alternative treatment approaches like chemotherapy only, chemotherapy 
followed by autologous stem cell transplantation, alternative donor transplantation and 
supportive care only. The question whether allogeneic SCT is a superior treatment option 
compared to other treatment modalities is difficult to answer. Most studies on allogeneic 
SCT report patients, who actually received an allogeneic transplantation, thereby 
neglecting patients, who do not reach the transplantation step, due to toxicity or early 
relapse. To avoid selection bias as much as possible, we performed this analysis in 
previously untreated MDS patients selected at time of HLA-typing of patient and siblings. 
This time was chosen since HLA-typing is only undertaken when the patient is considered 
to be suitable for allogeneic stem cell transplantation (SCT). In a random population 
sample about one third of patients are expected to have an HLA-identical sibling donor. In 
the present analysis about 50% of patients had a donor. This illustrates that pre-selection 
has occurred to a certain extent. A possible explanation is that transplant centres have 
reported the majority of patients and patients without siblings are less likely to be referred 
to a transplant unit. 
Our principal finding is that on intention-to-treat basis survival from HLA-typing is not 
different for patients with and without a matched family donor. In patients with a matched 
family donor allogeneic SCT is a feasible option. Overall 78% of patients in this group 
underwent allogeneic transplantation. In this analysis clinicians considered alternative 
donor transplantation the best alternative for patients without a matched family donor. 
Fifty patients (42%) were intended for alternative donor SCT and about half of the 
patients (46%) received this treatment. Clinicians were less likely to proceed to 
autologous SCT in MDS; this was the intended treatment in only 17% (20 out of 118) of 
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patients. Since attaining complete clinical remission is a prerequisite for autologous SCT, 
this treatment option was feasible in 50% of patients. Chemotherapy as only treatment 
was intended in a minority of patients (10%). In a quarter of patients without a matched 
family donor, no further intensive treatment was intended.  
These data clearly illustrate that selection occurs when different treatment strategies are 
analysed in a retrospective study. The majority of patients with a matched family donor 
received the intended treatment, so selection is limited at this stage in the procedure. 
However, alternative donor SCT was feasible in only 46% of patients, due to limited 
availability of alternative donors and the duration of the donor search procedure. The 
dropout frequency of patients intended for autologous stem cell transplantation was 50%. 
In a recent European study 61% of patients in complete remission after remission-
induction chemotherapy proceeded to autologous stem cell transplantation.14 A similar 
percentage (62%) was reported in a French study.17 Although a larger percentage of 
patients with a matched family donor underwent the intended treatment compared to the 
patients without a matched family donor, our present analysis fails to demonstrate a 
survival advantage of patients with a matched family donor over patients without a 
matched family donor.  
The estimated survival rate at 3 years after matched family donor transplantation of 49% 
is in accordance with the literature. The EBMT registry data reported 41% survival at 3 
years in patients with an HLA-identical donor.18 In a large series from Seattle disease-free 
survival at 5 years was 38%.19  
Alternative donor SCT resulted in a 3-year survival rate of 34% in the present analysis. In 
the EBMT experience survival was 26% after matched unrelated donor transplantation 
and 31% after non-identical family donor transplantation.18 The National Marrow Donor 
Program reported a 2-year survival rate of 30% after unrelated donor SCT.20  
In this analysis 3-year survival rate after autologous SCT was 67%. In an EBMT study 4-
year survival rate from CR was 33% for patients intended for autologous SCT 14 similar to 
an earlier EBMT report 18 and a French report.17 
The value of continued chemotherapy and chemotherapy followed by autologous SCT in 
the treatment of high-risk MDS patients is under investigation in the recently closed 
CRIANT study (EORTC 06961).21 In the present analysis 3-year survival rate of patients 
who received chemotherapy only was 9%. An earlier analysis compared outcome of 
patients treated at the M.D. Anderson Cancer Center, receiving chemotherapy only, with 
outcome of patients treated by the EORTC, who received chemotherapy followed by 
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transplantation. Overall survival at 4 years was 18% for patients receiving chemotherapy 
only.22  
Myelodysplastic syndrome differs from AML through the clinical behaviour in some 
subgroups of MDS, which may have a more indolent course compared to AML. The 
majority of patients with a protracted course belong to the RA(RS) FAB types. However, 
some of these RA(RS) patients have profound cytopenias and/or cytogenetic 
abnormalities, justifying a donor search. The present analysis included RA(RS) patients, 
who were on clinical grounds potential candidates for allogeneic SCT. Nowadays, the 
IPSS is a valuable instrument to predict the prognosis of an individual patient. However, 
when this analysis was designed the IPSS was not yet available and therefore data on 
cytopenias were not collected for the purpose of this analysis. To overcome this difficulty, 
we performed a multivariate analysis including the following variables: age, cytogenetic 
abnormalities, intended treatment and diagnosis of RA(RS) versus other FAB types. We 
adjusted for the RA(RS) FAB type, since earlier analyses showed that only a blast 
percentage less than 5% predicted for a better outcome after allogeneic SCT, but no 
differences were found for a blast percentage over 5%.11,18 Our analysis confirmed the 
importance of age and cytogenetic abnormalities on survival. Intended treatment was not 
prognostic for survival. Outcome of patients with RA(RS) was significantly better 
compared with other FAB types with a hazard ratio of 0.58 (95% CI 0.38-0.88). 
Multivariate analysis in the subgroup of patients with a matched family donor 
demonstrated the importance of age on survival. Cytogenetic abnormalities appeared 
prognostic in the entire group, but there was no significant difference in survival for 
patients with and without an abnormal karyotype. Presumably, the impact of cytogenetic 
abnormalities is less pronounced due to the graft-versus-MDS effect in the donor group. 
Intended treatment appeared not prognostic for survival in multivariate analysis.  
In patients with a donor intended for allogeneic stem cell transplantation the use of 
chemotherapy prior to SCT to lower disease burden is still controversial. An important 
argument against the use of chemotherapy before SCT is the risk of developing life-
threatening infections and bleeding complications due to prolonged periods of hypoplasia. 
In this analysis 78% of patients receiving chemotherapy before SCT reach the 
transplantation step, compared to 89% of patients who undergo SCT without preceding 
chemotherapy. Obviously, the FAB type was different for patients intended for allogeneic 
SCT with or without preceding chemotherapy. The subgroup of 58 patients intended for 
SCT after chemotherapy consisted of 2 RA(RS) patients, while the subgroup of 47 
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patients intended for SCT without preceding chemotherapy consisted of  28 RA(RS) 
patients at time of HLA-typing. To correct for this imbalance we adjusted for the RA(RS) 
FAB type in multivariate analysis. By doing this, no difference in survival was detected 
after SCT with or without preceding chemotherapy. This suggests that patients do not 
benefit from remisson-induction chemotherapy prior to transplantation. 
Nevertheless, the definitive answer to this important question can only be given by a 
prospective study and is currently under investigation in an EBMT trial, randomising MDS 
patients with less than 20% blasts cells in the bone marrow between immediate SCT and 
delayed SCT after chemotherapy. In patients with a matched family donor a diagnosis of 
RA(RS) was not significantly associated with a better survival. This cannot be explained 
by progression to a more aggressive disease at time of transplantation. The most likely 
explanation is that the survival advantage after allogeneic SCT is counterbalanced by the 
treatment-related mortality in these patients. In the present analysis patients with a 
matched family donor, who do not receive allogeneic stem cell transplantation have a 
good prognosis. Obviously clinicians are able to identify patients with a more indolent 
course in whom a wait-and-see policy is justified.  
In patients without a matched family donor younger age and a diagnosis of RA(RS) were 
prognostic for survival. The subgroup of patients with an abnormal karyotype showed a 
worse survival with a hazard ratio of 1.98. On intention-to treat basis outcome was not 
different after alternative donor SCT, autologous SCT, chemotherapy only or supportive 
care, although patients intended for supportive care showed a better survival compared 
to patients intended for alternative donor SCT with a hazard ratio of 0.36. In this analysis 
survival after autologous SCT appeared superior when compared to alternative donor 
SCT, but these patients are highly selected.  
The issue of selection, when different treatment strategies in MDS are assessed, is not 
frequently addressed in the literature. We performed an intention-to-treat analysis in a 
large European study of high-risk MDS and secondary AML patients, who underwent 
chemotherapy followed by allogeneic or autologous stem cell transplantation.23 Patients 
with an HLA-identical donor were scheduled for allogeneic SCT, patients without a donor 
for autologous transplantation. This study, confirming our present finding, did not 
demonstrate a survival advantage for patients with a donor with 4-year survival rates of 
33% and 39% respectively for patients with and without a donor.  
In 1993 Ljungman et al. performed a similar analysis to determine the optimal post-
remission therapy for patients with AML.24 Eighty-five percent of patients with a donor 
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received an allograft, while 32% of patients received the intended autologous SCT. In 
contrast to our analysis, Ljungman et al. demonstrated a survival advantage for patients 
with an HLA-identical donor over patients without a donor with survival rates at 3 years of 
44% and 21% respectively (p=0.02). In the AML-8A trial of the EORTC and GIMEMA 
patients with a donor showed a better DFS compared to patients without a donor, but no 
significant differences in overall survival could be detected. In this AML study patients 
without a donor were randomised between autologous stem cell transplantation and 
continued chemotherapy.25 Subsequently the framework of the EORTC/GIMEMA AML-10 
was used to investigate the value of allogeneic and autologous stem cell transplantation 
in patients younger than 46 years in complete remission after remission-induction and 
consolidation chemotherapy.26 The 4-year DFS rate of the donor group was superior to 
that of the no donor group: 52% versus 42% (p=0.04), but survival from CR was 
comparable, due to a rather high treatment-related mortality (TRM).  
In conclusion: this prospective analysis failed to demonstrate a survival advantage of 
MDS patients with a matched family donor over patients without a matched family donor. 
In contrast to AML, MDS is a more heterogeneous disease. Therefore, different treatment 
options like alternative donor transplantation, autologous stem cell transplantation, or 
high-dose chemotherapy should be considered in patients without a donor, preferentially 
based on a refined risk profile. This risk profile might be based on cytogenetic 
abnormalities, number of cytopenias and duration of antecedent disease (antecedent 
hematologic disorder).  
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ABSTRACT 
 
Comparisons of the effectiveness of chemotherapy and transplantation in AML in first 
complete remission (CR) have focused almost exclusively on patients with de novo 
disease. Here we used Cox modelling to compare these strategies in patients with MDS 
and sAML treated by the Leukemia Group of the EORTC or at the M.D. Anderson Cancer 
Center. All patients were aged 15-60. The 184 EORTC patients received conventional 
dose ara-C + idarubicin + etoposide for remission induction, and after one consolidation 
course, were scheduled to receive an allograft, or an autograft if a sibling donor was 
unavailable. The 215 MDA patients received various high-dose ara-C containing 
induction regimens, and in CR, continued to receive these regimens at reduced dose for 
6-12 months. CR rates were 54% EORTC and 63% MDA (p=0.09). Sixty-five of the 100 
EORTC patients who entered CR received a transplant in first CR. Disease-free survival 
in patients achieving CR was superior in the EORTC cohort, the 4-years DFS rates were 
28.9% (s.e. = 4.8%) EORTC vs. 17.3% (s.e. = 3.7%) MDA (p=0.017). Survival from CR 
was not significantly different in the EORTC and MDA groups, as was survival from start 
of treatment. After accounting for prognostic factors the conclusions were unchanged. 
Despite various problems with the analysis discussed below, the data suggest that 
neither transplantation nor chemotherapy, as currently practised, can be unequivocally 
recommended for these patients in first CR and that questions as to the superior modality 
may be less important than the need to improve results with both.  
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INTRODUCTION 
 
It is established that the prognosis of some patients presenting with myelodysplastic 
syndromes (MDS) resembles that of patients with AML. Such patients include those 
classified as having “intermediate-2” or  “high” risk MDS by the International Prognostic 
Scoring System (IPSS).1 These patients typically have RAEB or RAEB-t, or more rarely 
CMMoL or RA but with particularly severe cytopenias. These observations have led to the 
use of AML-type therapy in younger patients meeting these criteria.2-4 
It is similarly well-known, however, that outcome of AML-type therapy in such patients is 
poor, and, in particular, is worse than that seen in patients with de novo AML. The poor 
results in turn raise the question of the value of transplantation in first CR in patients with 
MDS. Although there have been frequent comparisons between continued chemotherapy 
and transplantation in this setting in patients with de novo AML, such comparisons are 
lacking in patients with MDS.5-7 Rather the literature is dominated by reports of one 
approach or the other, usually as conducted by a single centre or a single consortium of 
centres.8-15 
The purpose of this paper is to formally compare continued chemotherapy and 
transplantation in first CR in patients under age 60 years with high-risk MDS or secondary 
AML (sAML), recalling that the response to AML-type therapy in the latter is more 
reminiscent of that seen in MDS than in de novo AML. Patients were treated at the M.D. 
Anderson Cancer Center (MDA) or by the Leukemia Group of the European Organisation 
for Research and Treatment of Cancer (EORTC) in co-operation with SAKK, GIMEMA 
and EBMT (EORTC study 06921).16 All patients received AML-type therapy in order to 
achieve a CR. Subsequently, after an intensive consolidation course, patients treated by 
the EORTC received an allogeneic transplant, or lacking an HLA-matched sibling donor, 
an autologous transplant. In contrast, patients treated at M.D. Anderson continued to 
receive AML-type therapy but without a transplant. Below we report the results of 
analyses designed to determine, after accounting for important covariates such as age 
and cytogenetics, which strategy produced superior outcomes in the combined group of 
399 patients (184 EORTC, 215 MDA).   
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PATIENTS AND METHODS 
 
Between November 1992 and March 1997 184 evaluable patients from 35 European 
centres were entered in the EORTC 06921 study. Two hundred and fifteen comparable 
patients were treated between January 1990 and December 1997 at MDA. One hundred 
and thirty-eight of the EORTC patients (75%) had MDS, and 46 secondary AML. One 
hundred and thirty-one (61%) of the MDA patients had MDS and 84 sAML. AML and the 
various subtypes of MDS were defined using FAB criteria.17,18 Patients with AML M3 were 
excluded. The MDA reported 23 patients with more than 30% blasts in the peripheral 
blood and less than 30% bone marrow blasts. These patients were classified as 
peripheral acute leukaemia.19  
Selection criteria were those used in the EORTC 06921 study. Patients were included if 
they were aged 15-60 years, had a WHO / Zubrod performance status < 2 and had 
untreated (1) RAEBt, (2) RAEB with more than 10% blasts cells in the bone marrow, (3) 
other forms of MDS with multiple chromosomal abnormalities and/or profound cytopenias 
(neutrophil count < 0.5 x 109/l and/or platelet count < 20 x 109/l), or (4) CMMoL with > 5% 
blasts cells in the bone marrow or  > 16 x 109/l neutrophils or > 2.6 x 109/l monocytes in 
the blood. Since MDA used protocols not calling for AML-type therapy to treat CMMoL, 
MDA patients with CMMoL were not included in the study group. The outcome of CMMoL 
patients in the EORTC study was not different from that of the RAEBt patients and 
therefore these patients were not excluded from the analysis. Patients with secondary 
AML (sAML), i.e. AML supervening after overt MDS or after an antecedent hematological 
disorder (AHD) of more than 6 months duration or after prior chemotherapy and/or 
radiotherapy for another, presumably cured, disease were included. Criteria for an AHD 
included any of the following: hemoglobin < 12 g/dl, platelet count < 150 x 109/l, 
neutrophil count < 1.5 x 109/l or white blood count (WBC) > 20 x 109/l.  Many patients in 
whom a local physician first documented such abnormalities did not have bone marrow 
examined until referred to the treating centre (EORTC or MDA). Therefore, an AHD was 
said to be present when the blood count abnormality was first documented regardless of 
whether a marrow was done simultaneously. Karyotyping was done using standard 
techniques and criteria.20 A normal karyotype, minus Y, inv(16) or t(8;21) were considered 
to convey a better prognosis, abnormalities involving chromosomes 5 and/or 7 a worse 
prognosis and other abnormalities an intermediate prognosis. 
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Treatment in EORTC 06921 (Table 1) 
Remission-induction in the 06921 study consisted of conventional dose ara-C, idarubicin 
and etoposide (ICE, Table 1). In case of a partial response a second remission-induction 
course was given. Patients in CR received one consolidation course consisting of ara-C 
combined with mitoxantrone (NOVIA, Table 1). HLA family typing was initiated at the 
onset of remission-induction therapy, with the intention of allografting patients in first CR 
after the course of NOVIA if they had a compatible sibling donor. All patients without a 
donor were scheduled for autologous bone marrow transplantation or peripheral blood 
stem cell transplantation. In the initial phase of the study autologous bone marrow cells 
were used. Since the hematological recovery after transplantation was very prolonged, 
the protocol was adapted and bone marrow stem cells were replaced by peripheral blood 
stem cells mobilized with filgrastim during the recovery phase of the consolidation course. 
One of two conditioning regimens for allogeneic BMT and autologous stem cell 
transplantation was used: cyclophosphamide 60 mg/kg/day on 2 consecutive days and 
total body Irradiation (TBI) 12 Gy in four to six fractions over 2 or 3 days. The alternative 
regimen was busulfan 4 mg/kg/day on 4 consecutive days in combination with 
cyclophosphamide 60 mg/kg/day on 2 days.   
Prophylaxis for GVHD following allogeneic BMT consisted of cyclosporin A alone or in 
combination with methotrexate. 
The minimally required number of nucleated cells was 2 x 108/kg or 2 x 104 CFU-GM/kg 
for autologous bone marrow transplantation and 10 x 104 CFU-GM/kg or 2 x 106 CD34+ 
cells/kg for peripheral blood stem cell transplantation. All transplants were unpurged. 
 
 
MDA Treatments (Table 1) 
All remission-induction regimens used at the MD Anderson contained high dose ara-C 
alone (N=5 patients) or combined with (1) anthracycline (N=146: daunorubicin 15, 
idarubicin 131), (2) fludarabine (N=135) with (N=92) or without (N=43) idarubicin, or (3) 
topotecan (N=21). Growth factors were used in 136 patients during and after 
chemotherapy (GM-CSF: 15, G-CSF: 121). Once in CR patients received post-remission 
therapy of similar type but at a lower dose intensity every 5-6 weeks for 6-12 months. 
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Table 1. Treatment schedules (N = number of patients). 
EORTC   
 ICE (184) idarubicin 10 mg/m2/d iv days 1, 3, 5, ara-C 100 mg/m2/d iv days 1-10 cont. 
infusion, etoposide 100 mg/m2/d iv days 1-5 
 NOVIA ara-C 2 x 500 mg/m2/d iv days 1-6, mitoxantrone 12 mg/m2/d iv days 4-6 
MDA   
 IA   (39) idarubicin 12 mg/m2/d iv days 1, 2, 3, ara-C 1.5 g/m2/d iv days 1-4 cont. 
infusion 
 FA  (43) fludarabine 30 mg/m2/d iv days 1-5, ara-C 2 g/m2/d iv days 1-5 
 FAI (92) + idarubicin 12 mg/m2/d iv days 2, 3, 4 
 TA  (21) topotecan 1.25 mg/m2/d iv days 1-5, ara-C 1 g/m2/d iv days 1-5 
 DA  (15) daunorubicin 50 mg/m2/d iv days 1-3, ara-C 1.5 g/m2/d iv days 1-4 cont. 
infusion 
 A      (5) ara-C 1.5 g/m2/d iv days 1-4 cont. infusion 
 
 
Definitions 
CR was defined conventionally. Response in patients not achieving CR was called either 
“resistant” or “early death”. Disease was considered resistant if the post-day 28 marrow 
showed  > 5% blasts in a marrow that was > 20% cellular. We did not distinguish 
between failure to ever meet these criteria and regrowth of disease after meeting them 
prior to achievement of CR. Disease was also considered resistant if the marrow 
remained hypoplastic for more than 42 days from the start of treatment, because of the 
likelihood that had CR been achieved it would have been very transient.21 Early death 
was said to have occurred if death occurred before day 28 or between days 28 and 42 in 
patients in whom the marrow between these dates was < 20% cellular with < 5% blasts. 
 
Statistical analysis 
The duration of survival was calculated from the date of start of treatment until death, 
whatever the cause. For patients who achieved CR after induction, the disease-free 
survival was calculated from the date of first CR until the date of first relapse or until 
death in CR. The duration of survival of remitters corresponds to the time from first CR to 
the date of death. The actuarial curves were computed using the Kaplan-Meier 
technique.22 The Cox Proportional Hazards Model and the Wald test have been used to 
determine the prognostic importance of several factors regarding the time to event 
outcomes (DFS, survival from CR, overall survival) and to obtain estimates of the hazard 
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ratios and the corresponding 95% confidence intervals (CI).22 All analyses were 
performed according to the intent-to-treat principle. 
A total of 325 events are required to detect a 10% difference (20% versus 30%) in terms 
of DFS at 4 years between the two studies (alpha=5%, beta=20%). This corresponds to a 
hazard ratio of 0.75. A lower number of events (i.e. deaths) and a smaller difference in 
terms of survival from CR, provides a smaller statistical power for the statistical 
comparison between the outcome of the studies. 
The linear logistic model has been used to assess the prognostic importance of several 
factors, including the study (EORTC or MDA), for reaching CR after induction courses.23 
The Wald test has been used to obtain the p-value and assess the 95% confidence 
interval of the odds ratio. The distribution of patient characteristics in the two studies has 
been compared using the usual chi-square test. 
 
 
RESULTS 
 
Patients  
Patient characteristics are shown in Table 2. MDA patients were older and more likely to 
have a poor performance status and sAML, while EORTC patients were more likely to 
have MDS. Sixteen CMMoL patients were included in the EORTC study. The outcome of 
these patients was similar to the outcome of RAEBt patients, with 4-year survival rates of 
29% for CMMoL and 32% for RAEBt respectively. Excluding CMMoL patients from the 
analysis would emphasise the imbalance between the percentage RAEBt patients in the 
MDA (71%) and EORTC (43%) study. Abnormalities of chromosomes 5 and/or 7 denoting 
particularly poor prognoses were more common at MDA. The hemoglobin level and 
platelet count at the start of therapy were lower in MDA patients, while the white blood 
count (WBC) was higher. The median follow-up for EORTC patients was 3.6 years and 
for MDA patients 3.0 years. 
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Table 2. Patient characteristics. 
  EORTC (N) % MDA  (N) % P 
Cytogenetics Good 70 38 77 36 <0.001 
 Intermediate 42 23 50 23  
 Bad 39 21 79 37  
 ND/IM 33 18 9 4  
Age (years) < 35 38 21 39 18   0.038 
 35-45 40 22 47 22  
 46-55 72 39 64 30  
 > 55 34 18 65 30  
PS 0 or 1 164 89 162 76 <0.001 
 2 19 11 53 24  
Prior therapy No 144 79 135 63 <0.001 
 Yes 38 21 80 37  
AHD (months) < 6 130 71 135 67   0.22 
 > 6 54 29 75 32  
Disease MDS 138 75 131 61   0.003 
 sAML 46 25 84 39  
MDS FAB RA 7 5 - -   0.01a 
 RARS 1 1 - -  
 RAEB 54 39 38 29  
 RAEBt 60 43 93 71  
 CMMoL 16 12 - -  
BM blasts (%) < 5 9 5 9 4   0.296 
 5-10 22 12 37 17  
 11-20 58 32 55 26  
 21-30 46 25 52 24  
 > 30 45 24 61 28  
Hb (g/dl) < 10 136 74 185 86   0.004 
 > 10 48 26 30 14  
WBC (x 109/l) < 1 8 4 16 7   0.019 
 1-2.9 76 41 60 28  
 3-9.9 59 32 71 33  
 > 10 41 22 68 32  
Platelets (x 109/l) < 50 83 45 134 62   0.003 
 50-99 58 32 45 21  
 > 100 43 23 36 17  
Cytogenetics: Good: NN, -Y, inv(16), t(8,21); Bad: -5, 5q-, -7, 7q- ; Intermediate: +8, 11q, other;  
ND/IM: not done/insufficient metaphases; AHD: antecedent hematologic disorder; prior therapy: 
earlier radiotherapy or chemotherapy for a (non-)malignant disease; PS: performance status. 
a: Considering RA, RARS, RAEB versus RAEBt, CMMoL  
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Response Rates 
CR rates were 54% (100/184) in the EORTC and 63% (135/215) at MDA (p=0.09). The 
estimated odds ratio was 0.71 (=(100/84)/(135/80)) with a 95% confidence interval (CI) of 
0.47-1.05. Over 85% of the CRs occurred after the first course of treatment. The lower 
response rate in the EORTC reflected a higher rate of resistance (30% versus 17%), with 
rates of early death of 16% EORTC and 19% MDA. 
 
Outcome after CR 
Thirty-nine of the 100 EORTC patients who achieved a CR had a compatible sibling 
donor. Twenty-eight of these 39 received an allograft. Thirty-six out of 61 patients without 
a donor were autografted (19 autologous bone marrow transplantation and 17 peripheral 
blood stem cell transplantation). One additional patient underwent a matched unrelated 
donor transplantation in first CR after the consolidation course. Thirty-five patients were 
not transplanted in first CR. Two patients died due to toxicity of the consolidation course, 
26 patients showed an early relapse and 7 patients went off-study due to toxicity or 
treatment refusal.  
The outcome of patients with an HLA-identical donor (scheduled for allogeneic BMT) did 
not significantly differ from the outcome of patients without an HLA-identical donor 
(scheduled for autologous stem cell transplantation). The 4-year DFS rates in the group 
with or without an HLA-identical donor were 31% (s.e. = 7.9%) and 27% (s.e. = 6.1%), 
respectively. Therefore, for the purpose of this study, we did not discriminate between 
allogeneic and autologous transplantation and considered it as one strategy.  
DFS from time of CR was longer for the EORTC patients as compared to MDA patients 
(p=0.017, Figure 1). The median DFS was 1.0 years (EORTC) versus 0.8 years (MDA), 
the 4-year DFS rate estimates were 28.9% (s.e. = 4.8%) versus 17.3% (s.e. = 3.7%) and 
the hazard ratio was 0.69 with a 95% confidence interval (CI) of 0.50-0.95. Among 
EORTC patients who achieved CR, 32% remained alive in first CR, 52% had disease 
recurrence and 16% died in first CR. The corresponding figures at MDA were 20%, 72% 
and 8%. 
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Figure 1. Disease-free survival of patients who achieved complete remission by study.  
 
Figure 2. Survival of patients from complete remission by study.  
 
(years)
0 2 4 6 8
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk :
68 100 30 15 0
108 135 24 11 3
EORTC
MDA
Logrank test: p=0.017
%
P
a
t 
i
e
n
t
s
w
i
t
h
o
u
t
e
v
e
n
t
(years)
0 2 4 6 8
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk :
62 100 35 15 0
89 135 38 13 4
EORTC
MDA
Logrank test: p=0.29
%
P
a
t 
i
e
n
t
s
a
l 
i
v
e
                                                               CHEMOTHERAPY WITH OR WITHOUT TRANSPLANTATION 
73 
Survival  
Survival from CR was not statistically different (p=0.29) between the EORTC and MDA 
patients (Figure 2). The median survival from CR was 1.5 versus 1.4 years, the 4-year 
survival from CR rate estimates were 34.4% (s.e. = 5.1%) versus 25.5% (s.e. = 4.6%), 
the estimated hazard ratio was 0.84 with a 95% CI of 0.61-1.16. 
Survival from the start of treatment was also similar in EORTC and MDA (Figure 3). The 
median survival was 1.08 vs. 0.95 years, the 4-year survival estimates were 26.0% (s.e. = 
3.5%) versus 18.4% (s.e. = 3.2%), the estimated hazard ratio was 0.85 with a 95% CI of 
0.61-1.20. 
 
Figure 3. Survival of patients from start of treatment by study.  
 
Prognostic factors: univariate analyses 
The following variables appeared to be prognostic factors for overall survival considering 
all 399 patients: cytogenetics (4 categories: good, intermediate, bad prognostic, not 
done/insufficient metaphases), age as a continuous variable, platelet count as a 
categorial variable (< 50, 50-99, > 100 x 109/l), WBC as a continuous variable, 
hemoglobin as a categorial variable (Hb < 10 g/dl vs. > 10 g/dl) and performance status 
(WHO / Zubrod 0, 1 versus 2).  
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Important prognostic factors for disease-free-survival were cytogenetics, hemoglobin and 
disease category (RA, RARS, RAEB vs. RAEBt, CMMoL vs. sAML).  
 
Multivariate analyses  
The question remained whether the different outcomes in the EORTC and MDA cohorts 
(higher CR rate at MDA versus superior DFS, although comparable survival, once in CR 
in the EORTC) reflected the different treatment regimens (ICE/NOVIA and then transplant 
in CR by the EORTC vs. higher doses of ara-C in induction, continued chemotherapy 
without transplant in CR at the MDA) or, rather differences in the patients treated (e.g. a 
greater frequency of -5/-7 at MDA). We addressed this question by examining which 
factors (“covariates”) independently predicted the various outcomes (CR, DFS in CR, 
survival in CR, survival). We considered the following covariates: treatment site (EORTC 
or MDA), and the ones which appeared of prognostic importance in univariate analyses 
(cytogenetics, disease category, WBC, age, platelet count, hemoglobin and performance 
status). 
A linear logistic regression model showed (Table 3) that treatment site (EORTC or MDA) 
remained important for achievement of CR. 
 
Table 3. Results of linear logistic model for predicting the CR. 
Variablea Odds ratio 
Estimate 
95% CI P-value 
Cytogenetic    
  Good risk 1.89 1.22-2.94 0.004 
Platelets    
  50-99 2.14 1.27-3.57 0.004 
  > 100 1.84 1.06-3.20 0.030 
Study    
  EORTC 0.60 0.40-0.92 0.019 
a: Baseline category for cytogenetic risk group comprised all patients without good cytogenetic 
features, for platelets was < 50 x 109/l, for study was MDA 
 
The Cox’s model indicated (Table 4) that after accounting for relevant covariates, 
treatment in the EORTC was associated with longer DFS, while survival in CR and overall 
survival were not significantly influenced by treatment site. 
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DISCUSSION 
 
The relative merits of chemotherapy versus transplantation once patients with AML 
achieve CR have been debated for years. The discussion has focussed primarily on 
patients with de novo AML given that patients with MDS or sAML have often been 
ineligible for AML trials. Recently however, the possibility of including such patients in 
protocols examining AML-type therapy has gained attention, and hence questions about 
the relative benefits of various treatments for such patients have arisen. These questions 
prompted this paper, which we believe is the first to address the comparative benefits of 
chemotherapy and transplantation in MDS and sAML, recalling that these disease entities 
are more closely linked to each other than to de novo AML.  
In our study multivariate analyses revealed several independent prognostic factors for 
outcome. For disease-free-survival not only a treatment including transplantation, but also 
the absence of cytogenetic abnormalities and a hemoglobin level of at least 10 g/dl 
predicted for a better outcome. Since most institutions handle a cut-off value of 10 g/dl or 
less for a blood transfusion this value designates patients who are transfusion 
independent at diagnosis. 
For overall survival cytogenetics was also the most important independent prognostic 
factor. In addition several other factors had prognostic value. Increasing age was 
negatively associated with survival. A normal white blood cell count and a platelet count 
between 50-100 x 109/l predicted independently for a better survival and patients with a 
hemoglobin of at least 10 g/dl at the start of therapy also showed a better survival. 
Recently, various scoring systems for the prognosis of MDS patients were developed.1,24-
29 Several authors stressed the importance of a normal WBC and hemoglobin of at least 
10 g/dl.24-26 Morel et al. included cytogenetics in their scoring system.27,28 In 1997 
Greenberg et al. used the data of previously reported studies to generate an international 
prognostic scoring system (IPSS).1 They distinguished 4 risk groups based on 
cytogenetics, number of cytopenias and bone marrow blasts. However, the majority 
(75%) of patients in the IPSS study was older than 60 years and these patients have 
been treated with supportive care only or low intensity regimens. 
Our principal findings are that a strategy offering allografting in CR, or autografting if a 
compatible donor was unavailable appeared to produce longer disease-free survival, but 
similar survival than chemotherapy alone. Survival from start of treatment considering all 
399 patients was not significantly influenced by the two different treatment strategies. 
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These findings are thus reminiscent of those found when emphasis has been placed on 
patients with de novo AML.  
Several points must be stressed. First and perhaps most important, the value of 
chemotherapy versus transplantation as post-remission treatment was raised neither 
prospectively nor in the context of a randomized clinical trial. The EORTC study included 
high-risk MDS patients only and for the present analysis successive MDA patients were 
retrospectively selected on the basis of the EORTC eligibility criteria. The EORTC cohort 
included eight RA(RS) patients with multiple chromosome abnormalities and/or profound 
cytopenias and 16 CMMoL patients with bad prognostic features. Since MDA used 
protocols not calling for AML-like therapy to treat CMMoL, MDA patients with CMMoL 
were not included in the study group. RA(RS) patients with bad prognostic features were 
neither treated according to these protocols in MDA. At the time of initiating the present 
analysis the new WHO classification was not yet issued.30 This classification considers 
CMMoL rather as a myelodysplastic / myeloproliferative disease than a myelodysplastic 
syndrome. However, when we excluded the CMMoL patients from the EORTC cohort the 
overall results of the EORTC and the comparison with the MDA remained practically 
unchanged. The overall survival rate at 4 years of the EORTC cohort including the 
CMMoL patients was 26.0% compared to 25.9% by excluding them. The prognostic 
importance of the other factors did not change drastically. Excluding the CMMoL patients 
would further increase the imbalance of the WBC distribution. Similarly, the DFS rate at 4 
years was 28.9% including the CMMoL patients compared to 28.8% by excluding them. 
Finally, the survival rate from CR was 34.4% including CMMoL patients and 34.7% by 
excluding them (data not shown). So our results remained unchanged, if we had excluded 
the CMMoL patients. 
Secondly, although the multivariate regressions may have accounted for differences in the 
distribution of known covariates (e.g. age) between the MDA and EORTC cohorts, it is 
very difficult to ascertain whether these cohorts differed with regard to potentially 
important but unknown covariates. For example, it is impossible to ascertain whether the 
proportion of patients who were eligible for the studies described here but were not 
entered was similar in the EORTC and at MDA. 
A third difficulty is that we consider “transplantation” as one strategy regardless of whether 
patients received an allograft or an autograft and we have also assumed that results were 
equivalent at all EORTC centres contributing data to this analysis. Similarly, we have 
assumed that the various MDA chemotherapy regimens were approximately identical. A 
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fourth difficulty is that the EORTC and MDA induction regimens differed, with the latter 
employing higher doses of ara-C. Several reports have noted that the therapy given 
during induction can influence outcome in CR.31 For example, it can be argued that the 
higher CR rate produced by the MDA induction regimens, with these higher rates 
reflecting a lower “resistance” rate, would tend to make the MDA post-remission treatment 
strategy appear better a priori. It could also be contended, however, that because the 
MDA induction regimens produced CRs in patients who would not have achieved CR with 
the “ICE” regimen, the MDA post-remission strategy would appear inferior a priori given 
that the MDA patients were more likely to relapse perhaps due to factors that cannot 
currently be specified (“latent variables”).  
A final difficulty is that obviously we cannot speak to the strategy of transplantation at 
diagnosis rather than in CR. Several of these difficulties will be addressed in the ongoing 
prospective randomized European study (EORTC 06961) comparing high dose cytarabine 
with peripheral blood stem cell transplantation as post-consolidation treatment after a 
common remission-induction and consolidation course.      
Pending results of this trial, it appears that our results lend support to either strategy. 
Supporters of a transplant strategy can claim that this strategy appears to unequivocally 
lengthen disease-free survival in CR. Supporters of a chemotherapy strategy can point to 
the absence of a major effect of transplantation on survival. Perhaps then the important 
question may not be which strategy is superior, but rather whether either can be made to 
produce better results. 
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ABSTRACT 
 
This report used the framework of a large European study to investigate the outcome of 
patients with and without an HLA-identical sibling donor on an intention-to-treat basis. 
After a common remission-induction and consolidation course, patients with an HLA-
identical sibling donor were scheduled for allogeneic transplantation and patients lacking 
a donor for autologous transplantation. In all, 159 patients alive at 8 weeks from start of 
treatment were included in the present analysis. In total, 52 patients had a donor, 65 
patients did not have a donor and in 42 patients the availability of a donor was not 
assessed. Out of 52 patients, 36 (69%) with a donor underwent allogeneic transplantation 
(28 in CR1). Out of 65 patients, 33 (49%) received an autograft (27 in CR1). The actuarial 
survival rates at 4 years were 33.3% (s.e. = 6.7%) for patients with a donor and 39.0% 
(s.e. = 6.5%) for patients without a donor (p=0.18). Event-free survival rates were 23.1% 
(s.e. = 6.2%) and 21.5% (s.e. = 5.3%), respectively (p=0.66). Correction for alternative 
donor transplants did not substantially alter the survival of the group without a donor. 
Also, the survival in the various cytogenetic risk groups was not significantly different 
when comparing the donor versus the no-donor group. This analysis shows that patients 
with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia may 
benefit from both allogeneic and autologous transplantation. We were unable to 
demonstrate a survival advantage for patients with a donor compared to patients without 
a donor.  
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INTRODUCTION 
 
The myelodysplastic syndromes (MDS) form a heterogeneous group of diseases 
characterised by a hypercellular bone marrow and peripheral cytopenias, due to 
ineffective hematopoiesis. 
The natural history of MDS is variable and depends on the stage of the disease.1,2 
Numerous classification systems have been used to predict outcome of MDS patients. In 
1997, the International Prognostic Scoring System (IPSS) was developed based on the 
number of bone marrow blasts, number of cytopenias and the presence of cytogenetic 
abnormalities.3 
In elderly patients, supportive care is the mainstay of therapy. For young patients with 
high-risk MDS, allogeneic bone marrow transplantation (BMT) is a curative option. 
Unfortunately, an HLA-identical sibling is only available in one-third of patients. Disease-
free survival (DFS) after allogeneic BMT, ranges between 35% and 45%.4-10 Young 
patients (less than 40 years) 11 and patients with a low marrow blast count (less than 5%) 
9,12 have a better prognosis. The reported transplant results are likely to be influenced by 
selection of patients in a good clinical condition and excluding patients with an early 
relapse.  
For young patients (less than 60 years) with high-risk MDS who lack an HLA-identical 
donor, intensive chemotherapy results in complete remission (CR) rates of 15-65%.13-17 
The median remission duration is usually short because of a high incidence of early 
relapses. Therefore, the role of autologous stem cell transplantation (SCT) after 
remission-induction and consolidation chemotherapy has been investigated.18-20 The 
EBMT registry reported 79 patients with MDS, secondary acute myeloid leukemia (sAML) 
or therapy-related AML (tAML) who received an autograft in first CR after chemotherapy. 
The 2-year survival, DFS and relapse rate were 39%, 34% and 64%, respectively.19 
Until now there have been no reports comparing allogeneic transplantation and 
autologous transplantation. The optimal approach to evaluate the superiority of allogeneic 
BMT to autologous SCT is to compare these treatments in a randomised trial. For 
practical reasons this is not feasible.   
The Leukemia Groups of the EORTC, EBMT, GIMEMA and SAKK conducted a 
prospective multi-centre trial for bad prognostic MDS and AML secondary to MDS (sAML) 
in patients less than 60 years. The overall results of this study have been reported 
recently.21 After a common remission-induction and consolidation course, patients with an 
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HLA-identical sibling donor were scheduled for allogeneic BMT and patients without a 
donor for autologous SCT. Since all patients with an HLA-identical sibling donor were 
scheduled for allografting, this approach mimics a kind of randomisation by genetic 
chance. We decided to analyse the data of the above-mentioned study on an intention-to-
treat basis. For the present analysis 159 patients who were alive at 8 weeks from start of 
treatment were included. The main focus of this analysis was to address the question as 
to which subgroup of patients without a donor would achieve sustained DFS without 
allogeneic SCT. 
 
PATIENTS AND METHODS 
 
Patient’s selection criteria 
Patients were included if they were aged 16-60 years and had untreated (1) RAEBt, (2) 
RAEB with more than 10% blasts cells in the bone marrow, (3) other forms of MDS with 
multiple chromosomal abnormalities, and/or profound cytopenias defined as neutrophil 
count <0.5 x 109/l and/or platelet count <20 x 109/l, (4) CMMol with > 5% blasts cells in 
the bone marrow or with a neutrophil count >16 x 109/l or a monocyte count > 2.6 x 109/l 
in the blood, and (5) secondary AML supervening after overt MDS of more than 6 months 
duration. Patients with AML M3 were excluded. 
Exclusion criteria were the following: patients aged less than 16 years or more than 60 
years, patients already treated for MDS or AML by intensive chemotherapy and/or 
radiotherapy, treatment with biological response modifiers and/or low dose cytarabine 
within 2 months prior to entry, WHO performance status 3 or 4, no informed consent, or 
life expectancy less than 3 months.  
For the present analysis, only patients alive at 8 weeks from the start of treatment were 
selected since these patients were candidates for transplantation and the availability of 
an HLA-identical sibling donor should be known by this time. The impact of a donor is 
supposed to influence the outcome only from 8 weeks after start of treatment if the 
patient is treated according to the protocol.  
 
Prognostic factors  
Cytogenetic analysis was to be performed in all patients at the start of treatment using 
standard techniques and criteria.22 Patients were subdivided into different prognostic 
subgroups based on cytogenetics, number of cytopenias and percentage of bone marrow 
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blasts according to criteria of the IPSS 3 and according to the prognostic cytogenetic 
criteria as described by Keating et al.23   
 
Design of study protocol 
The remission-induction course (ICE) consisted of idarubicin 10 mg/m2/day by 
intravenous push injection on days 1, 3, 5 combined with cytarabine 100 mg/m2/day 
continuous intravenous infusion from days 1 to 10 and etoposide 100 mg/m2/day 1h 
intravenous infusion from days 1 to 5. In case of a partial response, a second remission-
induction course was scheduled. 
Patients entering CR after one or two remission-induction courses received a 
consolidation course (NOVIA) consisting of cytarabine 500 mg/m2 2h intravenous infusion 
every 12 hours from days 1 to 6 combined with mitoxantrone 12 mg/m2/day 30 min 
intravenous infusion on days 4-6. 
HLA typing of patient and family was initiated at the onset of induction therapy if patients 
were younger than 50 years (or younger than 55-60 years according to the policy of the 
centre). In case of an HLA-A, -B, -DR identical MLC nonreactive sibling, the patient was 
proposed for allografting after recovery from the consolidation course. 
All patients without an HLA-identical sibling were scheduled for autologous SCT. In the 
initial phase of the study, autologous BMT was performed. Since hematological recovery 
was slow, the protocol was adapted and autologous BMT was replaced by autologous 
peripheral blood SCT mobilised with filgrastim (dose 300 µg/day s.c.) from day 20 after 
start of the consolidation course until completion of the stem cell aphereses.  
Two conditioning regimens for allogeneic BMT and autologous SCT were recommended: 
cyclophosphamide 60 mg/kg/day on two consecutive days and total body irradiation 12 
Gy in four to six fractions over 2 or 3 days. The alternative regimen was busulphan 4 
mg/kg/day on four consecutive days in combination with cyclophosphamide 60 mg/kg/day 
on 2 days.   
Prophylaxis of graft-versus-host disease (GVHD) following allogeneic BMT consisted of 
cyclosporin A alone or cyclosporin A in combination with methotrexate. T-cell depletion of 
the allografts may be performed according to the policy of the centres. 
The minimally required number of nucleated cells was 2 x 108/kg or 2 x 104 CFU-GM/kg 
for autologous bone marrow transplantation and 10 x 104 CFU-GM/kg or 2 x 106 CD34+ 
cells/kg for peripheral blood SCT. All transplants were unpurged.  
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Definitions 
AML evolved from myelodysplasia was defined as sAML. AML after chemotherapy or 
radiotherapy for an earlier disease was defined as tAML. 
CR was defined as absence of clinical manifestations of leukemia and less than 5% 
blasts cells in a normocellular marrow with normal morphology. The peripheral blood 
neutrophil count should be > 1.5 x 109/l. and platelet count more than 100 x 109/l. 
Normalisation of cytogenetic abnormalities was not a prerequisite for CR.  
Partial remission (PR) was characterised by normocellular bone marrow containing less 
than 25% blasts and 50% or more decrease of blast percentage from pre-therapeutic 
levels with normal peripheral blood count without circulating blasts.   
 
Statistical analysis 
All patients were registered prospectively at the EORTC Data Center in Brussels. The 
duration of survival was calculated from the date of start of treatment until death, by 
whatever cause. The DFS was the time from CR until relapse or death in CR. The event-
free survival (EFS) was the time from CR until relapse or death in CR; patients who did 
not reach complete remission after the induction were considered events at time 0. The 
actuarial curves were computed using the Kaplan-Meier technique and the standard 
errors (s.e.) of the estimates were obtained via the Greenwood formula.24 The estimates 
of the incidence of death in first CR and of death of other cause were obtained using the 
cumulative incidence method, where the risk of death in CR and death of other cause 
were considered as competing risks.24 The same method has been used for estimating 
the cumulative incidence of relapse and of death in CR in patients who reached CR. The 
Cox Proportional Hazards Model has been used to determine the prognostic importance 
of several factors regarding survival and to obtain estimates of the hazard ratio (HR) and 
the corresponding 95% confidence interval (CI).24 All analyses were performed according 
to the intent-to-treat principle. 
The relationship between donor availability variable and patient characteristics or 
outcome has been tested for significance using the usual chi-square test. For ordered 
variables, like WBC or response to induction, the chi-square test for linear trend has been 
used. 
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RESULTS 
 
Overall results 
A total of 197 patients from 35 institutions were registered between December 1992 and 
April 1997. Data from 184 patients were evaluable. The median age was 47 years (range 
16-60 years). Of the patients, 138 (75%) had MDS, and 46 secondary AML. A total of 38 
patients developed MDS or AML after treatment with chemotherapy or radiotherapy for 
an earlier disease (tMDS/tAML). Out of 184 patients, 100 (54%) reached complete 
remission after one or two courses of chemotherapy. In all, 29 patients (16%) died during 
remission-induction chemotherapy. The median survival of all patients was 13 months, 
and the actuarial survival rate at 4 years was 26% (s.e. = 3.5%). The median actuarial 
follow-up for all patients was 3.6 years. Of 29 patients, 25 died before day 56 after start of 
treatment. The present analysis represents all 159 patients who were alive at 8 weeks 
from start of treatment.  
 
Donor availability  
Out of 159 patients, 122 had at least one living sibling; 11 patients had no sibling. The 
availability of a sibling was not known for 26 patients. HLA-typing was performed in 128 
out of 159 patients (81%). Of the 128 patients typed, 52 had an HLA-identical sibling and 
65 patients did not. In 11 additional patients, typing of the patient was performed, but 
family typing was not performed. Nine of these 11 patients were aged over 50 years. In 
31 of 159 patients no typing was performed. Reasons for not typing were no sibling 
available (N=3), too old (N=15), hypoplastic death (N=2), insufficient response (N=6), 
toxicity (N=2), patient refusal (N=2), unknown (N=1). Overall in 42 patients the availability 
of a donor was unknown (Figure 1). 
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Figure 1. Donor availability of 159 patients alive more than 8 weeks from start of treatment. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The patient characteristics according to the availability of a donor are given in Table 1. 
The median age of the patients with and without a donor was 43 years. Patients were 
subdivided in the cytogenetic risk groups as proposed by Greenberg et al.3 Of the 
patients, 52% with a donor and 49% without a donor showed intermediate and poor 
prognostic cytogenetic features. Cytogenetic risk group was unknown in 15% of patients 
with a donor and 12% of patients without a donor. The majority of MDS patients with a 
donor (76%) and without a donor (75%) belonged to the intermediate-2 and high-risk 
group of the IPSS. 
 
 
159 patients
 
128 typed 
 
31 no typing 
 
52 donor 
 
65 no donor 11 unknown 
donor
42 unknown 
donor 
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Table 1. Patient characteristics according to donor availability. 
 
Variable 
Donor N=52 
N    (%) 
No donor N=65 
N    (%) 
 
P-value 
Disease 
   MDS 
   sAML 
 
38  (73.1) 
14  (26.9) 
 
53  (81.5) 
12  (18.5) 
 
0.38 
 
Age at start (yr.) 
  < 50 
  > 50 
 
40  (76.9) 
12  (23.1) 
 
50  (76.9) 
15  (23.1) 
 
0.83 
FAB 
  RA(RS) 
  RAEB 
  RAEBt 
  CMMoL 
  sAML 
 
2    (3.8) 
16  (30.8) 
16  (30.8) 
4    (7.7) 
14  (26.9) 
 
4    (6.2) 
19  (29.2) 
26  (40.0) 
4    (6.2) 
12  (18.5) 
 
0.73 
WBC (x 109/l) 
  < 3 
  3-10 
  > 10 
 
23  (44.2) 
18  (34.6) 
11  (21.2) 
 
27  (41.5) 
23  (35.4) 
15  (23.1) 
 
0.75 
Cytogenetics IPSSa 
  Good 
  Intermediate 
  Poor 
  ND/IM 
 
17  (32.7) 
15  (28.8) 
12  (23.1) 
8   (15.4) 
 
25  (38.5) 
15  (23.1) 
17  (26.2) 
8   (12.3) 
 
0.81 
Cytogenetics Keatingb 
  Good 
  NN, -Y 
  Other 
  Poor 
  ND/IM 
 
4   (7.7) 
16  (30.8) 
11  (21.2) 
13  (25.0) 
8   (15.4) 
 
2   (3.1) 
25  (38.5) 
14  (21.5) 
16  (24.6) 
8   (12.3) 
 
0.60 
IPSS (MDS only) 
  Low 
  Intermediate-1 
  Intermediate-2 
  High 
  Unknown 
 
0    (0.0) 
4   (10.5) 
11  (28.9) 
18  (47.4) 
5   (13.2) 
 
1    (1.9) 
5    (9.4) 
20  (37.7) 
20  (37.7) 
7   (13.2) 
 
0.78 
a: Good: NN or -Y, 5q-, 20q- only; poor: chromosome 7 abnormalities, complex (> 3) abnormalities; 
intermediate: other abnormalities; ND/IM: not done/insufficient metaphases   
b: Good: t(8;21), inv(16); poor: -5, 5q-, -7, 7q-, 11q, complex (> 3); other: other abnormalities  
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Patients with an unknown donor 
In 42 patients, the availability of a donor was unknown. The median age of these patients 
was 55 years. A total of 35 patients (83%) were aged over 50 years. The availability of a 
sibling donor was not explored, since it was the intention to treat these patients without 
allogeneic SCT. Only seven patients aged less than 50 years were not typed for the 
following reasons: no sibling available (N=2), typing refused (N=1), early death (day 58) 
(N=1), toxicity (N=1) and unknown (N=2). The CR rate in the unknown donor group was 
only 45%, reflecting the older age of this group. Nine patients (21%) underwent 
autologous transplantation in first CR, none of the patients received an allograft from an 
alternative donor. The survival rate at 4 years was 10%. 
 
Outcome of patients according to donor availability 
Out of the 52 patients, 39 (75%) with a donor and 42 out of 65 (65%) without a donor 
attained CR after one or two remission-induction courses (p=0.31). Of the 52 patients 
with a donor five (10%) reached a partial response, five (10%) showed resistance, two 
(4%) showed persistent hypoplasia and one (2%) died in hypoplasia. Ultimately, out of 39 
patients with a donor, who achieved CR, 13 patients remained alive and free of disease, 
16 patients relapsed and 10 patients died in CR (Table 2). Of the 13 patients not attaining 
complete remission after remission-induction therapy according to the protocol, 10 
patients have died and three patients are still alive in CR after salvage allogeneic 
transplantation (Table 3). 
Of the 65 patients without a donor 10 (15%) reached a partial response, eight (12%) 
showed resistance, two (3%) had persistent hypoplasia and 3 (5%) died in hypoplasia. Of 
the 42 patients in CR without a donor, 15 patients remained alive and free of disease, 26 
relapsed and one died in complete remission (Table 2). Of these patients, 10, who did not 
achieve CR after remission-induction therapy according to the protocol, are still alive with 
seven of these patients in CR after salvage treatment (Table 4). 
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Table 2. Treatment results according to donor availability. 
 
 
Variable 
Donor 
N=52 
N      (%) 
No donora 
N=65 
N      (%) 
 
 
P-value 
Response induction 
  CR 
  PR 
  Resistance 
  Persistent hypoplasia 
  Death in hypoplasia 
 
39 (75.0) 
5   (9.6) 
5   (9.6) 
2   (3.8) 
1   (1.9) 
 
42 (64.6) 
10 (15.4) 
8 (12.3) 
2   (3.1) 
3   (4.6) 
 
0.31 
Stage at transplantation 
  No CR 
  CCR 
  After relapse 
  No transplantation 
 
7  (13.5) 
28 (53.8) 
1   (1.9) 
16 (30.8) 
 
10 (15.4) 
28 (43.1) 
3   (4.6) 
24 (36.9) 
 
0.65 
Event-free-survival 
  CCR 
  Relapse 
  Death in CR 
  No CR 
 
13 (25.0) 
16 (30.8) 
10 (19.2) 
13 (25.0) 
 
15 (23.1) 
26 (40.0) 
1   (1.5) 
23 (35.4) 
 
0.01 
Survival 
  Alive 
  Dead 
 
18 (34.6) 
34 (65.4) 
 
28 (43.1) 
37 (56.9) 
 
0.18 
CR: complete remission; PR: partial remission; CCR: continuous complete remission 
a: Nine patients in the no donor group received an allograft from an alternative donor: six not in 
CR, two after relapse and one in CCR. 
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Actually administered treatment  
Out of 39 complete remitters, 28 (72%) with an HLA-identical donor received an allograft 
in first CR according to the protocol. One patient was transplanted after relapse and 
seven patients received an allograft as salvage therapy. Overall 36 patients (69%) with 
an HLA-identical sibling donor underwent allogeneic transplantation. In all, 16 patients 
with an HLA-identical donor did not reach the transplantation step. Reasons for not 
performing BMT were treatment failure (N=12), toxicity (N=3) and treatment refusal 
(N=1). Two of the non-transplanted patients are still alive; one patient has relapsed and 
one patient is in continuous complete remission (Table 3).  
Of 42 complete remitters without an HLA-identical donor, 27 were autografted in first CR 
according to the protocol (64%) and five patients in more advanced disease stages: one 
patient after relapse and four patients not in CR after remission-induction chemotherapy 
according to the protocol. These five patients underwent rescue chemotherapy with stem 
cell mobilisation followed by SCT. Overall, 32 of 65 patients (49%) without a donor 
underwent autologous transplantation. In all, 33 patients received no autologous 
transplantation for the following reasons: treatment failure (N=21), toxicity (N=11) and 
protocol violation (N=1). Nine of these patients received an allograft from an alternative 
donor (one in first CR, two after relapse and six in partial response or resistance); 12 
patients, who did not receive an autologous transplantation, are still alive (including six of 
nine patients after allografting with an alternative donor) (Table 4).  
 
Time to event analysis according to donor availability 
The actuarial survival rate at four years of the 52 patients with a donor was 33.3% (s.e. = 
6.7%) versus 39.0% (s.e. = 6.5%) for the 65 patients without a donor (p=0.18) (Figure 
2A). The estimated HR for survival for the comparison donor versus no donor was 1.37 
and the 95% confidence interval was 0.86-2.19. The EFS rates at 4 years were 23.1% 
(s.e. = 6.2%) for the donor group and 21.5% (s.e. = 5.3%) for the no donor group 
(p=0.66) (Figure 2B).  
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Figure 2A. Survival from start of treatment according to donor availability.  
 
 
Figure 2B. Event-free survival from evaluation of remission-induction treatment according to donor 
availability.  
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The 4-year cumulative incidences of death in first CR were 19.9% and 1.5% in the two 
groups, respectively (Figure 3A). In total, 10 patients in the donor group died due to 
toxicity (N=2), infection (N=5), GVHD (N=2) and hemorrhage (N=1). One patient without a 
donor died of toxicity after autologous transplantation. The respective incidences of death 
due to other causes (progression of MDS/AML or related to transplantation not performed 
in first CR) were 46.8% and 59.5% (Figure 3B).  
In the 81 patients who reached CR after remission-induction chemotherapy (39 patients 
in the donor group, 42 patients in the group without a donor), the 4-year DFS rate was 
30.8% (s.e. = 7.9%) in the donor group and 33.3% (s.e. = 7.7%) in the no donor group. 
The cumulative incidences of relapse at 4 years from CR were 42.6% and 64.3%, 
respectively, and of death in first CR were 26.5% and 2.4%, respectively.  
 
 
Figure 3A. Cumulative incidence of death in first CR according to donor availability. 
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Figure 3B. Cumulative incidence of death after no CR or after relapse.  
To investigate the influence of the alternative donor transplantation in the patients without 
an HLA-identical sibling, we censored the survival at the time of alternative donor 
transplantation. The 4-year survival rate estimate for the no donor group was 37.1% (s.e. 
= 6.9%) if patients were censored at time of alternative donor transplantation compared to 
39.0% without correction. 
Since the upper age limit for allogeneic bone marrow transplantation was restricted to 
patients younger than 50 years in many centres we repeated the analysis for patients 
aged less than 50 years (40 patients with a donor, 50 patients without a donor). Outcome 
according to donor availability was not different for patients under 50 years. The 4-year 
survival rates were 33.6% (s.e. = 7.7%) for patients with a donor and 47.4% (s.e. = 7.4%) 
for patients without a donor.  
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Influence of cytogenetic abnormalities on survival 
In the combined group of 117 patients (52 with a donor, 65 without a donor) cytogenetic 
analysis was successfully performed in 101 patients. Cytogenetic features were highly 
predictive for overall survival. Patients with good and intermediate cytogenetic risk scores 
according to IPSS had a 4-year actuarial survival rate of 51% (s.e. = 8.7%) and 38% (s.e. 
= 9.2%), respectively, whereas in patients with poor prognostic cytogenetic features the 
4-year actuarial survival rate was only 10% (s.e. = 5.7%). In patients with an unknown or 
failed cytogenetic examination the 4-year survival rate was 44% (s.e. = 12.4%) (p< 
0.0001). In the subgroup with poor cytogenetic features (29 patients), we were unable to 
demonstrate a difference in survival for patients with or without a donor (Figure 4A). In 
the combined group of patients with good, intermediate and unknown cytogenetic 
features (40 patients with a donor and 48 patients without a donor) survival according to 
donor availability was likewise comparable (Figure 4B).  
 
 
Figure 4A. Survival according to donor availability in patients with poor prognostic cytogenetic 
features.  
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Figure 4B. Survival according to donor availability in patients with good, intermediate and 
unknown cytogenetic features.   
 
 
Characteristics of long-term survivors according to donor availability  
In all, 18 patients with an HLA-identical sibling donor are alive at the end of follow-up. A 
total of 16 patients survived in CR (Table 3). Patient number 2 did not receive any post-
consolidation therapy, the remaining patients have received an allograft either according 
to the protocol (12 patients) or as salvage treatment (three patients). Eight of 16 patients 
presented with good-risk cytogenetic abnormalities, five with intermediate-risk cytogenetic 
abnormalities and two patients with poor prognostic cytogenetic features. Cytogenetic 
analysis had failed in one patient. 
Two other patients are still alive after a relapse: one intermediate-risk patient, who 
showed a relapse after allogeneic transplantation and one poor-risk patient, who had 
relapsed before transplantation. 
A total of 28 patients without an HLA-identical sibling donor are alive at the end of follow-
up. In total, 20 patients survived in CR (Table 4). Four patients (patients number 6, 10, 
11, 14) did not receive any post-consolidation treatment, 10 patients received an 
autograft according to the protocol and six patients received an allogeneic SCT from an 
unrelated donor. Of 20 patients, 11 showed good-risk cytogenetic abnormalities, three 
intermediate cytogenetic abnormalities and one patient poor-risk cytogenetic 
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abnormalities. In five patients cytogenetic analysis failed. Eight patients are alive without 
CR. Three patients not in CR after remission-induction chemotherapy underwent rescue 
chemotherapy followed by autografting and failed to reach CR, three patients relapsed 
after autologous transplantation and two patients received no autograft because of 
persistent hypoplasia. Four of these eight patients had good-risk cytogenetic 
abnormalities, two intermediate-risk and in two patients cytogenetic analysis failed. 
  
Multivariate Cox's proportional hazards model for the duration of survival 
The results of the multivariate Cox’s proportional hazards model for survival are shown in 
Table 5. Cytogenetic risk categories according to IPSS appeared to be the most 
important prognostic variable for the duration of survival. The estimated HR for the poor-
risk cytogenetic subgroup compared to the good-risk cytogenetic subgroup was 3.88 with 
a 95% CI of 2.09-7.20 (p<0.0001). The estimated HR of older versus younger patients 
was 1.65 with a 95% CI of 0.97-2.83 (p=0.07), and of the donor versus no donor it was 
1.30 with a 95% CI of 0.81-2.09 (p=0.28). As age seemed not to have a constant 
influence on the outcome, we have applied a Cox model stratified for cytogenetic risk 
group and age to assess the relative prognostic importance of donor availability: the 
estimated HR was 1.17, with a 95% CI of 0.71-1.90 (p=0.54). 
 
Table 5. Results of Cox’s proportional hazards model for overall survival. 
Variable Hazard Ratio 95% CI P-value 
Cytogenetic risk group 
   Good risk  
   Intermediate risk 
   Poor risk 
   ND/IM 
 
1.00 
1.50 
3.88 
1.93 
 
 
0.78-2.90 
2.09-7.20 
0.85-4.36 
 
  
  0.22 
<0.0001 
  0.11 
Age (yr.) 
    < 50  
    > 50  
 
1.00 
1.65 
 
 
0.97-2.83 
  
  
  0.07 
Donor 
  No 
  Yes 
 
1.00 
1.30 
 
 
0.81-2.09 
  
 
  0.28 
CI = Confidence Interval, ND/IM = not done/insufficient metaphases
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DISCUSSION 
 
This analysis was performed to assess the role of allogeneic and autologous SCT in the 
treatment of patients with high-risk MDS and sAML. Reports in the literature suggest the 
superiority of allogeneic transplantation with DFS varying from 35-45%.4-10,12,25 However, 
all these studies have reported observational data. Selection of patients fit enough to go 
through allogeneic SCT may introduce a selection bias. 
The optimal way to avoid selection bias is to conduct prospective randomised trials in 
patients with an HLA-identical sibling donor. Since most clinicians consider it unethical to 
exclude the option of an allogeneic BMT from young patients with a donor, this approach 
might not be feasible. An alternative way to assess the value of allogeneic BMT without 
bias is to compare the outcome of patients with and without a donor on an intention-to-
treat basis, regardless of therapy actually received.26 We used the framework of a large 
European multi-centre study (EORTC 06921) to compare the results of allogeneic and 
autologous SCT. The original paper about this prospective study demonstrated feasibility 
of both treatment arms with common remission-induction and consolidation treatment 
followed by allogeneic SCT if a sibling donor was available and autologous SCT 
otherwise.21 Such a prospective study comparing autologous and allogeneic SCT as post-
consolidation therapy is hampered by the following phenomenon: patients may not 
receive the scheduled therapy because of early relapse or treatment-related toxicity. In 
the original paper an intention-to-treat analysis was performed in patients, who reached 
CR comparing outcome of patients with and without a donor. This resolves some of these 
biases but induces others. First, patients who did not enter CR were excluded from the 
analysis. Secondly, all patients without a known donor were categorised in the no donor 
group regardless of whether HLA-typing of patient and family was performed. Therefore, 
no firm conclusions could be drawn about the comparison between the two arms of the 
study. The present analysis is restricted to patients, alive at 8 weeks from the start of 
treatment, in whom HLA-typing was performed, irrespective of achievement of CR. Such 
an analysis at a fixed point of time minimises selection. Moreover, this policy includes the 
profit of salvage therapy for patients not in CR after remission-induction chemotherapy, 
since rescue therapy might be a curative option for patients with persistent disease. Our 
principal finding is that the overall survival at 4 years did not differ between the patients 
with and without an HLA-identical donor.  
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The reported survival rate of 33.3% for patients with a donor is in accordance with the 
literature.7,12,27,28 Of complete remitters, 72% received the intended allograft in first CR 
and 69% of all patients with a donor actually received an allograft.  
The experience with autologous transplantation in high-risk MDS and sAML patients is 
limited.18-20,28 The EBMT reported a 3-year survival of 38% for patients transplanted in 
first CR.28 The French study was the first reported prospective study on autologous stem 
cell transplantation in 83 patients with MDS and sAML.20 In 24/39 (62%) of the patients, 
who achieved CR, transplantation was performed. The median overall survival from 
transplantation was 33 months. In the present analysis, the overall survival rate at 4 years 
was 39.0% for the patients without a donor. The percentage of complete remitters who 
reached the transplantation step was 64% and overall 49% of patients without a donor 
underwent autologous transplantation. A significantly higher number of patients received 
the intended allogeneic transplantation compared to autologous transplantation (p<0.05), 
similar to observations in AML patients.29,30 The requirement to obtain a CR, in order to 
harvest normal stem cells, is the main cause of this difference. Nine patients without an 
HLA-identical donor received an allogeneic transplantation from an alternative donor. 
This might have contributed to the relatively good overall survival of the patients without 
an HLA-identical donor. However, by censoring the survival at the time of alternative 
donor transplantation, the 4-year survival estimate in the no-donor group was 37% 
compared to 39% without censoring.  
Several reports studied the same issue in primary AML.31,32 In order to answer the 
question as to whether allogeneic transplantation was superior or not compared to 
autologous transplantation or chemotherapy as post-remission therapy, the Leukemia 
Party of the European Group for Blood and Marrow Transplantation registered patients 
from the time of HLA-typing on an intention-to-treat basis.29 Of 26 patients with a donor, 
22 (85%) were allografted. In contrast, only 15 out of 47 patients (32%) intended for 
ABMT underwent ABMT. In this study the 3-year survival was significantly better for 
patients with a donor (p=0.02).29 Within the framework of the EORTC-GIMEMA AML 8A 
study a similar analysis was performed. Patients with an HLA-identical donor were 
scheduled for allogeneic BMT and patients without a donor were randomised between 
ABMT and chemotherapy.30 The AML 8A analysis showed an 8% difference in survival 
rate at the median follow-up of 6 years, the survival being 48% for patients with a donor 
compared to 40% for patients without a donor. This difference was not significant. The 
DFS for patients in CR with a donor was significantly longer than for those without (46% 
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versus 33%; p=0.01), owing to a lower relapse rate in the group with a donor (42% versus 
63%; p<0.001). 
In the present analysis the upper age limit for allogeneic transplantation was variable and 
depended on the policy of the different transplant centres. In most European centres, 
patients less than 50 years are candidates for allogeneic BMT. Several studies reported a 
decreased survival in patients over 40 years, mainly due to an increased transplant-
related mortality.7,10,28 In the present analysis, 12 patients in the donor group and 15 
patients in the group without a donor (23%) were aged over 50 years. Five of these 
patients received an allograft and three patients were autografted. If we confined the 
analysis to patients less than 50 years, the difference in overall survival between patients 
with and without a donor remained non-significant.  
Compared to the original paper, a second distinction is that the present analysis 
discriminates between patients with a donor, patients without a donor and patients with 
an unknown donor. The latter group comprises mainly patients in whom the availability of 
a donor was not explored, since there was no intention to treat these patients with 
allogeneic SCT. In the unknown donor group, 83% of patients were aged over 50 years. 
Apparently, age was the major reason for not performing HLA typing in patient and family. 
Nine out of 42 patients received autologous SCT and the overall survival rate at four 
years was 10%. If we had included this group of patients in the group without a donor, 
then the results of the donor group would have been superior to the reference group. This 
emphasises the importance of prospective studies analysed on an intention-to-treat 
basis.   
Cytogenetic abnormalities are highly prognostic in MDS and sAML. Patients were 
classified according to the cytogenetic risk groups of the IPSS.3 Patients with good and 
intermediate prognostic risk showed a survival rate at 4 years of 51% and 38% 
respectively. The 4-year survival rate of patients with bad prognostic cytogenetic features 
was only 10%. One could hypothesise that patients with poor prognostic cytogenetic 
features do better with allogeneic transplantation and patients with better prognostic 
cytogenetic features benefit by autologous transplantation. Therefore, we compared 
survival according to donor availability in the group with poor prognostic cytogenetic 
features and in the combined group with good, intermediate and unknown cytogenetic 
features. Outcome of patients with and without a donor was comparable, independent of 
the cytogenetic risk category. Only three patients with poor-risk cytogenetic features 
survived in CR: one patient with a histocompatible sibling who has not been allografted, 
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one patient who received an allograft after a partial response and one patient after 
salvage allogeneic SCT with an unrelated donor.  
Overall, the results of this analysis show that patients with high-risk MDS and sAML may 
benefit from intensive treatment strategies including allogeneic or autologous SCT. We 
were unable to demonstrate a survival advantage for patients with an HLA-identical donor 
over patients without a donor. The successful outcome of patients without a donor cannot 
be explained by salvage BMT with alternative donors. This analysis demonstrates that 
patients with an HLA-identical donor have a lower relapse risk compared to patients 
without a donor. Unfortunately, this advantage is neutralised by a substantial higher 
treatment-related mortality. Median follow-up was 3.6 years. We cannot disprove that 
after a longer follow-up, a higher percentage of patients without a donor might relapse, 
and that outcome of patients without a donor might become different. Despite small 
numbers at risk in both groups, only two patients without a donor and one patient with a 
donor relapsed after 2 years of follow-up.  
At present, most clinicians consider allogeneic SCT as the treatment of choice for 
younger patients with a donor. Nevertheless, 14 of 65 patients without a donor remained 
in first remission without allogeneic SCT. This outcome proves that long-term DFS is 
feasible without allogeneic SCT in a substantial proportion of patients with chemotherapy 
followed by autologous SCT. For patients lacking a donor, this treatment option must be 
considered as a reasonable alternative. Further development of accurate prognostic 
classification systems, incorporating response to chemotherapy, is needed to gear to a 
risk-adapted strategy for an individual patient. 
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ABSTRACT 
 
The present study applies the International Prognostic Scoring System (IPSS) to 306 
consecutive MDS patients diagnosed between August 1977 and September 2000 at the 
University Medical Centre Nijmegen. The aim was to investigate whether the IPSS could 
be used as a prognostic tool in MDS patients aged less than 61 years who were treated 
with acute myeloid leukemia (AML)-like chemotherapy with or without transplantation, and 
whether the scoring system discriminated between the subgroups of patients, who benefit 
from intensive treatment strategies. The patients were retrospectively assigned to the 
IPSS risk categories and compared with the IPSS workshop patients. Eighty-three of 159 
patients aged < 61 years, classified as intermediate-1, intermediate-2 and high risk 
according to the IPSS, received intensive treatment consisting of chemotherapy only 
(N=30), chemotherapy followed by either autologous stem cell transplantation (N=7) or 
allogeneic stem cell transplantation (N=46). After intensive treatment, the median survival 
was 2.6 years for the intermediate-1 risk group (N=33), 3.4 years for the intermediate-2 
risk group (N=27) and 0.9 years for the high-risk group (N=23). We conclude that the 
IPSS is an improved scoring system for patients receiving supportive care. Nevertheless, 
the scoring system does not seem to be the best method for predicting outcome after 
intensive antileukemic treatment. In particular, intermediate-2 risk patients may benefit 
from intensive treatment.  
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INTRODUCTION 
 
The myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by 
peripheral blood cytopenias in the presence of hypercellular bone marrow with features of 
ineffective hematopoiesis. Since 1982, MDS have been classified according to French-
American-British (FAB) criteria, based on the number of blasts in bone marrow and 
peripheral blood and the percentage of ringed sideroblasts in the bone marrow and 
monocytes in the blood.1 Five subgroups have been defined: refractory anemia (RA), 
refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess of 
blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEBt) and 
chronic myelomonocytic leukemia (CMML). Although this classification has shown its 
usefulness in predicting the outcome of patients, considerable variation still exists within 
the different subgroups regarding clinical features and survival. Numerous scoring 
systems have been proposed to predict the prognosis of individual patients.2,3  In 1997, 
an international workshop combined the data of seven previously reported studies 2-8  to 
generate an International Prognostic Scoring System (IPSS).9 The IPSS determined four 
risk groups for survival and acute myeloid leukemia (AML) evolution (low risk, 
intermediate-1 risk, intermediate-2 risk and high risk), based on karyotype, number of 
blasts in the bone marrow and number of cytopenias (Table 1). Age was an additional 
prognostic factor for survival, but not for AML evolution. The IPSS seemed to be an 
improved classification system for predicting the natural history in MDS.10 However, the 
IPSS was based on data of patients treated with transfusions, biologic response modifiers 
and low-dose oral chemotherapy. Patients treated with intensive chemotherapy and/or 
stem cell transplantation and patients with therapy-related MDS were excluded from this 
analysis.  
The present study is a retrospective analysis of 306 untreated MDS patients who have 
been seen in the Nijmegen University Hospital, many of whom subsequently received 
intensive antileukemic treatment consisting of AML-like chemotherapy with or without 
autologous stem cell transplantation, allogeneic transplantation with or without preceding 
chemotherapy. Classified according to the IPSS criteria, the outcome of our patients was 
compared with that of the IPSS workshop patients. 
The principle aim was to investigate whether the IPSS predicts outcome of patients aged 
less than 61 years treated with intensive therapy, and whether the scoring system 
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discriminates between subgroups of patients, who may benefit from these intensive 
treatment strategies.  
 
Table 1. The International Prognostic Scoring System (IPSS). 
Score value  
Prognostic variable 0 0.5 1.0 1.5 2.0 
BM blasts (%) 
Karyotypea 
Cytopeniasb 
5 
Good 
0/1 
5-10 
Intermediate 
2/3 
- 
Poor 
11-20 21-30 
Scores for risk groups are as follows: Low: 0; Intermediate-1: 0.5-1.0; Intermediate-2: 1.5-2.0; and 
High: > 2.5 
a: Good: normal, -Y, del(5q), del(20q); Poor: complex (> 3) abnormalities, chromosome 7 
abnormalities; Intermediate: other abnormalities 
b: Hemoglobin < 6.2 mmol/l, neutrophil count < 1.8 x 109/l, platelet count < 100 X 109/l 
 
PATIENTS AND METHODS 
 
Patients 
Between August 1977 and September 2000, 380 newly diagnosed MDS patients have 
been referred to the University Medical Centre Nijmegen. This group consisted of patients 
referred by their family practitioners or physicians from general hospitals in south-east 
Netherlands. We reviewed the data of all MDS patients. In 74 patients (19%), sufficient 
data were not available, mainly due to lack of cytogenetic data and these patients were 
excluded from the present analysis. In 302 out of the remaining 306 patients the 
karyotype was known. Four patients with unknown karyotype belonged to the high-risk 
group of the IPSS based on the number of blasts in the bone marrow (21-30%) and the 
number of cytopenias (2/3). Therefore, these patients were not withdrawn from the 
analysis. In all, 306 patients were retrospectively assigned to the various IPSS risk 
categories. 
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Treatment  
All patients received supportive care. The majority of elderly patients (aged 60 years or 
over) received supportive care without intensive treatment. Only nine elderly patients (7%) 
were treated with intensive chemotherapy followed by autologous stem cell 
transplantation in one patient.  
Generally, the accepted age limit for allogeneic stem cell transplantation varies between 
50 and 60 years. In Nijmegen, patients aged < 61 years are eligible for allogeneic stem 
cell transplantation, in the absence of other medical contraindications. Low-risk IPSS 
patients were not candidates for intensive antileukemic treatment, in view of their 
relatively good prognosis. In contrast, patients aged < 61 years, belonging to the 
intermediate-1, intermediate-2 and high-risk categories of the IPSS could be considered 
as candidates for intensive treatment strategies including allogeneic stem cell 
transplantation. We divided the patients into two groups diagnosed before and after 1 
January 1992. Before 1992, the decision to start intensive treatment was individually 
based. In those years, 13 patients with a human leukocyte antigen-identical donor 
underwent allogeneic stem cell transplantation: five patients with RA received a 
transplant without preceding chemotherapy, and eight RAEB/RAEBt patients underwent 
AML-like chemotherapy followed by an allogeneic transplantation. Six additional patients 
received chemotherapy but no transplantation at the time of progression of their disease. 
In January 1992, the department changed the treatment policy and, from 1992 onwards, 
all high-risk MDS patients were offered intensive antileukemic treatment, if they met the 
eligibility criteria of successive European Organization for the Research and Treatment of 
Cancer (EORTC) protocols.  Patients were candidates for intensive treatment if they were 
aged 16-60 years and had untreated (i) RAEBt, (ii) RAEB with > 10% blasts cells in the 
bone marrow, (iii) other forms of MDS with multiple chromosomal abnormalities and/or 
profound cytopenias defined as: neutrophil count < 0.5 x 109/l and/or platelet count < 20 x 
109/l, or (iv) CMML with > 5% blasts cells in the bone marrow or with a neutrophil count > 
16 x 109/l or a monocyte count > 2.6 x 109/l in the blood. 
After 1992, 64 patients were offered intensive antileukemic treatment. Twenty-two 
patients diagnosed after 1992 did not receive intensive treatment for the following 
reasons: treatment refused (N=3), psychiatric disorder (N=1), language barrier and 
platelet refractoriness (N=1), concomitant disease (N=2), death before start of treatment 
due to infection (N=2), cardiomyopathy (N=1), not eligible for the protocol (N=4), doctor’s 
decision (N=5), unknown (N=3).  
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Statistical analysis  
Chi-square tests were used to compare differences between groups. Kaplan-Meier 
survival analyses were used to estimate median survival time and to plot survival curves. 
To compare survival times in different strata, the log-rank test was used.11 
The prognostic effect of IPSS, age, diagnosis period, treatment, bone marrow blasts, 
cytopenias and cytogenetics on survival time was analysed in multivariate analyses using 
proportional hazards models. In this multivariate analysis we also evaluated the 
interaction between IPSS and age (< 61 years versus > 60 years). A p-value < 0.05 was 
considered statistically significant. 
 
RESULTS 
 
The Nijmegen patients were younger than the IPSS workshop patients, with a median 
age of 58 years versus 69 years (Table 2). Eighteen per cent of patients developed MDS 
after prior treatment with chemotherapy or radiotherapy for a non-related disease 
(therapy-related MDS). The Nijmegen patients presented with more cytopenias and more 
severe cytopenias resulting in median hemoglobin level, neutrophil and platelet counts of 
9.2 g/dl, 1.4 x 109/l and 75 x 109/l respectively. The corresponding blood counts for the 
IPSS workshop patients were 9.7 g/dl, 2.0 x 109/l and 132 x 109/l. Median survival was 
5.1 years in the low-risk group, 2.4 years for the intermediate-1 risk group, 1.2 years for 
the intermediate-2 risk group and 0.8 year for the high-risk group (p<0.0001) (Figure 1). 
Median survival in the low risk and intermediate-2 risk group was comparable in the 
Nijmegen and the IPSS workshop patients. However, the median survival in the 
intermediate-1 risk group was lower in the Nijmegen patients, and median survival in the 
high-risk group was better for the Nijmegen patients (Table 3). 
Intensive antileukemic therapy with or without stem cell transplantation was administered 
to patients younger than 61 years. Therefore, the outcome of patients aged < 61 years 
was compared with the same age category of the IPSS workshop patients. The 
differences in median survival between the Nijmegen patients and the IPSS workshop 
patients in the younger patient groups were similar to the differences found in the overall 
groups (Table 3).  
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Table 2. Characteristics of all Nijmegen MDS patients compared to IPSS workshop patients and of 
Nijmegen patients aged less than 61 years at diagnosis (low-risk excluded), according to applied 
treatment.   
   Nijmegen < 61 years  
 
 
Variable 
 
Nijmegen 
N (%) 
 
IPSS workshop 
N (%) 
No intensive 
treatment 
N (%) 
Intensive  
treatment 
N (%) 
 
 
P-valuea 
Number of patients 306 (100) 816 (100) 76 (100) 83 (100)  
Gender 
  Male 
  Female 
 
198 (65) 
108 (35) 
 
491 (60) 
325 (40) 
 
43 (57) 
33 (43) 
 
54 (65) 
29 (35) 
 
0.27 
Age (years) 
  < 60 
  > 60  
 
176 (58) 
130 (42) 
 
205 (25) 
611 (75) 
 
53b 
 
45b 
 
<0.001 
MDS 
  Primary 
  Therapy-related 
 
250 (82) 
  56 (18) 
 
816 (100) 
0 
 
56 (74) 
20 (26) 
 
72 (87) 
11 (13) 
 
0.04 
FAB 
  RA 
  RARS 
  RAEB 
  RAEBt 
  CMML 
  Unknown 
 
94 (31) 
37 (12) 
96 (31) 
64 (21) 
11   (4) 
  4   (1) 
 
294 (36) 
125 (15) 
208 (26) 
  61  (8) 
126 (15) 
 
29 (38) 
  8 (11) 
26 (34) 
  9 (12) 
  4   (5) 
 
18 (23) 
  5   (6) 
24 (29) 
34 (41) 
 2   (2) 
 
<0.001 
BM blasts  
       <5% 
    5-10% 
  11-20% 
  21-30%  
 
136 (44) 
  81 (27) 
 60 (20) 
  29 (10) 
 
483 (59) 
183 (22) 
114 (14) 
  36   (5) 
 
37 (49) 
20 (26) 
13 (17) 
6   (8) 
 
22 (27) 
26 (31) 
24 (29) 
11 (13) 
 
0.03 
Cytopenias 
  0/1 
  2/3   
 
114 (37) 
192 (63) 
 
474 (58) 
342 (42) 
 
27 (36) 
49 (64) 
 
24 (29) 
59 (71) 
 
0.37 
Cytogenetic subgroup  
  Good 
  Intermediate 
  Poor 
  Unknown 
 
139 (46) 
  83 (27) 
  80 (26) 
    4   (1) 
 
570 (70) 
112 (14) 
134 (16) 
 
22 (29) 
26 (34) 
28 (37) 
 
 
36 (44) 
22 (26) 
24 (29) 
1   (1) 
 
0.15 
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IPSS  
  Low 
  Intermediate-1 
  Intermediate-2 
  High   
 
   37 (12) 
124 (41) 
  88 (29) 
  57 (19) 
 
267 (33) 
314 (38) 
176 (22) 
  59   (7) 
 
 
38 (50) 
26 (34) 
12 (16) 
 
 
33 (40) 
27 (33) 
23 (28) 
 
 
0.17 
Intensive treatment 
  Yes 
  No 
 
   93 (30) 
 213 (70) 
 
0 
816 (100) 
 
0 
76 (100) 
 
83 (100) 
0 
 
 
Diagnosis 
  Before 1992 
  After 1992 
 
163 (47) 
143 (53) 
 
816 (100) 
0 
 
54 (71) 
22 (29) 
 
19 (23) 
64 (77) 
 
<0.001 
a: P-value for the comparison between intensive treatment and no intensive treatment in the 
Nijmegen patients 
b: Median age (years) 
 
 
Table 3. Survival of Nijmegen patients and IPSS workshop patients per IPSS risk group in all 
patients and in patients aged less than 61 years. 
 
IPSS 
Nijmegen 
all 
(N=306) 
N (%) 
 
Median 
survival 
(years) 
Greenberg
all 
(N=816) 
N (%) 
 
Median 
survival 
(years) 
Nijmegen
< 61 yr. 
(N=176) 
N  (%) 
 
Median
survival 
(years)
Greenberg  
< 61 yr. 
(N=205) 
N (%) 
 
Median
survival 
(years)
Low  37 (12) 5.1 267 (33) 5.7 17 (10) 11.1 60 (29) 11.8 
Int-1 124 (41) 2.4 314 (39) 3.5 71 (40) 2.5 87 (42) 5.2 
Int-2  88 (29) 1.2 176 (22) 1.2 53 (30) 1.4 49 (24) 1.8 
High  57 (19) 0.8   59  (7) 0.4 35 (20) 0.9 9   (4) 0.3 
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Figure 1. Survival from diagnosis in all patients according to IPSS risk group (N=306). 
 
Effect of intensive treatment in patients aged less than 61 years 
There were 176 patients who were aged < 61 years. Patients with intermediate-1, 
intermediate-2 and high-risk IPSS scores could be considered as candidates for intensive 
antileukemic treatment. Seventeen patients belonged to the low-risk group of the IPSS. 
Of the remaining 159 patients, classified as IPSS intermediate-1, intermediate-2 and 
high-risk categories, 83 patients (52%) received intensive treatment and 76 patients 
(48%) did not. Thirty patients received chemotherapy only, 7 patients underwent 
chemotherapy followed by autologous transplantation and, in 46 patients, allogeneic stem 
cell transplantation was performed (21 patients with RA(RS) without preceding 
chemotherapy). Four patients received a transplant from a voluntary unrelated donor 
(VUD). 
Intensive chemotherapy in patients < 61 years consisted of cytarabine only (N=3), 
cytarabine plus anthracycline (N=7), cytarabine plus amsacrine plus etoposide (N=2), 
cytarabine plus anthracycline plus vincristine (N=3) or cytarabine plus anthracycline plus 
etoposide (N=47).  
Seventy-six patients did not receive intensive treatment. Patient characteristics for both 
groups are shown in Table 2. Median age of the patients who received intensive 
treatment was 45 years versus 53 years for patients who received supportive care only. 
0
0,5
1
0 5 10 15
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The estimated 4-year survival of the 83 patients who underwent intensive treatment was 
36.3% versus 23.0% for the 76 patients, who received supportive care only (p=0.02). 
In the intensive treatment group, median survival from diagnosis was 2.6 years for the 
intermediate-1 risk group, 3.4 years for the intermediate-2 risk group and 0.9 years for the 
high-risk group. The estimated 4-year survival rates were 46%, 40% and 19% 
respectively (Table 4). In the intermediate-1 risk group, six patients received 
chemotherapy only, three patients received chemotherapy followed by autologous 
transplantation, and 24 patients underwent allogeneic stem cell transplantation. In the 
intermediate-2 risk group, 12 patients received chemotherapy only, three patients 
received chemotherapy followed by autologous transplantation, and 12 patients 
underwent allogeneic stem cell transplantation. These numbers were 12, 1 and 10, 
respectively in the high-risk group. The median time between diagnosis and start of 
treatment was 0.2 years (range 0-5.7 years). At the start of treatment, 15 patients had 
progressed to a higher IPSS risk category than at initial diagnosis. Hence, at the start of 
intensive treatment, 25 patients were classified in the intermediate-1 risk group, 23 
patients in the intermediate-2 risk group and 35 patients in the high-risk group. Survival 
from start of treatment for the different IPSS risk categories at start of intensive treatment 
is shown in Figure 2.  The survival from diagnosis in patients, who received no intensive 
treatment, is shown in Table 4. 
An additional analysis was performed, which excluded the secondary MDS patients, as 
these patients were not included in the IPSS workshop. Median survival according to 
IPSS risk groups of both intensively treated patients (N=72) and not-intensively treated 
patients (N=56) was not different, if the analysis was restricted to primary MDS patients 
(data not shown). 
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Table 4. Survival of patients aged less than 61 years according to IPSS risk group at diagnosis 
(low- risk excluded) for patients with and without intensive treatment (N=159). 
 
IPSS 
No intensive 
treatment 
(N=76)  
Median 
survival 
(years) 
4-year 
survival 
(%) 
Intensive 
treatment 
(N=83) 
Median 
survival 
(years) 
4-year 
survival 
(%) 
Intermediate-1 38  2.2 37 33  2.6 46 
Intermediate-2 26  0.8 11 27  3.4 40 
High 12  0.7 0 23  0.9 19 
 
 
Figure 2. Survival from start of treatment in patients aged less than 61 years after intensive 
antileukemic therapy according to IPSS risk group at start of intensive treatment (N=83). 
 
Effect of allogeneic stem cell transplantation in patients aged < 61 years 
Forty-six patients underwent allogeneic stem cell transplantation. Median survival of 
these 46 patients was 5.7 years compared to 0.9 years for the 37 patients who received 
chemotherapy with or without autologous stem cell transplantation (p=0.0005). Of the 46 
patients receiving an allogeneic transplantation, 24 belonged to the intermediate-1 risk 
group, 12 to the intermediate-2 risk group and 10 to the high-risk group. Median survival 
after allogeneic stem cell transplantation was 5.7 years for the intermediate-1 risk group, 
10.3 years for the intermediate-2 risk group and 1.1 years for the high-risk group 
0
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(p=0.28). The estimated 4-year survival rates were 50% for the intermediate-1 risk group, 
67% for the intermediate-2 risk group and 30% for the high-risk group.  
 
Effect of the year of diagnosis on treatment in patients aged < 61 years 
A total of 159 patients were assigned to the intermediate-1, intermediate-2 and high-risk 
groups of the IPSS. Eighty-three patients who were younger than 61 years received 
intensive treatment. Nineteen patients diagnosed before 1992 received intensive 
treatment and 64 patients thereafter. The median survival was 1.4 years versus 1.8 years 
respectively (p=0.5).   
Seventy-six patients received supportive care only. The median survival of 54 patients 
diagnosed before 1992 was 1.2 years versus 2.2 years for the 22 patients diagnosed 
after 1992 (p=0.7).  
 
Influence of cytogenetic abnormalities 
In 302 out of 306 patients the karyotype was known. A total of 139 patients (46%) 
showed good prognostic cytogenetic features according to IPSS (normal cytogenetics, 
5q-, 20q- or -Y). Poor prognostic features (three or more abnormalities, chromosome 7 
abnormalities) were observed in 80 patients (26%) and intermediate prognostic features 
(any other cytogenetic abnormality) in 83 patients (27%). Median survival of patients with 
a good karyotype was 2.8 years, with a poor karyotype 0.8 years and with an 
intermediate karyotype 2.0 years (p < 0.0001). 
According to the Keating classification 12 as used for AML, no patients had favourable 
cytogenetic abnormalities [inv(16), t(8,21) or t(15,17)]. Intermediate prognostic 
cytogenetic abnormalities (normal, -Y) occurred in 149 patients (49%), and unfavourable 
prognostic cytogenetic abnormalities (chromosome 5 or 7 abnormalities, 11q, other 
abnormalities) were found in 153 patients (61%). The median survival for the intermediate 
prognostic group according to this classification was 2.7 years versus 1.2 years for the 
unfavourable prognostic group. 
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Multivariate analyses 
Since the IPSS was designed to predict the survival of patients treated with supportive 
care or low-intensity regimens, we analysed the prognostic effect of the different IPSS 
categories and age on survival in 213 patients who received supportive care only. The 
results of the multivariate Cox's proportional hazards model are shown in Table 5. The 
classification into the four IPSS categories appeared to be highly prognostic for the 
duration of survival. The estimated hazard ratio for the high-risk group compared to the 
intermediate-1 risk group was 2.84 [95% confidence interval (CI), 1.80-4.49; p<0.0001]. 
The estimated hazard ratio of older versus younger patients was 1.01 (95% CI  0.99-1.02; 
p=0.18). 
 
Table 5. Results of Cox's proportional hazards model for overall survival in patients who received 
no intensive treatment (N=213). 
Variable Hazard Ratioa 95% CI P-value 
IPSS risk group 
    Low 
    Intermediate-1 
    Intermediate-2 
    High 
 
0.40 
1.00 
1.65 
2.84 
 
0.23-0.69 
 
1.14-2.40 
1.80-4.49 
 
   0.0009 
 
   0.008 
< 0.0001 
Age (years) 
    < 60  
    > 60  
 
1.00 
1.01 
 
 
0.99-1.02 
 
 
   0.18 
CI, Confidence Interval 
a: A value >1 indicates that the outcome is worse for that category in comparison with the baseline 
 
Secondly, the impact of intensive treatment was tested in 159 younger patients, 
belonging to the intermediate-1, intermediate-2 and high-risk categories of the IPSS. The 
results are shown in Table 6. The IPSS risk groups appeared to be of significant 
prognostic value. The comparison between patients who received intensive treatment 
and those who received supportive care only yielded a hazard ratio of 0.65 (95% CI of 
0.45-0.94). This indicates that the rate of death was 35% lower in patients receiving 
intensive antileukemic treatment (p=0.02).  
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Table 6. Results of Cox's proportional hazards model for survival of intermediate-1, intermediate-2 
and high-risk patients aged less than 61 years (N=159). 
Variable Hazard Ratioa 95% CI P-value 
IPSS risk group 
  Intermediate-1 
  Intermediate-2 
  High 
 
1.00 
1.46 
2.22 
 
 
0.96-2.23 
1.38-3.58 
 
   
   0.08 
   0.001 
Intensive treatment 
  Yes 
  No 
 
0.65 
1.00 
 
0.45-0.94 
 
   0.02 
Diagnosis 
  Before 1992 
  After 1992 
 
1.17 
1.00 
 
0.80-1.70 
 
   0.41 
CI, Confidence Interval 
a: A value >1 indicates that the outcome is worse for that category in comparison with the baseline 
 
Ultimately, we analysed the prognostic effect of the IPSS in 83 intensively treated 
patients aged < 61 years (excluding the low-risk group). The estimated hazard ratio for 
the high-risk group compared with the intermediate-1 risk group was 1.81 (95% CI 0.16-
21.16; p=0.63). The estimated hazard ratio for the intermediate-2 risk group compared 
with the intermediate-1 risk group was 0.83 (95% CI 0.22-3.13; p=0.78). The percentage 
of bone marrow blasts cells was not predictive for survival. There was a trend for better 
survival in patients with fewer cytopenias and without poor prognostic cytogenetic 
features, although this did not reach statistical significance. Outcome after allogeneic 
stem cell transplantation was significantly better than after chemotherapy with or without 
autologous stem cell transplantation (p=0.006). 
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DISCUSSION 
 
Since 1982, the FAB classification has been used to classify MDS patients and to predict 
outcome in terms of survival and risk of AML development. The FAB classification is 
based solely on morphological criteria. It has been increasingly acknowledged that 
biological and molecular variables are important for diagnosing and stratifying MDS 
patients.  
The development of the International Prognostic Scoring System (IPSS) in 1997, based 
on cytogenetic criteria, number of blasts in the bone marrow and number of cytopenias, 
was a major step forward towards a risk-adapted treatment strategy for an individual 
patient. We applied the IPSS to 306 MDS patients from a single university centre. The 
Nijmegen patients formed a rather heterogeneous group compared with the IPSS 
workshop patients (i.e. different age distribution, including secondary MDS patients and 
patients receiving intensive treatment). To investigate the effectiveness of the IPSS in a 
large group of unselected patients, we applied the IPSS to all Nijmegen patients. Despite 
the different nature of the Nijmegen patients, the IPSS stratified our patients effectively 
into the four different categories. The number of reports applying the IPSS is still 
limited.10,13-16  An overview of the reported results is given in Table 7. The patients from 
the M.D. Anderson Cancer Center 13 were younger, had more often RAEBt, two or three 
cytopenias and prognostically poor cytogenetic abnormalities. A shorter survival for each 
of the IPSS risk categories was found. In the Leuven analysis 10 patients were diagnosed 
during a different period. This analysis included only patients who underwent bone 
marrow biopsy. Out of 184 patients, 30 (16%) received high-dose chemotherapy. 
Outcome of low and high-risk patients was better (6.5 and 0.7 years) and outcome of 
intermediate-1 risk patients (2.6 years) was worse compared to the IPSS workshop 
patients. The median age of the patients in the Korean study was 53 years.14 This study 
included patients treated with low-dose cytarabine, androgen and all-trans retinoic acid. 
Jaiyesimi et al. applied the IPSS to 74 patients diagnosed between 1990 and 1997.15 
Compared with the workshop patients, their patients were older and presented with more 
cytopenias. The median survival for the intermediate-1 (3.4 years) and high-risk (0.5 
years) group was comparable, but an improved survival for the intermediate-2 risk group 
(4.1 years) was found. However, patient numbers in the low risk, intermediate-2 risk and 
high-risk groups were small.  
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The observed differences in median survival within the four risk categories raises several 
questions. Do the IPSS workshop patients represent patients diagnosed nowadays? 
Does the selection of patients play a role in the reported results? The IPSS workshop 
obtained clinical data of 816 primary MDS patients from seven previously reported 
studies. Together, these studies included over 1600 patients between 1970 and 1992. In 
about 50% of reported patients, insufficient data were available, and hence selection may 
have occurred. Compared with the IPSS workshop patients, the Nijmegen patients 
presented with more adverse prognostic features. As Nijmegen is a referral centre for 
MDS patients in the south-eastern part of The Netherlands, this may in part explain the 
observed differences. As in the series of Estey et al. 13, median blood counts in Nijmegen 
patients were lower than in the IPSS workshop patients. The workshop authors 17 
confirmed a shorter survival in patients with more profound cytopenias.  
Another point to consider is whether the natural history of MDS has changed over time, 
and whether supportive care has improved in recent years. All IPSS workshop patients 
were diagnosed before 1992. In the Nijmegen patients, a trend towards better survival 
was observed for both intensively treated and not-intensively treated patients diagnosed 
after 1992. However, this was not statistically significant. 
In the Nijmegen cohort, 213 out of 306 patients received supportive care only. In these 
patients, the IPSS was highly predictive for survival. Multivariate analysis showed a 
sevenfold risk of death for the IPSS high-risk patients compared with the low risk patients.  
The key question is whether the IPSS could also predict the outcome of MDS patients 
aged < 61 years treated with intensive therapies, including stem cell transplantation. 
Therefore, we evaluated survival in 83 intensively treated patients. In this study the 
median survival of intermediate-2 risk patients was better than that of intermediate-1 risk 
patients. This suggests that patients belonging to the intermediate-2 risk group, in 
particular, benefited from intensive treatment strategies. In multivariate analysis, the 
different IPSS risk groups were not predictive for survival. Hence, this analysis does not 
support the value of the IPSS to predict survival after intensive antileukemic treatment. 
Median survival after intensive antileukemic treatment was significantly better than 
median survival after supportive care only. Opponents of intensive treatment in MDS 
often argue that the reported results are biased by selection of patients with a relatively 
good prognosis. The present analysis establishes that survival of non-intensively treated 
patients did not deteriorate with the course of time. This supports the fact that we did not 
select patients with a relatively good prognosis for intensive treatment. Nevertheless, this 
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analysis was not designed to compare the outcome of intensively treated patients with 
that of patients who received supportive care only. An important pitfall of observational 
studies is that selection bias can never be ruled out completely. 
Another point to consider is whether the applied treatment was effective. Treatment 
included chemotherapy only, chemotherapy followed by autologous transplantation and 
allogeneic transplantation with or without preceding chemotherapy. We demonstrated 
that chemotherapy only and chemotherapy followed by autologous stem cell 
transplantation were less effective than allogeneic stem cell transplantation. One can 
argue that the imbalance of the different treatments in the various IPSS risk groups may 
have influenced the outcome. However, in the more homogeneous group of 46 patients 
who underwent allogeneic stem cell transplantation, the conclusions remained 
unchanged. 
Finally, it is still unclear which patients benefit most from intensive treatment strategies. 
The present study suggests that survival in the intermediate-2 risk group improved after 
intensive therapy. The estimated 4-year survival rate in the intermediate-2 risk group was 
40% for patients treated intensive therapy versus 11% for patients receiving supportive 
care only. Survival in the high-risk group of the IPSS was rather disappointing. After 
intensive antileukemic therapy, the 4-year survival rate of the high-risk patients was 19%, 
whereas none of the patients receiving supportive care only achieved prolonged survival. 
The literature contains only a few reports on the value of the IPSS in intensively treated 
patients. Appelbaum et al. 18 applied the IPSS to 251 patients who underwent allogeneic 
bone marrow transplantation. They concluded that the IPSS was useful to predict relapse 
and disease-free survival after allogeneic transplantation. The reported 5-year disease-
free survival rates were 60% for low-risk and intermediate-1 risk patients, 36% for 
intermediate-2 risk patients and 28% for high-risk patients. In our subanalysis of 46 
patients who received allogeneic stem cell transplantation, the estimated 4-year survival 
rates were 50% for the intermediate-1 risk patients, 67% for the intermediate-2 risk 
patients and 30% for the high-risk patients.  
Cytogenetic abnormalities occur in about 50% of MDS patients.3,19-21 Two large studies 
demonstrated that karyotype has independent prognostic value.3,8 Estey et al. 22 reported 
that cytogenetic risk groups were highly predictive for outcome after intensive 
chemotherapy. A study from Vancouver 23 showed that IPSS cytogenetic risk groups 
have impact on survival after allogeneic bone marrow transplantation. The Spanish group 
24 confirmed the prognostic value of the IPSS in 640 patients. Their main criticism was 
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that the intermediate cytogenetic prognostic risk group is a receptacle of single- and 
double-chromosome abnormalities and that some single abnormalities might well prove 
to be of good or poor prognosis when a larger number of cases are analysed.  
Although the Nijmegen patients showed worse prognostic features at diagnosis than the 
IPSS workshop patients, we conclude that the IPSS is an effective scoring system for 
MDS patients treated with supportive care only. However, the scoring system did not 
seem to be the best method for predicting outcome after intensive antileukemic 
treatment. In particular, the intermediate-2 risk patients seemed to benefit from intensive 
antileukemic treatment. Use of the IPSS is recommended for planning treatment for an 
individual patient. A scoring system based on the number of cytopenias and cytogenetic 
risk group might predict outcome after intensive therapy better than a scoring system that 
includes the percentage of bone marrow blasts. 
 
Table 7. Application of the International Prognostic Scoring System in the literature regarding 
clinical outcome of MDS patients. 
 IPSS Estey Maes Lee Jaiyesimi Sperr Nijmegen
Number of patients 816 219 184 91 79 102 306 
Median age 69 65 64 53 74 71 58 
Time period '70-'92 < '91 '80-'97 '89-'97 '90-'97 '89-'99 '77-'00 
Median survival (yr.) (%)a 
  Low 
  Intermediate-1 
  Intermediate-2 
  High 
        
5.7 (33) 
3.5 (38) 
1.2 (22) 
0.4   (7) 
 
2.1 (13)
1.2 (41)
0.7 (30)
0.4 (16)
 
6.5 (22)
2.6 (46)
1.3 (25)
0.7   (7)
 
3.8   (4)
3.6 (47)
0.8 (24)
0.7 (24)
 
NR (15) 
3.4 (49) 
4.1 (19) 
0.5 (16) 
 
7.5 (23) 
1.7 (41) 
1.9 (20) 
1.0 (17) 
 
5.1 (12) 
2.4 (41) 
1.2 (29) 
0.8 (19) 
NR, not reached 
a: Percentage of patients in the different IPSS risk groups 
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ABSTRACT 
 
High-risk MDS patients have a less favorable outcome after intensive treatment compared 
with AML. This may reflect disease-related factors or a higher frequency of patient-related 
factors. The purpose of this analysis was to identify clinical and biologic factors for 
outcome of MDS and AML patients. 981 patients (< 65 yr.) received identical remission-
induction and consolidation treatment in two European studies (EORTC AML-10 and 
CRIANT). Estimated 5-year survival was comparable (34% (AML-10) vs. 27% (CRIANT)) 
but DFS was better in the AML-10 study (40% vs. 28%). In multivariate analysis 
cytogenetics, white blood count, age, and study protocol were prognostic for survival in all 
patients. However, some variables appeared prognostic in only one of the studies. AML-
10: performance status, FAB M2/M4 and cytogenetics inv(16)/t(8;21), CRIANT: number of 
cytopenias and duration of Antecedent Hematologic Disorder. A prognostic score was 
developed for both studies. The scores distinguish 3 groups with a 5-year survival of 54%, 
38%, and 19% (AML-10) vs. 69%, 37%, and 5% (CRIANT). According to the scores 30% 
of AML-10 and 43% of CRIANT patients have a survival less than 20%. Our finding that 
prognostic factors differ in MDS and AML patients supports the hypothesis that MDS and 
AML are intrinsically different disorders. 
PROGNOSTIC FACTORS IN MDS AND AML 
135  
INTRODUCTION 
 
In the early eighties the French-American-British (FAB) classification has been developed 
for the classification of acute myeloid leukemia (AML) and myelodysplastic syndrome 
(MDS) based on the percentage of blast cells in the bone marrow and in the peripheral 
blood, as well as on the presence of Auer rods and monocytes.1,2 Although dysplastic 
features form the hallmark of the myelodysplastic syndromes, dysplastic features are also 
observed in de novo AML.3 The distinction between AML and MDS was based on an 
arbitrary cut-off of 30% bone marrow blasts. One of the major changes in the recently 
introduced WHO classification is lowering the blast percentage for the diagnosis of AML to 
20%.4  
The distinction between MDS and AML has important therapeutic consequences. 
Intensive chemotherapy regimens with or without stem cell transplantation (SCT) are 
widely used for de novo AML patients aged less than 60 years.5-10 In about 75% of 
patients combination chemotherapy induces a complete remission with 30-40% long-term 
leukemia-free survivors. The use of AML-like therapy in patients with high-risk MDS has 
been accepted less widely. Remission-induction chemotherapy results in complete 
remission rates between 15-65%.6,11-15  The median remission duration is usually short 
due to a high incidence of early relapses. The experience with autologous SCT in MDS is 
still limited.16,17 Allogeneic SCT is a curative option for younger MDS patients with HLA-
identical donors with reported disease-free survival of approximately 35-40%.18,19 
Recently, treatment of patients aged over 55 years resulted in a relapse-free survival of 
47%.20 
Important biologic differences between MDS and AML have been demonstrated.21 The 
question is whether the reported poorer outcome of high-risk MDS patients compared to 
de novo AML patients reflects an intrinsic property of the stem cells involved (disease-
related factors like cytogenetic abnormalities and molecular aberrations) and possibly of 
the microenvironment or reflects an increased incidence of poor prognostic patient-
related factors (like advanced age and poor performance status) in MDS.15  
In the present analysis we compared the treatment outcome of de novo AML patients with 
outcome of high-risk MDS and secondary AML (sAML) patients, after identical remission-
induction and consolidation chemotherapy. Patients with de novo AML or sAML after MDS 
of less than 6 months were treated in the EORTC-GIMEMA AML-10 study (06931). 
Patients with high-risk MDS or secondary AML after MDS of at least 6 months were 
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treated in the CRIANT study (06961), a joint study of the EORTC, GIMEMA, EBMT, 
HOVON, SAKK and Nordic MDS Groups. The purpose of the present analysis was to 
identify prognostic factors for outcome of MDS and AML patients. A second question was 
whether disease-related factors differ between MDS and AML and whether poor 
prognostic factors occur more often in MDS.  
 
PATIENTS AND METHODS 
 
AML-10 study 
Between November 1993 and December 1999 2157 patients were included in the AML-10 
study. Patients aged 15-60 years with de novo AML or sAML supervening after 
documented MDS of less than 6 months duration were eligible, after informed consent 
was obtained. Patients with AML M3 were excluded. The objective of the AML-10 study 
was to compare the effect of three different intercalating agents (idarubicin, daunorubicin 
and mitoxantrone) in the remission-induction and consolidation regimens. For the present 
analysis we selected the 717 patients treated in the idarubicin arm. By doing this, we 
selected the patients from both studies (AML-10/CRIANT), who received identical 
remission-induction and consolidation chemotherapy. In the AML-10 study 25 patients 
appeared to be ineligible for the following reasons: other disease (N=11), age (N=1), 
performance status (N=1), concomitant disease (N=2), poor quality of the data (N=9), 
other (N=1). So, 692 patients from the AML-10 study were included in the present 
analysis. 
 
CRIANT study 
Between December 1996 and December 2001 324 patients were included in the CRIANT 
study. Patient aged between 16-60 years (or -65 years according to the policy of the 
centre), with a WHO performance status of 0-2, after informed consent was obtained, 
were included in the study if they had (a) untreated RAEBt or RAEB with more than 10% 
blasts in the bone marrow (b) sAML supervening after overt MDS of more than 6 months 
duration (c) CMML with more than 5% blasts in the bone marrow, more than 16 x 109/l 
neutrophils or more than 2.6 x 109/l monocytes in the blood (d) other forms of MDS with 
multiple chromosome abnormalities and/or profound cytopenias defined as neutrophil 
count less than 0.5 x 109/l and/or platelet count less than 20 x 109/l.  
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Since there is no consensus about the use of chemotherapy in RA(RS) patients, these 
patients (N=8) were excluded from the present analysis. The CMML patients (N=19) were 
excluded as well, since these patients are considered to have a myeloproliferative / 
myelodysplastic disorder according to the new WHO classification instead of a MDS. So, 
for the present analysis 297 patients presenting with RAEB, RAEBt and sAML were 
eligible. Eight patients were not evaluable for the following reasons: other disease (N=1), 
performance status (N=1), and poor quality of the data (N=6). Ultimately 289 patients from 
the CRIANT study were included. 
 
Treatment  
Remission-induction chemotherapy consisted of idarubicin 10 mg/m2 iv. days 1, 3, 5, 
cytarabine 100 mg/m2 continuous iv. days 1-10 and etoposide 100 mg/m2 iv. days 1-5 
(ICE). In the AML-10 study a single extra bolus of cytarabine 25 mg/m2 was given on day 
1, before starting the continuous infusion. In case of a partial remission (PR) a second 
identical remission-induction course was given. In case of a complete remission (CR) a 
consolidation course was given consisting of idarubicin 10 mg/m2 iv. days 4-6 in 
combination with an intermediate dose of cytarabine 500 mg/m2 twice daily iv. days 1-6 
(IDIA).  
HLA typing of patient and family was initiated at the onset of protocol treatment in all 
patients younger than 45-55 years (according to the policy of the centre) in the AML-10 
study and in patients younger than 50-60 years in the CRIANT study. In case of an HLA-
A, -B, -DR identical sibling and confirmed CR after the consolidation course, the patient 
was proposed for allografting.  
In the AML-10 study patients lacking an HLA identical donor in continuous CR were 
eligible for autologous bone marrow transplantation (ABMT). In 1994, a second 
randomization was introduced comparing ABMT and autologous peripheral blood stem 
cell transplantation (APSCT).  
In the CRIANT study patients lacking an HLA identical donor in continuous CR were 
randomized between a second consolidation course consisting of cytarabine 1 g/m2 twice 
daily i.v. days 1-6 and APSCT.  
The minimal required number for a successful harvest was 1 x 108/kg nucleated cells and 
1 x 104/kg CFU-GM (ABMT) or 2 x 106 CD34+ cells/kg (APSCT).  
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Definitions 
Therapy-related MDS/AML (tMDS/tAML) was defined as MDS or AML supervening after 
chemotherapy or radiotherapy for an earlier (non)-malignant disease. 
Secondary AML was defined as AML after documented MDS. In the CRIANT study 
patients with a history of at least 6 months were included, in the AML-10 study patients 
with AML after MDS less than 6 months were included. 
The duration of Antecedent Hematologic Disorder (AHD) was defined as the time since 
initial diagnosis of MDS and the start of protocol treatment. For patients with sAML, AHD 
was defined as the time since diagnosis of MDS and the start of treatment for AML. For de 
novo AML, AHD was considered as the time between diagnosis of AML and the start of 
treatment. 
Complete remission (CR) was defined as the absence of clinical signs of the disease with 
(near-) normal peripheral blood counts and a normocellular bone marrow containing less 
than 5% blast cells. 
Partial remission (PR) was characterized by bone marrow containing less than 25% blasts 
and more than 50% decrease of blasts percentage from pre-therapeutic levels with (near-) 
normal blood counts and no circulating blasts. 
CR lasting less than 4 weeks and PR lasting less than 8 weeks were classified as failures. 
Early death was defined as death within 10 days from start of treatment.  
 
Statistical analysis 
The overall duration of survival was calculated from start of induction until date of death 
(whatever the cause); patients still alive were censored at their last follow-up. For patients 
who reached CR the disease-free survival (DFS) was calculated from the date of CR until 
the date of first relapse or of death in first CR. The time to relapse and time to death in 
CR were calculated as the DFS; patients who died in CR and those who relapsed were 
respectively censored at that moment for these 2 analyses. By definition all patients who 
died in CR were considered as death from treatment related mortality (TRM).  
Actuarial curves were calculated according to the Kaplan-Meier technique. The standard 
errors (SE) of the estimates were computed using the Greenwood formula.22 The 
estimates of the incidence of relapse and of death in CR, and their corresponding 
standard errors, were obtained using the cumulative incidence method, where the risks of 
death in CR and of relapse were considered as competing risks.22 The differences 
between actuarial curves were tested for statistical significance using the two-tailed log-
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rank test 22, whereas for the cumulative incidences the Gray test has been used.23 The 
Cox’s proportional hazards model has been used to obtain the estimate and the 95% 
confidence interval (CI) of the hazard ratio (HR) of the instantaneous event rate in one 
group vs. the one in another group, as specified by a given variable, and the Wald test 
has been used to determine the prognostic significance.22 The Cox model has also been 
used to determine the independent prognostic factors among those that appeared 
important in univariate analyses (p<0.1).  
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RESULTS 
 
Patients 
Median age of the 692 patients in the AML-10 study was 44 years versus 52 years for the 
289 patients in the CRIANT study. In the AML-10 study 591 patients (85%) were aged 
less than 56 years compared to 203 patients (70%) in the CRIANT study. The median 
follow-up was 5.3 versus 3.5 years, respectively. The performance status was better in 
the CRIANT study: 93% of CRIANT patients had a WHO performance status of 0/1 
versus 78% of AML-10 patients. The AML-10 study included 18 patients with 
performance status 3, whereas this was an exclusion criterion for the CRIANT study. In 
the AML-10 study 98% of patients did not have any AHD (Antecedent Hematologic 
Disorder). On the other hand 4% of patients in the CRIANT study did have an AHD with 
duration between 1 and 6 months and 14% an AHD with a duration of longer than 6 
months. In the AML-10 study 659 patients (94%) presented with de novo AML, 16 
patients (2%) with sAML and 17 patients (3%) with tAML. In the CRIANT study 197 
patients (68%) were diagnosed as primary MDS, 21 patients (7%) as tMDS, 55 patients 
(19%) as sAML, 8 patients (3%) as tAML after MDS. In addition, 8 patients (3%) in the 
CRIANT study were diagnosed as de novo AML by the reviewer and 14 of 55 sAML 
patients had a history of MDS less than 6 months at reviewing. In order to be consistent 
with the intention-to-treat principle, these patients were not excluded from the analysis. 
Cytogenetic data were unknown or failed in 45% and 14% of patients in the 2 studies. 
Poor prognostic cytogenetic data according to the IPSS (International Prognostic Scoring 
System) were less frequently found in AML-10 patients (11%) compared to CRIANT 
patients (28%). Since the IPSS is designed for MDS patients, the very good risk 
cytogenetic features for AML patients (inv(16), t(8;21)) are not separately recognized in 
this scoring system. The AML-10 study included 72 patients with inv(16) or t(8;21) and 
the CRIANT study 5 patients. For the purpose of this analysis these patients were 
included in the good risk group of the IPSS.  
In the majority of patients review of the pathology has been performed (65% (AML-10) 
and 80% (CRIANT)), but information on dysplasia was reported infrequently. Patient 
characteristics of both studies are given in table 1. 
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Table 1. Characteristics of AML-10 and CRIANT patients. 
Variable AML-10 CRIANT 
Number of patients  692 289 
Median age (yr.) (range) 44 (15-60) 52 (16-65) 
Sex (%) 
  Male  
  Female 
  Unknown  
 
364 (53) 
325 (47) 
   3    (-) 
 
163 (56) 
123 (43) 
   3   (1) 
Performance status (%) 
   0-1 
   2 
   3 
   Unknown 
 
538 (78) 
131 (22) 
  18   (3)     
    5   (1) 
 
268 (93) 
  17   (6) 
    0   (-) 
    4   (1) 
History of toxic exposure (%) 
  Yes 
  No 
  Unknown 
 
  41   (6) 
611 (88) 
  40   (6) 
 
  36 (13) 
212 (73) 
  41 (14) 
AHD (%) 
  No 
  1- 6 months 
  >  6 months 
  Unknown  
 
676 (98) 
  16   (2) 
   
     
 
226 (78) 
  12   (4) 
  41 (14) 
  10   (4) 
Disease (%) 
  De novo AML 
  De novo MDS  
  Secondary AML   
  Therapy-related AML  
  Therapy-related MDS 
 
659 (94) 
   
  16   (2) 
  17   (3) 
 
   8   (3) 
197 (68) 
  55 (19) 
   8   (3) 
 21   (7) 
Median Hemoglobin  (g/dl) (range) 8.8 (3.8-15.4) 8.1 (4.2-19.9) 
Median WBC (x 109/l) (range) 16.6 (0.4-590) 3.4 (0.8-293) 
Median PMN (x 109/l) (range) 1.4 (0-51.7) 1.0 (0-44.9) 
Median Platelets (x 109/l) (range) 50 (4-998) 49 (3-648) 
WBC (x 109/l) (%) 
  < 25 
  25-100 
> 100 
Unknown 
 
402 (58) 
201 (29) 
 89 (13) 
 
261 (90) 
  23   (8) 
    3   (1) 
    2 
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Number of cytopenias (%) 
  0/1 
  2 
  3 
  Unknown 
 
175 (25) 
310 (45) 
205 (30) 
    2   (-) 
 
  54 (19) 
111 (38) 
123 (43) 
    1   (-) 
Bone marrow blasts (%) 
    <   5% 
    5-10% 
  11-20% 
  21-30% 
    > 30% 
   Unknown 
 
    1   (-) 
 
 
    5   (1) 
684 (99) 
    2   (-) 
 
   5   (2) 
 45 (16) 
 89 (31) 
 63 (22) 
 56 (19) 
 31 (11) 
FAB (%) 
  AML / MDS 
 
 
 
 
 
 
  Unclassified 
 
M0        27   (4) 
M1      128 (19) 
M2      221 (32) 
M4      147 (21) 
M5      131 (19) 
M6        23   (3) 
M7          5   (1) 
             10   (1) 
 
RAEB < 10%    21   (7) 
RAEB > 10%    77 (27) 
RAEBt             120 (42) 
AML                  71 (25) 
Cytogeneticsa (%) 
  Good 
  Normal, -Y 
  Poor 
  Unknown / failed 
 
  72 (10) 
147 (21) 
163 (24) 
310 (45) 
 
   5   (2) 
102 (35) 
143 (50) 
  39 (14) 
Cytogeneticsb (%) 
  Good 
  Intermediate 
  Poor 
  Unknown / failed 
 
213 (31) 
  96 (14) 
  73 (11) 
310 (45) 
 
111 (38) 
  57 (38) 
  82 (28) 
  39 (14) 
a: Keating classification: Good: t(8;21) or inv(16); Poor: others 
b: IPSS classification: Good: normal, -Y, 5q-, 20q-; Poor: chromosome 7 abnormalities, complex  
(> 3) abnormalities; Intermediate: other abnormalities. For the purpose of this analysis the very 
good risk AML patients with inv(16) and t(8;21) were included in the good risk group  
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Response to remission-induction chemotherapy 
In the AML-10 study 472 patients (68%) achieved complete remission after one (440 
patients) or two (32 patients) remission-induction courses. In the CRIANT study 169 
patients (59%) entered CR after one (150 patients) or two (19 patients) courses. Ninety-
four patients (14%) died during the first 10 days after start of treatment or in hypoplasia in 
the AML-10 study versus 28 patients (10%) in the CRIANT study. The remaining 126 
patients and 92 patients showed a partial response (3% vs. 6%), failure (14% vs. 22%), 
extramedullary leukemic localization (0.3% vs. 0.7%), persistent hypoplasia (0.3 vs. 4%) 
or unknown response (AML-10: 0.7%) (Table 2).  
 
Response to consolidation course 
Four hundred forty-six out of 472 patients (94%) in CR after remission-induction treatment 
in the AML-10 study received the consolidation course compared to 157 out of 169 
patients (93%) in the CRIANT study. In the AML-10 study CR was confirmed after 
recovery from the consolidation course in 438 patients (98%), 6 patients showed early 
relapse (1%) and in 2 patients the response was unknown. In the CRIANT study the 
complete remission percentage after the consolidation course was lower 70% (110 
patients); among the remaining patients 20 (13%) had active disease, 25 patients (16%) 
showed persistent hypoplasia and in 2 patients (1%) the response was unknown. Median 
time to platelet recovery of > 20 x 109/l after the consolidation course was 26 days and 37 
days for the 2 studies (p< 0.0001). Median time to PMN recovery of > 0.5 x 109/l was 26 
versus 31 days, respectively (p=0.0002). 
 
Donor availability and transplantation 
In the AML-10 study 157 out of 472 patients in CR did have an HLA-identical sibling. One 
hundred-five patients (67%) underwent allogeneic SCT in first CR after the consolidation 
course according to the protocol and 9 patients received an autologous transplant in first 
CR. Of the 315 patients in CR after remission-induction chemotherapy without an HLA-
identical donor 136 (43%) underwent autologous SCT according to the protocol and two 
patients received an allogeneic SCT from an alternative donor in first CR. In the CRIANT 
study 52 out of 169 patients in CR after remission-induction treatment did have an HLA-
identical donor. Forty-two patients (81%) received an allogeneic SCT according to the 
protocol. In 117 patients in CR without a donor 59 patients (50%) were randomized 
between APSCT (N=30) and a second consolidation course (N=29). In all, 18 patients 
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underwent APSCT according to the protocol and 7 patients received an allogeneic 
transplant from an unrelated donor in first CR.   
 
Table 2. Treatment results in AML-10 and CRIANT studies. 
Variable AML-10 CRIANT 
Number of patients   692 (%)   289  (%) 
Response remission-induction (RI) 
  CR 
  PR 
  Resistance 
  Extra-medullary leukemic localization 
  Persistent hypoplasia 
  Death in hypoplasia 
  Early death (< 10 days) 
  Unknown 
 
  472 (68) 
   19  (3) 
   97 (14) 
    2 
    3 
   71 (10) 
   23  (3) 
     5  (1) 
 
  169 (59) 
   17  (6) 
   63 (22) 
    2   (1) 
   10  (4) 
   27  (9) 
    1   (-) 
Platelet recoverya > 20 x 109/l 
  Median days  
 
   26 
 
   37 
PMN recoverya > 0.5 x 109/l 
  Median days  
 
   26 
 
   31 
Stage at transplantation (SCT) 
  In first CR 
    Allogeneic SCT 
    Autologous SCT 
  After first CR 
  Unknown stage 
  After no CRb  
  No transplantation 
 
  252 (36) 
  107 
  145 
   24  (4) 
    4   (1) 
   29  (4) 
  383 (55) 
 
   67 (23) 
   49 
   18 
   15  (5) 
 
   23  (8) 
  184 (64) 
Disease-free survival 
  CCR 
  Relapse 
  Death in CR 
 
  196 (42) 
  218 (46) 
    58 (12) 
 
    55 (33) 
    97 (57) 
    17 (10) 
Survival 
  Alive  
  Dead 
 
  248 (36) 
  444 (64) 
 
    95 (33) 
  194 (67) 
a: After the start of consolidation course 
b: Salvage treatment (off protocol) 
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Outcome of patients 
Median survival was 1.5 years in the AML-10 study compared to 1.3 years in the CRIANT 
study. The estimated 5-year survival rates were 34% (s.e = 1.9%) versus 27% (s.e. = 
3.2%) (p=0.26) (Figure 1). The estimated 5-year DFS rate was higher in the AML-10 
study (40%, s.e = 2.3%) compared to the CRIANT study (28%, s.e. = 4.0%) (p=0.02) 
(Figure 2). The 5-year cumulative incidences of relapse were 48% (s.e. = 2.4%) and 62% 
(s.e. = 4.3%) (p=0.004). The 5-year incidences of death in CR were 13% (s.e. = 1.6%) 
and 11% (s.e. = 2.4%) (p=0.47).  
 
 
Figure 1. Overall survival in AML-10 and CRIANT study. 
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Figure 2. Disease-free survival in AML-10 and CRIANT study. 
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Prognostic factors 
In univariate analysis performed on all 981 patients the following variables appeared to 
be prognostic factors for overall survival: cytogenetic risk group according to IPSS, age, 
performance status (WHO), FAB classification in AML patients, white blood count (WBC) 
(both continuous and categorical variable), number of blasts in the peripheral blood, AHD 
and LDH (Table 3). The hazard ratio (HR) for the intermediate vs. the good cytogenetic 
risk group was 1.40 with a 95% Confidence Interval (CI) of 1.09-1.78, the HR for the poor 
prognostic cytogenetic risk group was 2.53 (95% CI: 2.01-3.19). 
The prognostic importance for survival was not significant for: study protocol (AML-10 
versus CRIANT), FAB classification in MDS patients, number of cytopenias, percentage 
of blasts in the bone marrow, primary disease (therapy-related MDS/AML versus other), 
and the number of lineages with dysplastic features (data not shown). Table 3 
summarizes the variables assessed in univariate analyses. 
For disease-free survival the following variables appeared to be of prognostic importance: 
cytogenetic risk group according to IPSS, FAB in AML, WBC, age, LDH, study and 
primary disease. The HR for the intermediate cytogenetic risk group was 1.31 (95% CI: 
0.97-1.78) and 2.68 (95% CI: 1.98-3.63) for the poor cytogenetic risk group. The time 
until hematological recovery (platelets > 20 x 109/l and PMN > 0.5 x109/l) from start of the 
consolidation course had no impact on DFS. The hazard ratio for the time to recovery (< 
4 weeks vs. > 4 weeks) was 0.84 (95% CI: 0.68-1.04) for platelet recovery and 0.99 (95% 
CI: 0.79-1.23) for PMN recovery. 
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Multivariate analyses 
To correct for the imbalance in poor performance status (PS=3) between both studies, 0 
(CRIANT) versus 18 patients (AML-10), the latter patients have been excluded from the 
subsequent analyses. Study effect remained practically unchanged regarding overall 
survival and DFS (data not shown). In multivariate analysis cytogenetics, WBC, age and 
study protocol appeared to be of prognostic importance for both overall survival and DFS, 
whereas initial performance status was important only for survival (Table 4). For survival 
the estimated hazard ratio for the presence of poor prognostic cytogenetic abnormalities 
was 2.52 (95% CI: 1.99-3.20). The hazard ratio for the intermediate prognostic 
cytogenetic abnormalities was 1.54 (95% CI: 1.20-1.99).  
The importance of AHD was not assessable in a model containing both the variables 
AHD and study protocol, since all patients with an AHD of longer than 6 months were 
included in the CRIANT study. Therefore, a separate multivariate analysis for survival in 
both studies is given in table 5. Cytogenetics, WBC and age appeared highly prognostic 
in both studies. In the CRIANT study an AHD with a duration of longer than 6 months 
negatively influenced survival. The number of cytopenias was of prognostic importance in 
the CRIANT study, but not in the AML-10 study. On the other hand the FAB subtype 
M2/M4 and cytogenetic abnormalities inv(16)/t(8;21) predicted for a better prognosis in 
the AML-10 study, but these variables were not applicable to the CRIANT study. 
Performance status appeared highly predictive only in the AML-10 study. The presence 
of poor prognostic cytogenetic features had a greater impact on survival in the CRIANT 
study (hazard ratio 3.51) compared to the AML-10 study (hazard ratio 1.75, when 
corrected for baseline).  
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Table 4. Results of Cox’s proportional hazards models for outcome in all patients with an initial 
performance status < 3. 
Endpoint Survival Disease-free survival 
Variable Hazard 
Ratioa 
95% CI P-value Hazard 
Ratioa 
95% CI P-value 
Cytogenetics (IPSS) 
  Goodb 
  Intermediate 
  Poor 
  Unknown 
 
1.00 
1.54 
2.52 
1.64 
 
 
1.20-1.99 
1.99-3.20 
1.33-2.02 
 
 
   0.0008 
< 0.0001 
< 0.0001 
 
1.00 
1.48 
2.59 
1.49 
 
 
1.05-2.09 
1.86-3.60 
1.13-1.95 
 
 
   0.03 
< 0.0001 
   0.004 
WBC (x 109/l)   
  <  25 
  25-100  
  > 100  
 
1.00 
1.31 
2.31 
 
 
1.07-1.60 
1.76-3.02 
 
 
   0.009 
< 0.0001 
 
1.00 
1.40 
1.97 
 
 
1.07-1.84 
1.29-3.02 
 
 
   0.01 
   0.002 
Age (yr.) 
  15-45 
  46-55 
   > 55 
 
1.00 
1.42 
1.56 
 
 
1.18-1.70 
1.26-1.94 
 
 
   0.0002 
< 0.0001 
 
1.00 
1.40 
1.82 
 
 
1.09-1.81 
1.36-2.44 
 
 
   0.009 
< 0.0001 
PS (0, 1, 2) 1.21 1.08-1.36    0.001 1.05 0.90-1.23    0.55 
Study 
  AML-10 
  CRIANT 
 
1.00 
1.23 
 
 
1.01-1.50 
 
 
   0.04 
 
1.00 
1.33 
 
 
1.02-1.75 
 
 
   0.04 
a: A value >1 indicates that the outcome is worse for that category in comparison with the baseline 
b: Patients with inv(16) and t(8;21) included 
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Table 5. Results of Cox’s proportional hazards model for survival in AML-10 and CRIANT study.  
Study AML-10   CRIANT   
Variable Hazard 
Ratioa 
95% CI P-value Hazard 
Ratioa 
95% CI P-value 
Cytogenetics (IPSS) 
  inv(16), t(8;21) 
  Good 
  Intermediate 
  Poor 
  Unknown 
 
1.00 
1.52 
2.03 
2.66 
2.17 
 
 
0.94-2.46
1.24-3.32
1.60-4.41
1.39-3.40
 
 
   0.08 
   0.005 
   0.0002 
   0.0007 
 
 
1.00 
1.79 
3.51 
1.57 
 
 
 
1.15-2.78 
2.43-5.07 
0.97-2.55 
 
 
 
   0.009 
< 0.0001 
   0.07 
WBC (x 109/l)   
  < 100     (< 25)b 
  > 100     (> 25)b 
 
1.00 
1.77 
 
 
1.35-2.32
 
 
< 0.0001
 
1.00 
2.01 
 
 
1.21-3.32 
 
 
   0.007 
FAB 
  M0, M1, M5, M6, M7
  M2, M4 
  FAB unknown 
 
1.53 
1.00 
0.79 
 
1.25-1.86
 
0.32-1.91
 
< 0.0001 
    
   0.60 
   
Age (yr.) 
  15-45 
  46-55 
   > 55 
 
1.00 
1.27 
1.26 
 
 
1.02-1.57
0.96-1.66
 
 
   0.03 
   0.10 
 
1.00 
1.91 
2.16 
 
 
1.29-2.81 
1.41-3.30 
 
 
0.001 
0.0004 
PS (0, 1, 2) 1.24 1.08-1.41    0.002    
Number of cytopenias
  0-2 
  3 
    
1.00 
1.70 
 
 
1.24-2.32 
 
 
0.0009 
AHD (months) 
  0-6 
> 6 
    
1.00 
1.54 
 
 
1.04-2.29 
 
 
0.03 
a: A value >1 indicates that the outcome is worse for that category in comparison with the baseline 
b: For the CRIANT study the cut-point 25 x 109/l was considered, as only 3 patients had a WBC > 
100 x 109/l 
 
Prognostic scores 
For both studies a prognostic score was created based on the multivariate analyses in 
table 5: ∑(variable x ln(hazard ratio)). For the AML-10 study the following variables were 
incorporated in the scoring system: cytogenetic risk group, WBC, FAB in AML, age and 
PS. In the AML-10 study the cut-point for WBC was 100 x 109/l, as the prognosis was 
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very similar for patients with a WBC < 25 x 109/l and 25-100 x 109/l, whereas for the 
CRIANT study the cut-point 25 x 109/l was retained, since only 3 patients had a WBC > 
100 x 109/l. The score values are given in table 6.  
 
Table 6. Prognostic scores for overall survival in AML-10 study and CRIANT study. 
Variable Points Points 
 AML-10 CRIANT 
Cytogenetics IPSS 
  inv(16), t(8;21) 
  Good 
  Intermediate 
  Poor 
  Unknown 
 
0 
15 
30 
40 
30 
 
0 
0 
20 
40 
20 
WBC (x 109/l)   
  <  25 
  25-100 
  > 100  
 
0 
0 
25 
 
0 
20 
20 
FAB 
  M0, M1, M5, M6, M7 
  M2, M4 
  FAB unknown 
 
15 
0 
7 
 
0 
0 
0 
Age (yr.) 
  15-45 
  46-55 
   > 55 
 
0 
10 
10 
 
0 
20 
22 
Performance status 
  0 
  1 
  2 
 
0 
10 
20 
 
0 
0 
0 
AHD > 6 months 0 13 
Number of cytopenias 
  0/1 
  2 
  3 
 
0 
0 
0 
 
0 
0 
15 
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In the AML-10 study 3 groups were distinguished: score < 20, score 20 - < 60, score > 
60. The 5-year estimated survival rates were 54% (s.e. = 7.0%), 38% (s.e. = 2.5%), and 
19% (s.e = 2.9%) respectively for the 3 groups (Figure 3). 
The model was validated on a group of 677 AML patients not included in the present 
analysis. These patients were treated in the AML-10 study with a different anthracycline: 
mitoxantrone instead of idarubicin. In the patients receiving mitoxantrone the 5-year 
estimated survival rates were 72% (s.e. = 6.5%), 37% (s.e. = 2.5%), and 21% (s.e. = 
3.0%) respectively for the 3 groups (p<0.0001) (Figure 4). 
 
 
 
Figure 3. Prognostic score in AML-10 study. 
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Figure 4. External validation of prognostic score in mitoxantrone arm of the AML-10 study.  
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For the CRIANT study the following variables were incorporated in the scoring system: 
cytogenetic risk group according to IPSS, WBC, age, number of cytopenias and AHD. 
Performance status was not incorporated in the model, since PS appeared not to be of 
any prognostic importance. Three groups were distinguished: score < 20, score 20 - < 50, 
score > 50. In the CRIANT study the 5-year estimated survival rates were 69% (s.e. = 
10.2%), 37% (s.e. = 5.6%), and 5% (s.e = 2.1%) for the 3 groups (Figure 5). 
 
Figure 5. Prognostic score in CRIANT study. 
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DISCUSSION 
 
The FAB classification separates MDS as a distinct disorder from AML.1 Nowadays high-
risk MDS is recognized as a clonal stem cell disorder that shares genetic, molecular and 
clinical features with AML generally arising in older individuals.24 This had led to the 
concept that MDS and AML are part of a continuous disease spectrum rather than distinct 
disorders. Nevertheless, the use of intensive antileukemic treatment is less widely 
accepted in high-risk MDS patients than in de novo AML patients due to the reported 
worse outcome.13 The treatment outcome is determined both by patient-related factors 
and by disease-related factors. Age, co-morbidity, performance status and genetic 
variations in drug-metabolism can be considered as patient-related factors, while 
disease-related factors comprise factors related to the characteristics of the stem cells 
involved like cytogenetic abnormalities and molecular aberrations. The question is 
whether the disease-related factors differ between MDS and AML and whether poor 
prognostic factors occur more often in MDS compared to AML. The present analysis was 
designed to identify clinical and biologic prognostic factors reflecting the underlying 
disease-related and patient-related factors. To our knowledge this study is the first to 
address this question in a large group of MDS and AML patients, who received identical 
remission-induction and consolidation treatment in two different clinical studies. The 
analysis included primary MDS patients, de novo AML patients, secondary AML patients 
and patients with therapy-related MDS and AML.  
In multivariate analysis in the combined study group, the presence of cytogenetic 
abnormalities, age, white blood count and treatment in the AML-10 or CRIANT study 
appeared prognostic for both overall survival and DFS. Performance status was 
predictive for overall survival, but not for DFS. Poor prognostic cytogenetic abnormalities 
appeared to be the most important prognostic factor for outcome in both patient groups. 
Unfortunately, in 45% of AML-10 patients data on cytogenetics were missing. This was 
due to the lack of data on cytogenetic examinations in some smaller participating centres 
and not because cytogenetic data were missing in patients who died early. Some other 
factors appeared prognostic in only one of the studies. In the CRIANT study the number 
of cytopenias and the presence of an AHD with a duration of longer than 6 months 
negatively influenced survival, while in the AML-10 study, FAB subtype M2/M4 and the 
presence of inv(16)/t(8;21) independently predicted for a better survival. Performance 
status was predictive in the AML-10 study, but not in the CRIANT study. In this analysis 
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poor prognostic cytogenetic features produced a more pronounced effect in the CRIANT 
study (Hazard ratio: 3.51) compared to the AML-10 study (Hazard ratio: 1.75). The 
observed differences in prognostic factors between MDS and AML suggest that despite 
an overlap between MDS and AML, the diseases are intrinsically different. 
Multilineage dysplasia is considered as a hallmark of MDS, but dysplastic features are 
also observed in de novo AML and have been associated with an unfavourable prognosis 
in some analyses.3,25,26 In the present analysis only limited data on dysplasia were 
available and no firm conclusions could be drawn. Recently, Haferlach et al. 
demonstrated in a group of 614 patients with de novo AML the association of dysplastic 
features with poor prognostic cytogenetic features without independent prognostic 
importance for outcome.27 In general, interpretation of different studies on the prognostic 
value of dysplastic features in AML and MDS is laborious due to subjective and variable 
criteria used for the definition of dysplasia.28  
The M.D. Anderson Cancer Center reported on 530 patients with AML, RAEB and 
RAEBt.15 Complex cytogenetic abnormalities involving chromosome 5 and/or 7 were more 
frequently found in RAEBt (17%) and particularly RAEB (35%) than in AML (11%). 
Multivariate analysis indicated the prognostic value of cytogenetic abnormalities, age, 
AHD, performance status and applied treatment on survival and event-free survival (EFS). 
Their main conclusion was that outcome after intensive chemotherapy is not different for 
MDS and AML patients after adjustment for the poor-prognostic disease-related and 
patient-related factors. Our analysis confirms that AHD is an independent disease-related 
prognostic factor in MDS. 
In our analysis treatment in the AML-10 study predicted for a better outcome than 
treatment in the CRIANT study. Although patients in both studies received identical 
remission-induction and consolidation courses, we cannot discard that the differences in 
outcome are influenced by differences in post-consolidation treatment. In the AML-10 
study 36% of patients underwent allogeneic or autologous stem cell transplantation in first 
remission compared to 23% of patients in the CRIANT study.  
The clinical outcome of MDS and AML patients after intensive antileukemic treatment 
shows similarities. However, important biologic differences have been reported. Several 
studies showed that apoptosis is a contributing factor to the ineffective hematopoiesis in 
MDS.29-31 The highest apoptotic rates are found in RA, RARS, and RAEB with a 
progressive decline in apoptosis when the disease progresses to acute leukemia. Albitar 
et al. studied 802 patients with newly diagnosed AML or MDS. Apoptosis as measured by 
CHAPTER 6 
160 
annexin V expression in CD34 positive cells was significantly higher in all subtypes of 
MDS compared with AML and patients with high apoptotic activity were more likely not to 
respond to applied chemotherapy.21  
The higher incidence of the multidrug resistance 1 gene (MDR1) expression in MDS 
compared to de novo AML may be another explanation for the inferior response to 
chemotherapy.32-35 MDR1 codes for the transmembrane efflux pump P-glycoprotein (Pgp). 
When overexpressed in leukemic cells, P-glycoprotein reduces intracellular accumulation 
of several anticancer drugs. A French study demonstrated that response to chemotherapy 
is worse in Pgp-positive patients.32 Wattel et al. employed quinine as a Pgp modulator in 
patients with high-risk MDS and secondary AML. In a subgroup of Pgp-positive cases a 
significantly better survival was observed in patients treated with quinine in combination 
with chemotherapy.36 
Apart from stem cell abnormalities, abnormalities in the hematopoietic microenvironment 
are involved in the pathogenesis of hematopoietic failure in MDS. Bone marrow stroma 
plays a regulatory role by direct contact mediated by adhesion molecules and through the 
production of cytokines. Increased levels of TNF-alpha are observed and are able to 
induce apoptosis via free radical formation and upregulation of Fas expression.37,38 We 
hypothesized that a longer duration of hypoplasia after intensive chemotherapy might 
reflect the influence of pre-existing stroma damage in MDS after chemotherapy. The time 
to platelet and PMN recovery after the consolidation course was significantly longer in the 
CRIANT study compared to the AML-10 study. The longer post-consolidation marrow 
hypoplasia in MDS patients might have interfered with post-consolidation therapy in some 
patients, but this did not translate in an inferior DFS. We noticed in an earlier analysis of 
the AML-10 study that patients with higher numbers of mobilized CD34+ cells and a short 
post-consolidation hypoplasia had a poor outcome due to a higher relapse risk.39  
A second aim of this analysis was to predict the outcome of an individual patient. Based 
on the prognostic factors in multivariate analysis, a prognostic score has been developed 
for each of the studies. According to this score, 48% of patients in the CRIANT study 
show a 5-year survival rate of approximately 40%, when treated with AML-like therapy. A 
minority of younger patients, lacking poor prognostic cytogenetic features and profound 
cytopenias, with a short AHD and a low WBC has a good prognosis, with an estimated 5-
year survival 69%. On the other hand, this study identifies a subgroup of 43% of MDS 
and 30% of AML patients, with a poor prognosis despite intensive chemotherapy with or 
without stem cell transplantation. These patients are characterized by the presence of 
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poor prognostic cytogenetic features according to IPSS, age over 45 years, multiple 
cytopenias, AHD with a duration of longer than 6 months, FAB subtype other than M2, 
M4 and/or a high WBC.  
To our opinion the scoring system for the CRIANT patients is a valuable alternative for 
the IPSS, since the IPSS gives considerable weight to the blast percentage in the bone 
marrow, while this seems less prognostic in intensively treated patients. The scoring 
systems may help to identify both MDS and AML patients with an estimated 5-year 
survival of less than 20%. For these high-risk patients current treatment modalities are 
unsatisfactory. In recent years, progress has been made in knowledge of the molecular 
mechanisms that underlie the ineffective hematopoiesis and leukemic transformation in 
MDS. Insight gained from this molecular analysis may provide the basis for a more 
targeted therapeutic approach. Novel treatment strategies should be offered to these 
poor prognosis MDS and AML patients in the context of prospective clinical trials.  
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SUMMARY 
 
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal stem cell 
disorders characterized by a hypercellular bone marrow, peripheral blood cytopenias and 
dysplastic features in blood and bone marrow. The natural history of the disease ranges 
from an indolent course over several years to a rapid course toward leukemic progression.  
Since 1982 the myelodysplastic syndromes have been classified according to FAB 
(French-American-British) criteria. Five subgroups have been described: refractory 
anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with 
excess of blasts (RAEB), refractory anemia with excess of blasts in transformation 
(RAEBt), and chronic myelomonocytic leukemia (CMML). This classification was a 
milestone in MDS-related research. Numerous studies have demonstrated the diagnostic 
usefulness and the prognostic impact of the FAB classification. Nonetheless, this 
classification has several weaknesses. In the FAB classification, both the definition of 
chronic myelomonocytic leukemia (CMML) and its inclusion in the scheme are 
problematic, since many patients with CMML have features resembling a 
myeloproliferative disorder rather than a myelodysplastic disorder. The definition of 
CMML is based primarily on the peripheral blood monocyte count with less consideration 
of marrow findings. The FAB distinction between RAEBt and acute myeloid leukemia 
(AML) has been criticized as unimportant, since there are little differences between 
RAEBt and AML in terms of prognosis and response to therapy. On the other hand, the 
category of RAEB includes a fairly heterogeneous group of patients with a blast 
percentage ranging from five to twenty percent.  
In 1997 a new classification system has been proposed by the World Health Organization 
(WHO), which attempts to correct some of the imperfections of the FAB classification. 
The conventional FAB classification has been used throughout this thesis. 
Since the introduction of the FAB classification, multiple scoring systems have been 
proposed to predict the natural history of an individual patient. At present, the most widely 
accepted system is the International Prognostic Scoring System (IPSS). This score is 
based on data of 816 patients with de novo MDS, who primarily received supportive care. 
The IPSS distinguishes four risk groups for survival and AML evolution, based on 
cytogenetic features, percentage of blasts in the bone marrow and the number of 
cytopenias. Median survival for the low risk group is 5.7 years, 3.5 years for the 
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intermediate-1 risk group, 1.2 years for the intermediate-2 risk group and 0.4 years for the 
high-risk group. Age is an additional risk factor for survival, but not for AML evolution. 
The majority of MDS patients are aged over 60 years. For most of these patients 
supportive care and/or low-intensity regimens is the mainstay of treatment. This thesis 
discusses intensive treatment strategies, mainly used with the aim to cure younger MDS 
patients.  
 
Chapter one of this thesis describes the classification of the myelodysplastic syndromes 
(MDS) according to the French-American-British (FAB) classification and the newer World 
Health Organization (WHO) classification. Data on incidence and aetiology are given. 
Poor risk MDS patients can be identified by the International Prognostic Scoring System 
(IPSS). Patients belonging to the intermediate-1, intermediate-2 and high-risk groups of 
the IPSS may be considered as potential candidates for intensive treatment strategies. 
Different treatment strategies are discussed in this chapter. Allogeneic stem cell 
transplantation (SCT) is the treatment of choice in young patients with an HLA-identical 
sibling donor. Approximately 40% of patients are likely to be cured after allogeneic stem 
cell transplantation. Long-term disease-free survival (DFS) can be attained if the 
transplant is performed in an early stage of the disease. An increased blast percentage 
and poor prognostic cytogenetic features are associated with an increased risk of relapse 
and a shorter disease-free survival. Longer disease duration, advanced patient age, 
therapy-related MDS and the use of alternative donors are associated with increased 
non-relapse mortality. Reduced Intensity Conditioning (RIC) regimens are currently 
investigated, in view of the high treatment-related mortality after conventional 
myeloablative conditioning regimens. Through lack of HLA-identical sibling donors in the 
majority of MDS patients, alternative donor sources like unrelated donors and 
mismatched family donors have been used. Transplant-related mortality is higher after 
alternative donor SCT, resulting in a disease-free survival of circa 30%. The transplant-
related mortality is significantly influenced by age. 
For patients lacking a suitable donor intensive chemotherapy with AML-like schedules 
may be an alternative approach. Although the remission rate has improved over the past 
years, the remission duration is short due to a high relapse rate. For disease-free survival 
karyotype appears to be the most important prognostic factor. In view of the high relapse 
rate after chemotherapy, transplantation with autologous stem cells has been applied in 
an attempt to intensify the post-remission therapy. Although the data on autologous SCT 
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in MDS are still limited, DFS after autologous SCT seems comparable with DFS after 
allogeneic SCT with alternative donors. The high incidence of relapse in autologous SCT 
is counterbalanced by the high treatment-related mortality after alternative donor SCT. A 
prerequisite for autologous SCT is entering a complete remission before transplantation 
and harvesting a sufficient number of stem cells. For a patient who fulfils these criteria, 
autologous SCT is a valid option. For patients who fail to enter complete remission, 
allogeneic SCT with an alternative donor may constitute an alternative. 
 
The primary curative treatment option for patients with MDS is allogeneic SCT with an 
HLA-identical sibling donor. However, the reported superior results after allogeneic 
transplantation may be due to selection of patients fit enough to undergo SCT and by 
excluding patients with an early relapse. The value of SCT compared to alternative 
treatment options has never been defined. Randomisation, the classical approach to test 
the value of different treatment strategies is not feasible. An alternative approach is 
registration at a fixed point in time: the time of HLA-typing of patient and siblings.  
Chapter 2 describes a prospective registration study by the EBMT (European Group for 
Blood and Marrow Transplantation). The physicians were asked to give the intention-to-
treat depending on the outcome of the donor search at time of registration. In case of an 
HLA-identical sibling donor, the possibilities were immediate SCT (without preceding 
chemotherapy), SCT after remission-induction chemotherapy or SCT at progression of 
disease. In case no donor was available, the options were search for an alternative 
donor, intensive chemotherapy only, chemotherapy followed by autologous SCT or 
supportive care. The registration forms have been collected before the outcome was 
known. Since the number of registered patients was not sufficient for statistical analysis, 
the HLA-typing laboratories have been asked to report all MDS patients, who had HLA 
family typing in their centre. The physicians have been asked to provide us with the 
clinical data of the patients and the intention-to-treat according to the policy of the centre 
depending on the availability of a donor. In all, 11 European centres have registered 248 
patients, who were untreated at time of HLA-typing. A matched family donor has been 
identified in 52% of patients. On intention-to-treat basis outcome was not significantly 
different for patients with and without a donor, with estimated 3-year survival rates of 46% 
and 43%, respectively. Seventy-eight percent of patients with a donor received the 
intended allogeneic SCT. In patients without a donor a lower percentage received the 
intended treatment; 46% of patients underwent the intended alternative donor SCT, 50% 
SUMMARY 
171 
underwent autologous SCT, 67% underwent intensive chemotherapy only and 97% of 
patients received supportive care. In multivariate analysis age, chromosomal 
abnormalities and RA(RS) FAB subtype appeared prognostic for survival, while intended 
treatment was not prognostic for survival. On intention-to-treat basis the estimated 3-year 
survival was 48% for immediate allogeneic SCT, 34% for allogeneic SCT after remission-
induction chemotherapy, 37% for alternative donor SCT, 36% for autologous SCT, and 
35% for patients intended for chemotherapy only. This analysis confirms that alternative 
donor SCT, autologous SCT and high-dose chemotherapy may provide an alternative 
therapy for patients lacking a matched family donor. 
 
The prognosis of high-risk MDS patients resembles that of patients with AML. However, 
outcome of AML-like therapy is generally disappointing in MDS patients, and is worse 
than observed in de novo AML. The poor results raise the question of the value of 
transplantation in first complete remission in these patients. The purpose of chapter 3 is 
to compare continued chemotherapy and transplantation in first CR in patients under age 
60 years with high-risk MDS or secondary AML (sAML). Patients have been treated by 
the Leukemia group of the EORTC (European Organization for Research and Treatment 
of Cancer) or at the M.D. Anderson Cancer Center. All patients received AML-like 
chemotherapy in order to achieve a CR. Subsequently, after an intensive consolidation 
course, patients treated by the EORTC centres received an allogeneic transplant in case 
of an HLA-identical sibling donor, or an autologous transplant in the absence of an HLA-
identical sibling donor. In contrast, patients treated at M.D. Anderson continued to receive 
AML-like therapy without a transplant. One hundred and eighty-four patients have been 
treated in the EORTC 06921 study and 215 comparable patients at M.D. Anderson. The 
M.D. Anderson patients were older and more likely to have a poor performance status 
and secondary AML, while EORTC patients were more likely to have MDS. Abnormalities 
of chromosomes 5 and/or 7 were more common at M.D. Anderson (37% versus 21%). 
The hemoglobin level and platelet count at the start of therapy were lower in M.D. 
Anderson patients, while the white blood count was higher. The complete remission rates 
were 54% (100/184) in the EORTC and 63% (135/215) at M.D. Anderson (p=0.09). In the 
EORTC study, 28 patients received an allograft from an HLA-identical donor, 36 patients 
have been autografted and one patient underwent matched unrelated donor 
transplantation in first CR after the consolidation course. Thirty-five out of 100 patients in 
CR after remission-induction chemotherapy did not reach the transplantation step. The 
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outcome of patients with an HLA-identical donor did not significantly differ from the 
outcome of patients without an HLA-identical donor. Therefore, for the purpose of this 
study, we did not discriminate between allogeneic and autologous SCT and considered it 
as one strategy.  
Survival form the start of treatment was not statistically different between the EORTC and 
M.D. Anderson patients. The 4-year survival estimates were 26.0% versus 18.4% 
(p=0.16). However, DFS in patients achieving CR was superior in the EORTC cohort, the 
4-year DFS estimates were 28.9% versus 17.3% (p=0.02). To investigate whether the 
different outcome reflects the different treatment regimens in the EORTC and at M.D. 
Anderson or, rather differences in the two patients groups, a multivariate analysis has 
been performed including the following variables: treatment site (EORTC or M.D. 
Anderson), cytogenetics, age, white blood count, disease category (RA, RARS, RAEB vs. 
RAEBt, CMML vs. sAML), hemoglobin and performance status. Multivariate analysis 
confirmed that chemotherapy followed by transplantation in first CR is associated with 
longer disease-free survival. Nevertheless, in this analysis overall survival was not 
improved by a regimen including transplantation in first remission.  
 
In Chapter 4 we use the framework of the EORTC 06921 study to investigate the 
outcome of patients with and without an HLA-identical sibling donor on an intention-to-
treat basis. After a common remission-induction and consolidation course, patients with 
an HLA-identical sibling donor were scheduled for allogeneic transplantation and patients 
lacking a donor for autologous transplantation. Only patients alive at 8 weeks from the 
start of treatment were selected since these patients were candidates for transplantation 
and the availability of an HLA-identical sibling donor would be known by this time. Out of 
159 patients, alive at 8 weeks from the start of treatment, 52 had an HLA-identical sibling, 
65 did not have an HLA-identical sibling donor and in 42 patients the availability of a 
donor was unknown. The majority of the patients in the unknown donor group (83%) were 
aged over 50 years. In these patients, the availability of a donor was not explored, since it 
was the intention to treat these patients without allogeneic SCT. The complete remission 
rate in the unknown donor group was only 45%, reflecting the older age of this group, 
with a survival rate at 4 years of 10%. 
Thirty-nine out of 52 patients (75%) with a donor and 42 out of 65 (65%) patients without 
a donor attained CR after remission-induction chemotherapy. Overall, 36 patients (69%) 
with an HLA-identical donor underwent allogeneic SCT and 32 patients (49%) without an 
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HLA-identical donor underwent autologous SCT. Nine patients without an HLA-identical 
donor received an allograft from an alternative donor (one in first CR, two after relapse 
and six in partial response or resistance).  
The actuarial survival rate at 4 years of the 52 patients with a donor was 33.3% versus 
39.0% for the 65 patients without a donor (p=0.18). In the 81 patients who reached CR, 
the DFS rate was 30.8% in the donor group and 33.3% in the no donor group. The 
cumulative incidences of relapse at 4 years from CR were 42.6% and 64.3% in the two 
groups, respectively. The cumulative incidences of death in first CR were 26.5% and 
2.4%. 
In this analysis cytogenetic abnormalities were highly predictive for survival. Patients with 
good and intermediate cytogenetic risk scores according to IPSS had a 4-year survival 
rate of 51% and 38%, respectively, whereas in patients with poor prognostic cytogenetic 
features the 4-year survival rate was only 10%. In the subgroup of 29 patients with poor 
prognostic cytogenetic features, we were unable to demonstrate a survival difference for 
patients with and without a donor.  
In all, 18 patients with an HLA-identical donor were alive at the end of follow-up. Sixteen 
patients survived in CR: one patient did not receive any post-consolidation therapy, 
twelve patients underwent SCT according to the protocol and three as salvage treatment. 
Eight of 16 patients presented with good-risk cytogenetic abnormalities, five with 
intermediate-risk cytogenetic abnormalities and two patients with poor prognostic 
cytogenetic abnormalities. Cytogenetic analysis has failed in one patient.  
A total of 28 patients without an HLA-identical sibling donor were alive at the end of 
follow-up. In total, 20 patients survived in CR: four patients did not receive any post-
consolidation treatment, ten patients received an autograft according to the protocol and 
six patients received an allogeneic SCT from an unrelated donor. Of 20 patients, 11 
showed good-risk cytogenetic abnormalities, three intermediate cytogenetic abnormalities 
and one poor-risk cytogenetic abnormality. Cytogenetic analysis has failed in five 
patients.  
The results of this analysis show that patients may benefit from intensive treatment 
strategies including allogeneic or autologous SCT. We were unable to demonstrate a 
survival advantage for patients with an HLA-identical donor over patients without a donor. 
Patients with a donor have a lower relapse risk compared to patients without a donor. 
Unfortunately, this advantage is neutralised by a substantially higher treatment-related 
mortality after allogeneic transplantation.  
CHAPTER 7 
174 
The International Prognostic Scoring System (IPSS) is a valuable instrument to predict 
the natural history in MDS. However, the IPSS is based on data from patients treated with 
transfusions, biological response modifiers and low-dose oral chemotherapy. Patients 
treated with intensive chemotherapy and/or stem cell transplantation and patients with 
therapy-related MDS are not incorporated in the scoring system. Chapter 5 is a 
retrospective analysis of 306 untreated MDS patients who have been referred to our 
hospital, many of whom subsequently received intensive antileukemic treatment 
consisting of AML-like chemotherapy with or without autologous SCT, or allogeneic SCT 
with or without preceding chemotherapy. Patients have been classified according to the 
IPSS and survival has been compared with survival of the IPSS workshop patients. The 
principle aim of the study was to investigate whether the IPSS predicts the outcome of 
patients aged less than 61 years treated with intensive therapy, and whether the scoring 
system discriminates between subgroups of patients who benefit from these intensive 
treatment strategies. In patients aged less than 61 years, median survival in the low-risk 
group was comparable in the Nijmegen and the IPSS workshop patients (11.1 years 
versus 11.8 years) and in the intermediate-2 risk group (1.4 years versus 1.8 years). 
However, the median survival in the intermediate-1 risk group was lower in the Nijmegen 
patients (2.5 years versus 5.2 years), and median survival in the high-risk group was 
better for the Nijmegen patients (0.9 years versus 0.3 years). Out of 176 patients, aged 
less than 61 years, 159 belonged to the intermediate-1, intermediate-2 and high-risk 
group. These patients may be considered as candidates for intensive treatment.  
Seventy-six patients received supportive care only (48%). Eighty-three patients (52%) 
received intensive treatment consisting of chemotherapy only in 30 patients, 
chemotherapy followed by autologous SCT in 7 patients and allogeneic SCT in 46 
patients. The median age of the intensively treated patients was 45 years versus 53 
years for patients receiving supportive care only. In the intensive treatment group, median 
survival from diagnosis was 2.6 years for the intermediate-1 risk group, 3.4 years for the 
intermediate-2 risk group and 0.9 years for the high-risk group. The estimated 4-year 
survival rates were 46%, 40% and 19%, respectively. In patients, who received no 
intensive treatment, median survival was 2.2 years for the intermediate-1 risk group, 0.8 
years for the intermediate-2 risk group and 0.7 years for the high-risk group. The 
estimated 4-year survival rates were 37%, 11% and 0%, respectively. These results have 
to be interpreted with caution, since no randomisation has been performed between 
intensive treatment and supportive care. Opponents of intensive treatment often argue 
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that the reported results are biased by selection of patients with a relatively good 
prognosis. In the present analysis we demonstrate that survival of non-intensively treated 
patients did not deteriorate in subsequent periods during which the percentage of 
intensively treated patients increased substantially. This supports that we have not 
selected patients with a relatively good prognosis for intensive treatment.  
Multivariate analysis in patients who received supportive care only, confirmed the 
prognostic value of the IPSS. However, in the subgroup of 83 intensively treated patients 
aged < 61 years the IPSS was not prognostic for survival. The hazard ratio for the high-
risk group compared with the intermediate-1 risk group was 1.81 (p=0.63), the hazard 
ratio for the intermediate-2 risk group being 0.83 (p=0.78). This suggests that patients 
belonging to the intermediate-2 risk group, in particular benefit from intensive treatment 
strategies.  
 
The use of intensive antileukemic treatment is less common in high-risk MDS compared 
to de novo AML, due to the reported inferior results. It is questionable whether the 
reported poorer outcome of high-risk MDS patients compared to de novo AML patients 
reflects an intrinsic property of the stem cells involved (disease-related factors like 
cytogenetic abnormalities and molecular aberrations) or reflects an increased incidence 
of patient-related poor prognostic factors (like advanced age and poor performance 
status) in MDS.  
In chapter 6 we compare outcome of 981 patients with MDS and AML, who received 
identical remission-induction and consolidation treatment in two different studies. Patients 
with de novo AML have been treated in the AML-10 study and patients with high-risk 
MDS or secondary AML after MDS of at least 6 months in the CRIANT study. In both 
studies, post-consolidation therapy consisted of allogeneic SCT for patients aged < 45-55 
years if an HLA-identical family donor was available. In the AML-10 study patients lacking 
an HLA-identical donor in continuous CR after the consolidation course were eligible for 
autologous bone marrow transplantation (ABMT). In 1994, a second randomisation has 
been introduced comparing ABMT with autologous peripheral blood stem cell 
transplantation (APSCT). In the CRIANT study, patients lacking an HLA-identical donor in 
continuous CR after the consolidation course were randomised between APSCT and a 
second consolidation course. The purpose of this analysis was to identify prognostic 
clinical and biologic factors for outcome. The estimated 5-year survival rates were 34% 
(AML-10) versus 27% (CRIANT) (p=0.26). The estimated 5-year DFS rate was higher in 
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the AML-10 study (40%) compared to the CRIANT study (28%) (p=0.02). In multivariate 
analysis in the overall group cytogenetic risk group according to IPSS, white blood count 
(WBC) and age appeared highly prognostic for both overall survival and DFS. Initial 
performance status was prognostic for survival as well. In the overall group, treatment in 
the AML-10 study predicted for a better overall survival and DFS than treatment in the 
CRIANT study. Apart from these shared variables, some variables appeared prognostic in 
one of the studies. Therefore, a separate multivariate analysis for survival was performed 
for the AML-10 and the CRIANT study. In the AML-10 study performance status, FAB 
subtype M2/M4 and cytogenetic abnormalities inv(16)/t(8;21) predicted for a better 
survival, while in the CRIANT study the number of cytopenias and the presence of an 
Antecedent Hematologic Disorder (AHD) of more than 6 months were prognostic. Our 
finding that prognostic factors differ in MDS and AML supports the hypothesis that MDS 
and AML are intrinsically different disorders. For both studies a prognostic score has 
been created based on the multivariate analyses. For the AML-10 study the following 
variables have been incorporated in the score: cytogenetic abnormalities, WBC, FAB 
classification, age and performance status. Three groups were distinguished with an 
estimated 5-year survival rate of 54%, 38%, and 19%, respectively. The score for the 
CRIANT study included cytogenetic abnormalities according to IPSS, WBC, age, number 
of cytopenias and AHD. Performance status was not incorporated in this model, since it 
appeared not predictive for survival. Three groups were distinguished with an estimated 
5-year survival rate of 69%, 37%, and 5%, respectively.   
The present analysis demonstrates that 48% of patients with high-risk MDS show a 5-
year survival rate of approximately 40%, when treated with AML-like therapy. A minority 
of younger patients, lacking poor prognostic cytogenetic features and profound 
cytopenias, with a short AHD and a low WBC has a good prognosis, with an estimated 5-
year survival 69%. On the other hand, this study identifies a subgroup of 43% of MDS 
patients and 30% of AML patients, with a 5-year survival of less than 20% despite 
intensive chemotherapy combined with stem cell transplantation. These patients are 
characterized by the presence of poor prognostic cytogenetic features according to IPSS, 
age over 45 years, multiple cytopenias, AHD over 6 months, FAB subtype other than M2, 
M4 and/or a high WBC. To our opinion the scoring system for the CRIANT patients is a 
valuable alternative for the IPSS, since the IPSS gives considerable weight to the blast 
percentage in the bone marrow, while this seems less prognostic in intensively treated 
patients. The presented prognostic scores enable us to identify patients with a poor 
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prognosis. Novel treatment strategies have to be offered to these patients in the context 
of prospective clinical trials. 
 
CONCLUSIONS 
 
The myelodysplastic syndromes (MDS) form a heterogeneous group of clonal stem cell 
disorders. Since the introduction of the FAB (French-American-British) classification in 
1982, multiple scoring systems have been proposed to predict the natural history of an 
individual patient. At present the most widely used system is the International Prognostic 
Scoring System (IPSS), based on the percentage of blasts in the bone marrow, the 
number of cytopenias and the presence of cytogenetic abnormalities. MDS is 
predominantly diagnosed in elderly patients. Intensive treatment strategies, as described 
in this thesis, aiming at eradication of the malignant clone are restricted to younger 
patients in a good clinical condition. Patients belonging to the intermediate-1, 
intermediate-2 and high-risk groups of the IPSS may be considered as candidates for 
intensive treatment strategies. A major challenge lies in predicting which patient is most 
likely to respond favourably to which treatment. 
Allogeneic stem cell transplantation (SCT) is considered as the only curative treatment 
option by many clinicians. In the first part of this thesis we demonstrated that survival of 
patients with and without an HLA-identical sibling donor was not different on intention-to-
treat basis. Therefore, alternative treatment options like SCT with mismatched family 
donors and matched unrelated donors, autologous SCT and high-dose chemotherapy 
have to be considered in patients lacking an HLA-identical family donor. In another 
analysis we compared the outcome of patients with high-risk MDS and secondary AML, 
who received AML-like chemotherapy with or without stem cell transplantation. Although 
survival of patients treated with AML-like chemotherapy only or with AML-like 
chemotherapy followed by stem cell transplantation was not different, disease-free 
survival was significantly longer after treatment including SCT.  
In the second part of this thesis, we focused on the value of the IPSS in predicting the 
outcome of patients. We confirmed that the IPSS is an improved scoring system for 
patients receiving supportive care. However, the scoring system does not seem to be the 
best method for predicting outcome in younger patients after intensive antileukemic 
treatment. In particular, intermediate-2 risk patients may benefit from intensive treatment. 
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Finally, we compared outcome of high-risk MDS and AML patients, who received identical 
remission-induction and consolidation treatment in two different studies, to identify 
prognostic clinical and biologic factors for outcome. In the combined studies, cytogenetic 
risk group according to IPSS, white blood count, age and performance status appeared 
highly prognostic for outcome. However, some variables appeared prognostic in only one 
of the studies. Our finding that prognostic factors differ in AML and MDS supports that the 
diseases are intrinsically different. Based on the multivariate analyses two prognostic 
scores have been developed: one for the AML-10 study and one for the CRIANT study. 
To our opinion the scoring system for the CRIANT patients is a valuable alternative for 
the IPSS, since the IPSS gives considerable weight to the blast percentage in the bone 
marrow, while this seems less important in intensively treated patients. The scores enable 
us to predict survival after intensive treatment including SCT and to identify patients with 
a poor prognosis. In recent years, progress has been made in the knowledge of the 
molecular mechanisms that underlie the ineffective hematopoiesis and leukemic 
transformation in MDS. Insight gained from this molecular analysis may provide the basis 
for a more targeted approach.  
 
FUTURE PERSPECTIVES 
 
Considerable progress has been made in the treatment of MDS patients over the last 
years, especially in the field of allogeneic stem cell transplantation. New insights in the 
biology of MDS open the way to new treatment approaches.  
 
Improvement of intensive chemotherapy 
Gemtuzumab ozogamicin is an anti-CD33 antibody, which is linked to calicheamicin, a 
potent cytotoxic agent. The drug has shown encouraging results in relapsed AML 
patients. Clinical trials with gemtuzumab in combination with other drugs as first-line 
treatment in MDS patients are under investigation. 
An alternative approach is to overcome drug resistance with new Pgp (P-glycoprotein) 
inhibitors like zosuquidar. 
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Reduction of treatment-related mortality after allogeneic stem cell transplantation 
Supportive care has improved over the years. Better diagnosis and (pre-emptive) 
treatment of opportunistic infections may reduce the treatment-related mortality after 
SCT. 
The risk of severe Graft versus Host Disease after unrelated donor transplantation is 
reduced by refined HLA-typing of patient and donor at the DNA level. This may 
ameliorate the outcome after unrelated donor transplantation. 
The introduction of reduced intensity conditioning (RIC) schedules is a promising 
development, with a lower reported transplant-related mortality compared with 
myeloablative conditioning regimens. However, whether this treatment will improve long-
term outcome of patients has to be proven in prospectiverandomised trials. 
 
Use of novel agents 
In the last decade, the therapeutic arsenal for MDS has been extended. New molecular 
targets have been identified as the mosaic of pathophysiologic pathways in MDS is being 
unraveled. Several new agents with anti-angiogenic properties (thalidomide, 
lenalidomide, bevacizumab), anti-apoptotic properties (infliximab), farnesyl transferease 
inhibitors (tipifarmib, lonafarmib), DNA methyltransferase inhibitors (5-azacytidine, 5-aza-
2’-deoxycytidine), and tyrosine kinase inhibitors have shown encouraging results and 
may offer durable benefit to patients with MDS. Up till now, these drugs are used as 
single agents and in general without the intention to cure the patients. The challenge lies 
in combining these agents with existing treatment modalities.  
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SAMENVATTING 
 
De myelodysplastische syndromen (MDS) vormen een heterogene groep van klonale 
afwijkingen van de hematopoïetische stamcel die gekenmerkt wordt door een 
toegenomen celrijkdom in het beenmerg, deficiënte cellijnen in het bloed (=cytopenieën) 
en dysplastische afwijkingen in bloed en beenmerg. Het ziektebeloop van MDS is variabel 
en varieert van een indolent verloop gedurende vele jaren tot een snelle overgang naar 
een acute leukemie. 
Sinds 1982 wordt de “French-American-British” (FAB) classificatie gebruikt om de 
verschillende vormen van MDS in te delen. De FAB classificatie onderscheidt vijf 
groepen: refractaire anemie (RA), refractaire anemie met ringsideroblasten (RARS), 
refractaire anemie met toename van blasten (RAEB), refractaire anemie met toename 
van blasten in transformatie (RAEBt) en chronische myelomonocyten leukemie (CMML). 
De FAB classificatie was een doorbraak in het onderzoek naar MDS. Talrijke studies 
toonden aan dat deze indeling zeer bruikbaar was en dat hiermee een inschatting van de 
prognose gemaakt kon worden. Deze classificatie heeft echter ook een aantal 
beperkingen. De definitie van chronische myelomonocyten leukemie kan problematisch 
zijn, omdat CMML vaak een mengbeeld is met zowel dysplastische als 
myeloproliferatieve kenmerken. Daarnaast is de definitie alleen gebaseerd op het aantal 
monocyten in het bloed en wordt er minder aandacht besteed aan het percentage onrijpe 
cellen (=blasten) in het beenmerg. De FAB classificatie onderscheidt RAEBt van acute 
myeloïde leukemie. Sommigen vinden dit onderscheid onbelangrijk omdat de prognose 
en de behandelingsresultaten weinig van elkaar verschillen. Daarentegen vormen de 
patiënten met RAEB een heterogene groep met een blastenpercentage variërend van vijf 
tot twintig procent. 
In 1997 heeft de “World Health Organization“ (WHO) een nieuw classificatievoorstel 
gedaan, waarin een aantal van de genoemde kritiekpunten is verbeterd. In dit proefschrift 
wordt echter gebruik gemaakt van de oorspronkelijke FAB classificatie.  
Talrijke scoringssystemen zijn ontwikkeld sinds de introductie van de FAB classificatie 
met als doel om de overleving van een individuele patiënt beter te kunnen voorspellen. 
Tegenwoordig is de “International Prognostic Scoring System” (IPSS) vrij breed 
geaccepteerd. Deze score is gebaseerd op de klinische gegevens van 816 patiënten met 
MDS, die voor het merendeel behandeld zijn met alleen supportieve zorg. De IPSS 
maakt gebruik van het percentage blasten in het beenmerg, het type cytogenetische 
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afwijkingen en het aantal cytopenieën in het bloed om de levensverwachting en de kans 
op het ontwikkelen van een acute myeloïde leukemie te voorspellen. Er worden vier 
groepen onderscheiden. De mediane overleving voor de laag risicogroep is 5.7 jaar, 
intermediair-1 risico 3.5 jaar, intermediair-2 risico 1.2 jaar en 0.4 jaar voor de hoog 
risicogroep. Daarnaast is leeftijd een extra risicofactor voor overleving, maar niet voor het 
ontwikkelen van leukemie.  
De meerderheid van de patiënten met MDS is ouder dan 60 jaar. Deze patiënten hebben 
naast hun hematologische ziekte vaak ook andere, bij de leeftijd horende, aandoeningen. 
De standaardbehandeling voor de meerderheid van de oudere patiënten bestaat uit 
ondersteunende behandeling met bloedtransfusies en antibiotica. Dit proefschrift 
beschrijft intensieve behandelingen, die vooral worden toegepast met de intentie om 
jonge patiënten te genezen. 
 
In hoofdstuk 1 van dit proefschrift worden de FAB classificatie en de WHO classificatie 
beschreven. Gegevens over het voorkomen van MDS en de ontstaanswijze worden 
besproken. Patiënten met een intermediair-2 en een hoog risicoscore volgens de IPSS 
hebben onbehandeld een zeer slechte prognose. Patiënten met een intermediair-1, 
intermediair-2 en een hoog risicoscore volgens de IPSS kunnen in aanmerking komen 
voor intensieve behandeling. Verschillende vormen van intensieve behandeling worden 
besproken. Allogene stamceltransplantatie, waarbij gebruik wordt gemaakt van de 
stamcellen van een HLA-identieke familiedonor (meestal een broer of een zus) is de 
behandeling van voorkeur, indien de patiënt over een donor beschikt. Met deze 
behandeling is het mogelijk om circa 40% van de patiënten te genezen. Langdurige 
ziektevrije overleving wordt bereikt wanneer de behandeling vroeg in het ziektebeloop 
wordt toegepast. Een toegenomen aantal blasten en prognostisch slechte cytogenetische 
afwijkingen vergroten de kans op terugkeer (=recidief) van de ziekte. Een langere 
ziekteduur voor transplantatie, hogere leeftijd, een MDS ontstaan na eerdere behandeling 
met chemotherapie en/of bestraling alsmede het gebruik van alternatieve donoren 
verhogen de kans op overlijden na de transplantatie. Als voorbehandeling voor de 
transplantatie wordt veelvuldig gebruik gemaakt van een zogenaamde myeloablatieve 
conditionering. Hierbij wordt het beenmerg van de patiënt bijna volledig afgebroken door 
de toegepaste chemotherapie. Omdat de sterfte gerelateerd aan de behandeling hoog is, 
na deze myeloablatieve conditionering, wordt onderzoek gedaan naar de effecten van 
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minder intensieve voorbehandeling, de zogenaamde “Reduced Intensity Conditioning” 
(RIC). 
Aangezien slechts een minderheid van de patiënten beschikt over een identieke 
familiedonor, wordt gebruik gemaakt van niet volledig identieke familie donoren en van 
onverwante donoren uit de donorbank. De behandeling gerelateerde sterfte is hoger na 
transplantatie met onverwante donoren, waardoor de ziektevrije overleving circa 30% 
bedraagt. De behandeling gerelateerde sterfte is sterk leeftijdsafhankelijk. 
Patiënten zonder donor kunnen behandeld worden met intensieve chemotherapie, zoals 
ook bij acute myeloïde leukemie wordt toegepast. De resultaten van deze behandeling 
zijn in de afgelopen jaren verbeterd, maar de kans is groot dat de ziekte na behandeling 
terugkeert. Dit risico wordt met name bepaald door de aanwezigheid van cytogenetische 
afwijkingen. Om de behandeling met chemotherapie te intensiveren, wordt autologe 
stamceltransplantatie toegepast, waarbij de stamcellen van de patiënt zelf worden terug 
gegeven na intensieve chemotherapie. De ervaring met autologe transplantatie bij MDS 
is nog beperkt, maar de ziektevrije overleving lijkt vergelijkbaar met de ziektevrije 
overleving na allogene stamcel transplantatie waarbij gebruik wordt gemaakt van 
alternatieve donoren. Na autologe transplantatie is de recidiefkans hoger dan na allogene 
transplantatie met een alternatieve donor, maar dit nadeel wordt tenietgedaan doordat 
het risico van overlijden na autologe transplantatie veel lager ligt dan na allogene 
transplantatie met een alternatieve donor. Hierdoor is de ziektevrije overleving 
vergelijkbaar voor beide behandelingen. Een voorwaarde voor autologe transplantatie is 
dat een complete remissie van de ziekte wordt bereikt voor de transplantatie en dat 
voldoende stamcellen worden geoogst. Indien de patiënt geen complete remissie bereikt 
is een allogene transplantatie met een alternatieve donor een optie. 
 
De behandeling van voorkeur bij patiënten met een MDS is een allogene transplantatie 
met een HLA-identieke familiedonor. Echter, bij rapportage van behandelingsresultaten 
van allogene transplantatie treedt een vorm van selectie op. Dit komt doordat alleen 
patiënten met een donor die fit genoeg zijn voor de transplantatie worden 
getransplanteerd en dat patiënten, die door bijvoorbeeld andere ziektes of een recidief 
voor de transplantatie niet aan de transplantatie toekomen, niet worden gerapporteerd. 
Onderzoeken waarbij transplantatie direct met andere behandelingen wordt vergeleken 
zijn niet uitgevoerd. De beste manier om verschillende behandelingen met elkaar te 
vergelijken is om bij patiënten met een identieke familiedonor door loting vast te stellen (= 
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randomiseren) of patiënten een allogene stamceltransplantatie ondergaan of een ander 
soort behandeling. Dit is echter in de praktijk niet goed mogelijk. Een alternatief is om alle 
patiënten te registreren op het moment dat er gekeken wordt of ze een identieke 
familiedonor hebben, het tijdstip van HLA-typering. Hoofdstuk 2 is als een 
registratiestudie door de EBMT (Europese groep voor Bloed en Beenmerg 
Transplantatie) ontworpen. Patiënten zijn aangemeld op het moment dat de HLA-typering 
plaats vond. Aan de behandelende dokters werd gevraagd welke behandeling zij 
voorstelden aan een patiënt indien hij/zij wel over een familiedonor beschikte en ook 
indien geen familiedonor beschikbaar zou zijn, voordat de uitslag van de HLA-typering 
bekend was. Zo zijn de behandelingsintenties (intention-to-treat) verkregen. Indien de 
patiënt wel een donor had waren de behandelingsmogelijkheden: directe transplantatie, 
transplantatie na voorbehandeling met chemotherapie en transplantatie bij verergering 
van de ziekte. Als geen identieke familiedonor werd gevonden waren de 
behandelingsmogelijkheden: zoeken naar een alternatieve donor, intensieve 
chemotherapie, autologe transplantatie of supportieve zorg. Helaas zijn er niet genoeg 
patiënten aangemeld om een statistisch verantwoorde analyse uit te voeren. Daarom 
werd aan diverse laboratoria, waar HLA-typering wordt verricht, gevraagd om alle 
patiënten te rapporteren met een MDS waarbij HLA-typering heeft plaats gevonden. 
Daarna is de vragenlijst voorgelegd aan de behandelend arts. Op deze manier zijn de 
gegevens verkregen van 248 MDS patiënten uit 12 centra in Europa. Een HLA-identieke 
familie donor was aanwezig in 52% van de patiënten. De uitkomst van de patiënten met 
en zonder donor bleek niet verschillend te zijn wanneer gekeken werd naar de 
behandelingsintentie. De geschatte overleving na 3 jaar bedroeg 46% voor patiënten met 
een donor en 43% voor patiënten zonder donor. Van de patiënten met een donor 
onderging 78% uiteindelijk een allogene stamceltransplantatie. In de patiëntengroep 
zonder donor bereikte een lager percentage de geplande behandeling: 46% van de 
patiënten waarbij de behandelingsintentie een alternatieve donor transplantatie was, 
onderging deze behandeling ook daadwerkelijk, 50% van de patiënten onderging de 
geplande autologe stamceltransplantatie, 67% onderging intensieve chemotherapie en 
97% van de patiënten werd behandeld met supportieve zorg. In multivariate analyse 
waren leeftijd, cytogenetische afwijkingen en FAB classificatie RA(RS) prognostisch voor 
overleving, terwijl de behandelingsintentie niet prognostisch was. Uitgaande van de 
behandelingsintenties bedroeg de geschatte 3-jaars overleving 48% voor directe 
stamceltransplantatie, 34% voor transplantatie na voorbehandeling met chemotherapie, 
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37% voor transplantatie met een alternatieve donor, 36% voor autologe transplantatie en 
35% voor supportieve zorg. Deze analyse laat zien dat transplantatie met een 
alternatieve donor, autologe transplantatie en intensieve chemotherapie goede 
behandelingsalternatieven kunnen zijn voor patiënten die niet over een HLA-identieke 
familie donor beschikken. 
 
De prognose van patiënten met een hoogrisico MDS verschilt weinig van de prognose 
van een patiënt met acute myeloïde leukemie. Echter de behandelingsresultaten van 
intensieve chemotherapie bij MDS patiënten zijn vaak teleurstellend en over het 
algemeen slechter dan bij behandeling van patiënten met acute myeloïde leukemie. Het 
is de vraag, of stamceltransplantatie de resultaten verbetert. Het doel van hoofdstuk 3 
was om intensieve chemotherapie en intensieve chemotherapie gevolgd door 
stamceltransplantatie in eerste remissie bij patiënten onder de 60 jaar met hoog risico 
MDS en secundaire acute myeloïde leukemie met elkaar te vergelijken. De patiënten zijn 
behandeld in een grote Europese studie (EORTC 06921) en in het M.D. Anderson 
Cancer Center in Houston, Texas. Alle patiënten ondergingen intensieve chemotherapie 
om de ziekte in remissie te brengen, gevolgd door een consolidatiekuur. De EORTC 
patiënten ondergingen vervolgens een allogene stamceltransplantatie of een autologe 
stamceltransplantatie, afhankelijk van de beschikbaarheid van een donor. De patiënten in 
het M.D. Anderson werden doorbehandeld met chemotherapie in een lagere dosering 
zonder transplantatie. In de EORTC studie werden 184 patiënten behandeld en 215 
patiënten in het M.D. Anderson. De M.D. Anderson patiënten waren ouder, hadden vaker 
een slechtere algemene conditie (=performance status) en leukemie na een voorfase van 
MDS, terwijl de EORTC patiënten vaker MDS hadden. Afwijkingen aan chromosoom 5 of 
7 werden vaker gezien in het M.D. Anderson (37% versus 21%). Het hemoglobinegehalte 
en het aantal bloedplaatjes waren lager in het M.D. Anderson, terwijl het aantal witte 
bloedcellen hoger was. Het remissiepercentage na de eerste kuur bedroeg 54% in de 
EORTC en 63% in het M.D. Anderson (p=0.09). In de EORTC studie ondergingen 28 
patiënten een allogene stamceltransplantatie met een HLA-identieke donor, 36 patiënten 
een autologe transplantatie en 1 patiënt werd getransplanteerd met een onverwante 
donor. Van de 100 patiënten die een complete remissie behaalden kwamen 35 patiënten 
niet toe aan de transplantatie. De uitkomst van de patiënten met een HLA-identieke 
donor verschilde niet van de uitkomst van de patiënten zonder donor. Daarom werd in 
deze studie geen onderscheid gemaakt tussen allogene en autologe transplantatie, en 
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werd dit als één behandelingstrategie beschouwd. De overleving vanaf de start van 
behandeling was niet verschillend voor de EORTC en M.D. Anderson patiënten. De 
geschatte 4-jaars overleving was 26.0% versus 18.4% (p=0.16). Echter de ziektevrije 
overleving was beter in de EORTC studie, namelijk 28.9% versus 17.3% (p=0.02). Omdat 
de twee onderzoeksgroepen verschillend waren, werd er een multivariate analyse 
uitgevoerd waarin de volgende variabelen zijn opgenomen: studie (EORTC of M.D. 
Anderson), cytogenetica, leeftijd, aantal witte bloedcellen, FAB classificatie (RA, RARS, 
RAEB vs. RAEBt, CMML vs. sAML), hemoglobinegehalte en performance status. De 
multivariate analyse bevestigde dat patiënten die intensieve chemotherapie gevolgd door 
transplantatie ondergaan, een betere ziektevrije overleving hebben dan patiënten die 
alleen chemotherapie krijgen toegediend. Helaas konden we niet aantonen dat deze 
behandeling ook tot een betere overleving leidt.   
 
In hoofdstuk 4 wordt de studieopzet van de EORTC 06921 studie gebruikt om de 
uitkomst te vergelijken van patiënten met en zonder HLA-identieke donor volgens de 
geplande behandelingsstrategie (=intention-to-treat principle). Nadat alle patiënten een 
remissie-inductie kuur en consolidatiekuur hadden ondergaan, was het de bedoeling om 
patiënten met een HLA-identieke donor allogeen te transplanteren en patiënten zonder 
donor autoloog te transplanteren. In deze analyse werden de patiënten die 8 weken na 
start van de behandeling nog in leven waren geïncludeerd omdat deze patiënten in 
aanmerking kwamen voor transplantatie en de resultaten van de HLA-typering op dit 
tijdstip bekend waren. Acht weken na start van de behandeling waren er nog 159 
patiënten in leven: 52 patiënten beschikten over een HLA-identieke donor, 65 patiënten 
hadden geen donor en van 42 patiënten was niet bekend of ze een donor hadden. De 
meerderheid van de patiënten met een onbekende donor (83%) was ouder dan 50 jaar. 
Kennelijk had HLA-typering niet plaatsgevonden omdat de behandelend arts van mening 
was dat de patiënt niet in aanmerking kwam voor een allogene stamceltransplantatie. 
Doordat de groep met een onbekende donor voornamelijk uit oudere patiënten bestond, 
was het complete remissie percentage aanzienlijk lager (45%) en bedroeg de 4-jaar 
overleving slechts 10%. 
In de groep met een HLA-identieke donor bereikten 39 van de 52 patiënten (75%) een 
complete remissie na de remissie-inductie kuur tegenover 42 van de 65 patiënten (65%) 
zonder donor. Zesendertig patiënten (69%) in de groep met een donor ondergingen een 
allogene transplantatie en 32 patiënten (49%) in de groep zonder donor ondergingen een 
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autologe transplantatie. Negen patiënten in de groep zonder donor ondergingen een 
transplantatie met een alternatieve donor.  
De 4-jaars overleving voor de 52 patiënten met een donor was 33.3% versus 39.0% voor 
de 65 patiënten zonder donor (p=0.18). In de 81 patiënten die een complete remissie 
bereikten bedroeg de ziektevrije overleving 30.8% in de donor groep en 33.3% in de 
groep zonder donor. De kans op een recidief bedroeg respectievelijk 42.6% en 64.3% 
voor de beide groepen. Het risico van overlijden in complete remissie bedroeg 26.5% 
versus 2.4%.  
In deze studie hadden cytogenetische afwijkingen een grote invloed op de overleving. 
Patiënten in de prognostisch goede en intermediaire cytogenetische risicogroep volgens 
de IPSS toonden een 4-jaars overleving van 51% en 38%, terwijl in de prognostisch 
slechte cytogenetische groep de 4-jaars overleving slechts 10% bedroeg. In de subgroep 
van 29 patiënten met prognostisch slechte cytogenetische afwijkingen bleek geen 
verschil in overleving te bestaan tussen patiënten met en zonder donor. 
Uiteindelijk waren nog 18 patiënten met een donor in leven aan het einde van de studie. 
Zestien patiënten verkeerden in complete remissie: 1 patiënt zonder transplantatie, 12 
patiënten na transplantatie volgens het protocol en 3 patiënten na transplantatie als 
rescue behandeling. Acht van de 16 patiënten behoorden tot de groep met prognostisch 
goede cytogenetische afwijkingen, 5 patiënten tot de groep met intermediaire 
cytogenetische afwijkingen en 2 patiënten met slechte cytogenetische afwijkingen. Het 
cytogenetische onderzoek was in 1 patiënt mislukt.  
Van de patiënten zonder donor waren er 28 nog in leven aan het einde van de studie. 
Twintig patiënten verkeerden in complete remissie: 4 patiënten zonder transplantatie, 10 
patiënten hadden autologe transplantatie ondergaan volgens het protocol en 6 patiënten 
een allogene transplantatie met een onverwante donor. Van deze 20 patiënten 
behoorden 11 patiënten tot de groep met prognostisch goede cytogenetische afwijkingen, 
3 tot de groep met intermediaire cytogenetische afwijkingen en 1 patiënt met slechte 
cytogenetische afwijkingen. Het cytogenetische onderzoek was in 5 patiënten mislukt. 
De resultaten van deze studie laten zien dat de prognose van patiënten met MDS en 
secundaire AML verbetert met intensieve behandeling inclusief allogene of autologe 
stamcel transplantatie. Wij konden geen overlevingsvoordeel aantonen voor patiënten 
met een HLA-identieke donor in vergelijking met patiënten zonder donor. Weliswaar 
hebben patiënten met een donor een lagere kans op een recidief van de ziekte, maar dit 
wordt tenietgedaan door de hogere kans op overlijden na een allogene transplantatie.  
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De International Prognostic Scoring System (IPSS) is een waardevol instrument om het 
beloop te voorspellen van een MDS patiënt, die geen intensieve behandeling ondergaat. 
Het is echter de vraag of de IPSS ook geschikt is voor patiënten die intensieve 
behandeling ondergaan en voor patiënten die een secundaire MDS hebben na eerdere 
behandeling met chemotherapie of bestraling in verband met een andere aandoening. 
Hoofdstuk 5 is een retrospectieve analyse van 306 onbehandelde MDS patiënten die 
naar het UMC St. Radboud zijn verwezen. Een aanzienlijk deel van deze patiënten is 
behandeld met intensieve chemotherapie al dan niet gevolgd door autologe transplantatie 
of allogene transplantatie met of zonder voorafgaande chemotherapie. De patiënten 
werden geclassificeerd volgens de IPSS criteria en de overleving is vergeleken met de 
overleving van de patiënten uit de oorspronkelijke IPSS workshop. Het doel van de studie 
was om te onderzoeken of de IPSS ook bruikbaar is om de overleving te voorspellen van 
patiënten jonger dan 61 jaar, die een intensieve behandeling ondergaan. Daarnaast was 
de vraag of binnen de IPSS groepen kunnen worden geïdentificeerd, die het meest 
profiteren van intensieve behandeling. In de patiënten onder de 61 jaar was de mediane 
overleving van de Nijmeegs patiënten in de laag risico groep (11.1 versus 11.8 jaar) en in 
de intermediair-2 risicogroep (1.4 vs. 1.8 jaar) vergelijkbaar met de overleving van de 
IPSS  workshop patiënten. Daarentegen was de mediane overleving in de intermediair-1 
risicogroep lager in de Nijmeegse patiënten (2.5 vs. 5.2 jaar), en de mediane overleving 
in de hoog risicogroep beter in de Nijmeegse patiënten (0.9 vs. 0.3 jaar). Van de 176 
patiënten onder de 61 jaar, behoorden er 159 tot de intermediair-1, intermediair-2 en 
hoog risicogroep. Deze patiënten zijn potentiële kandidaten voor intensieve behandeling. 
Zesenzeventig patiënten (48%) zijn behandeld met alleen supportieve zorg. Drieëntachtig 
patiënten (52%) hebben intensieve behandeling ondergaan bestaande uit chemotherapie 
(30 patiënten), chemotherapie gevolgd door autologe transplantatie (7 patiënten) en 
allogene stamcel-transplantatie  (46 patiënten). De mediane leeftijd van de intensief 
behandelde patiënten bedroeg 45 jaar, de mediane leeftijd van de niet-intensief 
behandelde patiënten bedroeg 53 jaar. In de intensief behandelde groep bedroeg de 
mediane overleving vanaf diagnose 2.6 jaar voor de intermediair-1 risicogroep, 3.4 jaar 
voor de intermediair-2 risicogroep en 0.9 jaar voor de hoog risicogroep. De geschatte 4-
jaars overleving bedroeg 46%, 40% en 19%, respectievelijk. In de patiënten groep die 
geen intensieve behandeling onderging, was de mediane overleving 2.2 jaar voor de 
intermediair-1 risicogroep, 0.8 jaar voor de intermediair-2 risicogroep en 0.7 jaar voor de 
hoog risicogroep. De geschatte 4-jaars overleving bedroeg 37%, 11% en 0%, 
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respectievelijk. Uit deze resultaten kan niet zonder meer geconcludeerd worden dat 
intensieve behandeling beter is, omdat de patiëntengroepen mogelijk niet vergelijkbaar 
zijn en geen randomisatie heeft plaats gevonden tussen intensieve en niet-intensieve 
behandeling. Tegenstanders van intensieve behandeling zijn van mening dat de 
resultaten vertekend zijn, doordat alleen de patiënten die in goede conditie verkeren en 
die goed hebben gereageerd op de voorbehandeling, worden getransplanteerd. De 
huidige analyse toont aan dat de resultaten van de groep patiënten, die geen intensieve 
behandeling hebben ondergaan, niet zijn verslechterd in de loop van de tijd. Dit 
ondersteunt dat niet alleen de goede patiënten voor behandeling zijn geselecteerd. 
In de patiëntengroep die geen intensieve behandeling heeft ondergaan bleek in 
multivariate analyse, dat de IPSS een goede maat is om de prognose van een patiënt te 
voorspellen. Echter in de subgroep van 83 patiënten onder de 61 jaar, die intensief zijn 
behandeld, was de IPSS niet voorspellend voor overleving. De hazard ratio voor de hoog 
risicogroep in vergelijking met de intermediair 1 risicogroep was 1.81 (p=0.63), de hazard 
ratio voor de intermediair-2 risicogroep was 0.83 (p=0.78). Deze analyse suggereert dat 
patiënten in de intermediair-2 risicogroep het meest profiteren van intensieve 
behandeling. 
 
Intensieve behandelingsopties worden bij hoog risico MDS patiënten minder vaak 
toegepast dan bij patiënten met AML (acute myeloïde leukemie), omdat de resultaten 
slechter zijn. Het is de vraag of dit komt door verschillen in de aangedane stamcel 
(ziekte-gerelateerde faktoren zoals genetische afwijkingen of moleculaire veranderingen) 
of doordat ongunstige variabelen die de uitkomst beïnvloeden, zoals oudere leeftijd, en 
een slechte algehele conditie, nu eenmaal vaker voorkomen bij MDS dan bij AML 
(patiënt-gerelateerde faktoren). In hoofdstuk 6 worden de uitkomsten vergeleken van 
981 patiënten met hoog risico MDS en AML, die in twee verschillende studies van de 
EORTC Leukemia Groep zijn behandeld en een zelfde remissie-inductie en 
consolidatiekuur hebben gekregen. Patiënten met primaire AML zijn behandeld in de 
AML-10 studie en patiënten met hoog risico MDS en secundaire AML na een MDS 
voorstadium van tenminste 6 maanden in de CRIANT studie. De postconsolidatie 
behandeling in beide studies bestond uit allogene stamceltransplantatie bij patiënten 
jonger dan 45-55 jaar, die over een HLA-identieke donor beschikken. In de AML-10 
studie ondergingen de patiënten zonder donor een autologe stamceltransplantatie. Vanaf 
1994 werden de patiënten zonder donor gerandomiseerd tussen autologe 
SAMENVATTING 
189 
beenmergtransplantatie (ABMT) en autologe perifere bloed stamceltransplantatie 
(APSCT). In de CRIANT studie werden de patiënten zonder donor gerandomiseerd 
tussen APSCT en een tweede consolidatiekuur. Het doel van deze studie was om 
klinische en biologische factoren te identificeren, die voorspellend zijn voor de uitkomst 
van patiënten. De geschatte 5-jaars overleving bedroeg 34% (AML-10) versus 27% 
(CRIANT) (p=0.26). De geschatte 5-jaars ziektevrije overleving was langer in de AML-10 
studie (40%) vergeleken met de CRIANT studie (28%) (p=0.02). In multivariate analyse 
waren de volgende factoren van belang voor overleving en ziektevrije overleving: 
cytogenetische risicogroep, leukocytenaantal en leeftijd. In de gehele groep was de 
overleving en ziektevrije overleving beter voor patiënten die in de AML-10 studie zijn 
behandeld, dan voor patiënten die in de CRIANT studie zijn behandeld. Echter naast 
deze gemeenschappelijke variabelen die voor beide studies van belang waren, waren 
sommige variabelen slechts in één van de studies van belang. Om deze reden is een 
aparte multivariate analyse voor overleving in beide studies verricht. In de AML-10 studie 
hadden patiënten met een goede performance status (PS), FAB subtype M2/M4 en met 
de cytogenetische afwijkingen inv(16)/t(8;21) een betere prognose, terwijl in de CRIANT 
studie het aantal cytopenieën en het tijdsinterval tussen het begin van de ziekte en het 
starten van intensieve behandeling (=Antecedent Hematologic Disorder) van belang 
waren. Onze bevinding dat prognostische factoren verschillen in MDS en AML geeft 
steun aan onze veronderstelling dat MDs en AML verschillende ziektes zijn. Voor beide 
studies is een prognostische score ontwikkeld gebaseerd op de multivariate analyse. De 
score voor de AML-10 studie omvatte de volgende variabelen: cytogenetische 
afwijkingen, leukocytenaantal, FAB classificatie, leeftijd en performance status. De drie 
onderscheiden groepen hadden een geschatte 5-jaars overleving van 54%, 38%, en 
19%, respectievelijk. De score voor de CRIANT studie omvatte cytogenetische 
afwijkingen, leukocytenaantal, leeftijd, aantal cytopenieën, en Antecedent Hematologic 
Disorder. Performance status was niet opgenomen in het model, omdat dit in de CRIANT 
studie niet van belang bleek te zijn voor overleving. De drie groepen hadden een 
geschatte 5-jaars overleving van 69%, 37%, en 5%, respectievelijk.  
Deze analyse toont aan dat 48% van de hoog risico MDS patiënten een 5-jaars 
overleving van circa 40% hebben, wanneer zij worden behandeld met intensieve 
chemotherapie. Een minderheid van vooral jongere patiënten zonder slecht 
prognostische cytogenetische afwijkingen en ernstige cytopenieën, met een korte 
ziektegeschiedenis en een laag leukocytenaantal hebben een relatief goede prognose 
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met een 5-jaars overleving van 69%. Daartegenover onderscheidt deze studie 43% van 
de CRIANT patiënten en 30% van de AML-10 patiënten die een geschatte 5-jaars 
overleving hebben van minder dan 20% ondanks intensieve behandeling. Deze patiënten 
worden gekenmerkt door slecht prognostische cytogenetische afwijkingen, leeftijd boven 
de 45 jaar, meerdere cytopenieën, een ziektegeschiedenis langer dan 6 maanden, FAB 
classificatie anders dan M2/M4 en/of een hoog leukocytenaantal. 
Wij zijn van mening dat de risico score voor de CRIANT studie als alternatief kan dienen 
voor de IPSS. De IPSS geeft veel gewicht aan het percentage beenmergblasten, terwijl 
dit percentage minder van belang lijkt voor intensief behandelde patiënten. De huidige 
scores stellen ons in staat om patiënten met een slechte prognose te onderscheiden. 
Nieuwe behandelingsstrategieën bij deze patiëntenpopulatie dienen plaats te vinden in 
de context van prospectieve klinische studies, waarbij de intensiteit van de behandeling 
aangepast kan worden aan de prognose van de patiënt. 
 
CONCLUSIES 
 
De myelodysplastische syndromen (MDS) vormen een heterogene groep van klonale 
afwijkingen in de hematopoïetische stamcel. Sinds de introductie van de FAB (“French-
American-British”) classificatie in 1982, zijn meerder scoringssystemen ontworpen om het 
natuurlijk verloop van de ziekte bij een individuele patiënt te voorspellen. Vandaag de dag 
wordt de International Prognostic Scoring System (IPSS), gebaseerd op het aantal 
blasten in het beenmerg, het aantal cytopenieën en het type cytogenetische afwijkingen, 
het meest gebruikt.  
MDS is een ziekte die vooral bij oudere patiënten voorkomt. Dit proefschrift beschrijft 
intensieve behandelingsmethoden, die als doel hebben om de kwaadaardige kloon uit te 
roeien. Deze behandelingen worden alleen bij jongere patiënten in een goede conditie 
toegepast. Patiënten die tot de intermediair-1, intermediair-2 en hoog risicogroep van de 
IPSS behoren, komen in aanmerking voor intensieve behandeling. Het is een uitdaging 
om te voorspellen welke patiënt de meeste baat heeft bij welke behandeling. 
Veel clinici beschouwen allogene stamceltransplantatie (SCT) als de enige curatieve 
optie. In het eerste deel van dit proefschrift laten we zien dat de overleving van patiënten 
met en zonder een HLA-identieke donor niet van elkaar verschilt, wanneer de 
behandelingsintentie als uitgangspunt wordt genomen. Andersoortige behandelingen, 
zoals stamceltransplantatie met niet HLA-identieke familieleden en onverwante donoren, 
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autologe SCT en intensieve chemotherapie, vormen een alternatief voor patiënten zonder 
HLA-identieke donor. In een volgende analyse hebben we de uitkomsten vergeleken van 
patiënten met hoog risico MDS en acute leukemie na een voorstadium van MDS, die zijn 
behandeld met intensieve chemotherapie met of zonder stamceltransplantatie. Hoewel 
de overleving van patiënten die behandeld zijn met chemotherapie in combinatie met 
transplantatie, niet langer is dan de overleving van patiënten die alleen chemotherapie 
krijgen toegediend, is de ziektevrije overleving langer in de patiëntengroep die met SCT 
wordt behandeld. 
Het tweede gedeelte van dit proefschrift onderzoekt de waarde van de IPSS in het 
voorspellen van de prognose van een individuele patiënt. We bevestigen dat de IPSS 
een waardevol instrument is om de overleving van niet-intensief behandelde patiënten te 
voorspellen. Echter de IPSS is minder geschikt om de uitkomst na intensieve 
behandeling te voorspellen. We laten zien dat patiënten in de intermediair-2 risicogroep 
de meeste baat hebben bij intensieve behandeling.  
Tenslotte vergelijken we de uitkomst van patiënten met hoogrisico MDS en AML, die in 
twee verschillende studies zijn behandeld met identieke remissie-inductie en 
consolidatiekuren, met als doel om voorspellende klinische en biologische factoren te 
onderscheiden. In de gecombineerde patiëntengroep zijn cytogenetische risicogroep, 
leukocytenaantal, leeftijd en performance status van belang voor de uitkomst. Echter, een 
aantal andere factoren is slechts in één van de studies van belang. Gebaseerd op deze 
factoren hebben we twee prognostische scores ontwikkeld: één voor de AML-10 studie 
en één voor de CRIANT studie. De score voor de CRIANT studie kan een goed 
alternatief zijn voor de IPSS, omdat de IPSS veel gewicht geeft aan het percentage 
blasten in het beenmerg, terwijl dit minder van belang is bij patiënten die intensieve 
behandeling ondergaan. De scores stellen ons in staat om de overleving te voorspellen 
na intensieve behandeling inclusief stamceltransplantatie en om patiënten te identificeren 
met een slechte prognose na behandeling. In de afgelopen jaren is de kennis van de 
moleculaire mechanismen, die verantwoordelijk zijn voor de ineffectieve aanmaak van 
bloedcellen en de leukemische ontaarding toegenomen. Deze kennis kan leiden tot een 
meer oorzakelijke behandeling van de ziekte. Nieuwe behandelingsstrategieën bij 
patiënten met een slechte prognose dienen toegepast te worden in de context van 
klinische studies, waarbij de intensiteit van de behandeling aangepast kan worden aan de 
prognose van de patiënt. 
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TOEKOMSTIGE ONTWIKKELINGEN 
 
In de afgelopen jaren is er een aanzienlijke winst geboekt in de behandeling van MDS 
patiënten, met name door het toepassen van allogene stamceltransplantaties. Nieuwe 
inzichten in het biologisch gedrag van MDS bieden mogelijkheden voor nieuwe 
behandelingsmethodes.  
 
Verbeteren van intensieve chemotherapie 
Gemtuzumab ozogamicine is een antistof gericht tegen CD33, gebonden aan 
calicheamicine en heeft een sterk celdodend effect. De resultaten van behandeling van 
patiënten met een recidief AML zijn bemoedigend. Nieuwe studies met gemtuzumab in 
combinatie met andere cytostatica als eerste lijnsbehandeling bij MDS worden 
momenteel gestart. 
Een alternatieve benaderen is het combineren van chemotherapie met Pgp (P-
glycoproteïne) remmers zoals zosuquidar om chemotherapie-resistentie tegen te gaan. 
 
Verminderen van de transplantatie-gerelateerde sterfte na allogene transplantatie 
De supportieve zorg is in de afgelopen jaren sterk verbeterd. Een intensievere monitoring 
en effectievere behandeling van potentiële infecties heeft geleid tot een lagere 
transplantatie-gerelateerde mortaliteit. 
De kans op ernstige omgekeerde afstoting na SCT met een onverwante donor is 
verminderd sinds HLA-typering op DNA-niveau wordt verricht. Mede hierdoor zijn de 
resultaten van transplantatie met een onverwante donor sterk verbeterd. 
Het toepassen van de zogenaamde “Reduced Intensity Conditioning” (RIC) schema’s is 
veelbelovend, omdat de transplantatie-gerelateerde sterfte lager is dan na zogenaamde 
myeloablatieve conditionering. Echter, of deze behandeling de lange termijn uitkomst van 
patiënten zal verbeteren, moet nog worden onderzocht in prospectief gerandomiseerde 
studies. 
 
Toepassen van nieuwe geneesmiddelen  
In de laatste 10 jaar zijn een aantal nieuwe geneesmiddelen ontwikkeld. Deze middelen 
grijpen min of meer specifiek aan op moleculaire mechanismen, die van belang zijn voor 
het ontstaan van MDS. De resultaten van behandeling met deze nieuwe middelen  
(angiogenese-remmers, farnesyl-transferase remmers, hypomethylerende middelen, 
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tyrosine kinase remmers, anti-apoptose middelen) zijn bemoedigend. Echter, tot nu toe 
zijn deze middelen als monotherapie getest in verschillende studies, in de meeste 
gevallen zonder de intentie om de ziekte te genezen. De uitdaging is om deze nieuwe 
geneesmiddelen te combineren met bestaande behandelingen.  
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CURRICULUM VITAE 
 
De schrijfster van dit proefschrift werd op 8 november 1964 in Amersfoort geboren. Zij 
woonde achtereenvolgens in Groede en Ameide. In 1970 verhuisde zij naar Engwierum, 
waar de lagere school  werd afgemaakt. Het VWO diploma werd in 1982 in Dokkum 
behaald (Christelijke scholengemeenschap Oostergo). In datzelfde jaar werd gestart met 
de studie Scheikunde aan de Rijksuniversiteit Groningen. In 1984 werd gestart met de 
studie Geneeskunde aan de Rijksuniversiteit Groningen. Het doctoraalexamen werd in 
1988 behaald en het artsexamen (cum laude) in 1991.  
In de zomer van 1991 startte zij als arts-assistent niet in opleiding in het toenmalige 
Bonifatius hospitaal in Leeuwarden (thans Medisch Centrum Leeuwarden). Vanaf 1 
oktober 1992 was ze in opleiding tot internist in de regio Noord-Oost Nederland (opleider 
Prof. dr. W.D. Reitsma). Zij was van 1992 tot 1996 werkzaam in het Sophia Ziekenhuis in 
Zwolle (opleider Dr. T. Tjabbes) en van 1996-1997 in het Medisch Spectrum Twente in 
Enschede (opleider Prof. dr. D.J. Richel). In 1997 verhuisde zij naar Nijmegen om te 
starten met het aandachtsgebied hematologie (hoofd Prof. dr. T.J.M. de Witte). 
Registratie als internist vond op 1 oktober 1998 plaats (opleider Prof. dr. J.W.M. van der 
Meer). Registratie als hematoloog vond plaats op 18 maart 2003. 
Van 1 oktober 1997 tot 1 mei 2005 is zij verbonden aan de afdeling Hematologie van het 
Universitair Medisch Centrum Sint Radboud. In deze periode werd ook het onderzoek 
verricht dat is beschreven in dit proefschrift.  
Vanaf 1 mei 2005 zal zij als internist werkzaam zijn in het Elkerliek ziekenhuis in 
Helmond. 
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